


**CUMULATIVE
SUPPLEMENT 7
JULY 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 7

July 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 7
July 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS)	ACTAVIS LABORATORIES INC (ACTAVIS LABS FL INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885	15823		
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)	2516 (15.9%)		
MULTISOURCE	13194 (84.0%)	13345 (84.0%)	13307 (84.1%)		
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)	13169 (83.2%)		
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)	138 (0.9%)		
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	20	12	6		
NUMBER OF APPLICANTS	866	873	889		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.

CFTG Change. A first time generic for the innovator product. A TE Code is added.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug.

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM
AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE
@ WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC
@ EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
PHRENILIN FORTE
@ VALEANT 650MG;50MG A088831 001 Jun 19, 1985 Apr DISC
TABLET;ORAL
BUTAPAP
@ MIKART 650MG;50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
ESGIC-PLUS
@ MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Apr DISC
TABLET;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
@ MIKART 750MG;50MG;40MG A040496 001 Dec 23, 2003 Apr DISC
@ MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC
AA + VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD
@ 500MG;50MG;40MG A040513 001 Aug 25, 2003 Apr DISC
@ WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Jan DISC
ESGIC-PLUS
@ MIKART 500MG;50MG;40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
PHRENILIN WITH CAFFEINE AND CODEINE
@ VALEANT 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
@ MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC
@ MIKART 500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC
@ PHARM ASSOC 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC
AA VINTAGE PHARMS 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN
@ 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC
TABLET;ORAL
ANEXSIA
@ MALLINCKRODT 500MG;5MG A089160 001 Apr 23, 1987 Jan DISC
@ 750MG;10MG A040468 001 Oct 31, 2002 Jan DISC
ANEXSIA 7.5/650
@ MALLINCKRODT 650MG;7.5MG A089725 001 Sep 30, 1987 Jan DISC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
@ AMNEAL PHARMS NY 500MG;5MG A040729 001 Aug 25, 2006 Apr DISC
@ 500MG;7.5MG A040748 001 Aug 25, 2006 Apr DISC
@ 500MG;10MG A040813 001 Feb 23, 2007 Apr DISC
@ 650MG;7.5MG A040754 001 Aug 25, 2006 Apr DISC
@ 650MG;10MG A040757 001 Aug 25, 2006 Apr DISC
@ 750MG;7.5MG A040769 001 Aug 28, 2006 Apr DISC
@ CARACO 500MG;5MG A090265 001 Dec 23, 2008 Apr DISC
@ 500MG;7.5MG A090265 002 Dec 23, 2008 Apr DISC
@ 500MG;10MG A090265 003 Dec 23, 2008 Apr DISC
@ 650MG;7.5MG A090380 001 Dec 23, 2008 Apr DISC
@ 650MG;10MG A090380 002 Dec 23, 2008 Apr DISC
@ 660MG;10MG A090380 003 Dec 23, 2008 Apr DISC
@ 750MG;7.5MG A090380 004 Dec 23, 2008 Apr DISC
@ MALLINCKRODT 500MG;5MG A040084 002 Jun 01, 1995 Jan DISC
@ 500MG;7.5MG A040201 001 Feb 27, 1998 Jan DISC
@ 500MG;10MG A040201 002 Feb 27, 1998 Jan DISC
@ 650MG;10MG A040084 004 Oct 16, 1996 Jan DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
	@	660MG;10MG	A040084	003	Jul 29, 1996	Jan	DISC
	@	750MG;7.5MG	A040084	001	Jun 01, 1995	Jan	DISC
	@ MIKART	500MG;7.5MG	A089699	001	Aug 25, 1989	Apr	DISC
	@	650MG;7.5MG	A089689	001	Jun 29, 1988	Apr	DISC
	@	650MG;10MG	A081223	001	May 29, 1992	Apr	DISC
AA	SUN PHARM INDS INC	325MG;5MG	A090118	001	Dec 23, 2008	Jun	CAHN
AA		325MG;7.5MG	A090118	002	Dec 23, 2008	Jun	CAHN
AA		325MG;10MG	A090118	003	Dec 23, 2008	Jun	CAHN
AA	VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CAHN
AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CAHN
AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CAHN
	@	500MG;2.5MG	A040144	002	Apr 25, 1997	Apr	DISC
	@	500MG;5MG	A089971	001	Dec 02, 1988	Apr	DISC
	@	500MG;7.5MG	A040144	001	Feb 22, 1996	Apr	DISC
	@	500MG;10MG	A040356	001	May 31, 2000	Apr	DISC
	@	650MG;7.5MG	A040155	001	Apr 14, 1997	Jan	DISC
	@	650MG;10MG	A040143	001	Feb 22, 1996	Apr	DISC
	@	660MG;10MG	A040358	001	May 31, 2000	Apr	DISC
	@	750MG;7.5MG	A040157	001	Apr 12, 1996	Jan	DISC
	@ WATSON LABS	500MG;2.5MG	A081079	001	Aug 30, 1991	Apr	DISC
	@	500MG;5MG	A089883	001	Dec 01, 1988	Apr	DISC
	@	500MG;7.5MG	A081080	001	Aug 30, 1991	Jan	DISC
	@	650MG;7.5MG	A040094	001	Sep 29, 1995	Apr	DISC
	@	650MG;10MG	A040094	002	Sep 29, 1995	Apr	DISC
	@	660MG;10MG	A040094	003	Aug 08, 2000	Apr	DISC
	@	750MG;7.5MG	A081083	001	Aug 30, 1991	Jan	DISC
	@	750MG;10MG	A040094	004	Mar 22, 1999	Apr	DISC
	@ WATSON LABS FLORIDA	660MG;10MG	A040495	001	May 28, 2003	Apr	DISC
LORTAB							
	@ UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Apr	DISC
	@	500MG;10MG	A040100	001	Jan 26, 1996	Apr	DISC
ZYDONE							
	@ VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998	Apr	DISC
	@	400MG;7.5MG	A040288	002	Nov 27, 1998	Apr	DISC
	@	400MG;10MG	A040288	003	Nov 27, 1998	Apr	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE AND ACETAMINOPHEN

	@ DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999	Apr	DISC
	@ MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998	Jan	DISC
	@ VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996	Apr	DISC
	@ WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997	Jan	DISC

ROXILOX

	@ ROXANE	500MG;5MG	A040061	001	Jul 03, 1995	Apr	DISC
--	----------	-----------	---------	-----	--------------	-----	------

TYLOX

	@ JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984	Apr	DISC
--	------------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

	@ AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007	Apr	DISC
	@	650MG;10MG	A040789	002	Nov 27, 2007	Apr	DISC
>D>	AA	CARACO	A090535	001	Dec 26, 2013	Jul	CAHN
>D>	AA		A090535	002	Dec 26, 2013	Jul	CAHN
>D>	AA		A090535	003	Dec 26, 2013	Jul	CAHN
>D>	AA		A090535	004	Dec 26, 2013	Jul	CAHN
	@ COASTAL PHARMS	500MG;7.5MG	A090177	005	Oct 20, 2008	Apr	DISC
	@	650MG;10MG	A090177	006	Oct 20, 2008	Apr	DISC
	@ MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004	Apr	DISC
	@	650MG;10MG	A040550	002	Jun 30, 2004	Apr	DISC
	@ MIKART	400MG;5MG	A040687	001	Apr 27, 2006	Apr	DISC
	@	400MG;7.5MG	A040698	001	Apr 27, 2006	Apr	DISC
	@	400MG;10MG	A040692	001	Apr 27, 2006	Apr	DISC
	@	500MG;10MG	A040676	001	Apr 19, 2006	Apr	DISC
>A>	AA	SUN PHARM INDS INC	A090535	001	Dec 26, 2013	Jul	CAHN
>A>	AA		A090535	002	Dec 26, 2013	Jul	CAHN
>A>	AA		A090535	003	Dec 26, 2013	Jul	CAHN
>A>	AA		A090535	004	Dec 26, 2013	Jul	CAHN
	@ WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000	Jan	DISC
	@	650MG;10MG	A040371	002	Dec 29, 2000	Jan	DISC
PERCOCET							
	@ VINTAGE PHARMS LLC	500MG;7.5MG	A040341	001	Jul 26, 1999	Jan	DISC

	TABLET;ORAL								
	PERCO CET								
	@	650MG;10MG		A040341	002	Jul 26, 1999		Jan	DISC
	TABLET, EXTENDED RELEASE;ORAL								
	XARTEMIS XR								
	+	MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014		Mar	NEWA
	<u>ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE								
	@	GAVIS PHARMS	650MG;EQ 25MG BASE	A076202	001	Aug 02, 2002		Apr	DISC
	@	WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000		Apr	DISC
	<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE</u>								
	TABLET;ORAL								
	TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN								
AB		ALLIED PHARMA INC	325MG;37.5MG	A202076	001	Mar 30, 2012		Apr	CAHN
AB		APOTEX INC	325MG;37.5MG	A078778	001	Apr 07, 2014		Mar	NEWA
>D>	AB	CARACO	325MG;37.5MG	A077184	001	Dec 16, 2005		Jul	CAHN
>A>	AB	SUN PHARM INDS INC	325MG;37.5MG	A077184	001	Dec 16, 2005		Jul	CAHN
	@	WATSON LABS	325MG;37.5MG	A076914	001	Jul 26, 2006		May	DISC
	<u>ACETAZOLAMIDE</u>								
	TABLET;ORAL								
	DIAMOX								
>D>	@	DURAMED PHARMS BARR	125MG	N008943	001			Jul	CAHN
>D>	@		250MG	N008943	002			Jul	CAHN
>A>	@	TEVA BRANDED PHARM	125MG	N008943	001			Jul	CAHN
>A>	@		250MG	N008943	002			Jul	CAHN
	<u>ACETOHEXAMIDE</u>								
	TABLET;ORAL								
	ACETOHEXAMIDE								
	@	WATSON LABS	250MG	A071893	001	Nov 25, 1987		May	DISC
	@		500MG	A071894	001	Nov 25, 1987		May	DISC
	<u>ACETYLCYSTEINE</u>								
	SOLUTION;INHALATION, ORAL								
	ACETYLCYSTEINE								
AN		INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014		Jan	NEWA
AN		ROXANE	10%	A072323	001	Apr 30, 1992		Jun	CAHN
AN			20%	A072324	001	Apr 30, 1992		Jun	CAHN
	<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	SEMPREX-D								
	+	AUXILIUM PHARMS LLC	8MG;60MG	N019806	001	Mar 25, 1994		Apr	CAHN
	<u>ACYCLOVIR</u>								
	CAPSULE;ORAL								
	ACYCLOVIR								
AB		CADILA PHARMS LTD	200MG	A201445	001	Mar 06, 2014		Feb	NEWA
AB	+	DEL COR ASSET	200MG	N018828	001	Jan 25, 1985		Jun	CAHN
	OINTMENT;TOPICAL								
	ACYCLOVIR								
AB		AMNEAL PHARMS	5%	A204605	001	Jun 18, 2014		Jun	NEWA
	TABLET;BUCCAL								
	SITAVIG								
	+	INNOCUTIS HOLDINGS	50MG	N203791	001	Apr 12, 2013		Apr	CMFD
	+		50MG	N203791	001	Apr 12, 2013		Apr	CAHN
	TABLET;ORAL								
	ZOVIRAX								
AB		DEL COR ASSET	400MG	N020089	001	Apr 30, 1991		Jun	CAHN
AB	+		800MG	N020089	002	Apr 30, 1991		Jun	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

+	BEDFORD	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CRLD
@	HIKMA MAPLE	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Feb	DISC
@		EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Feb	DISC

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

AP	AGILA SPECLTS	3MG/ML	A078640	001	Mar 21, 2014	Mar	NEWA
AP		3MG/ML	A078686	001	May 13, 2009	Feb	CAHN
AP	HOSPIRA INC	3MG/ML	A203883	001	Mar 24, 2014	Mar	NEWA
AP	SAGENT STRIDES	3MG/ML	A090212	001	Mar 28, 2014	Mar	NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION
ACCUNEB

AN	+	MYLAN SPECLT	EQ 0.021% BASE	N020949	002	Apr 30, 2001	May	CAHN
AN	+		EQ 0.042% BASE	N020949	001	Apr 30, 2001	May	CAHN

TABLET; ORAL
ALBUTEROL SULFATE

@	WATSON LABS	EQ 2MG BASE	A072764	001	Aug 28, 1991	May	DISC
---	-------------	-------------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION
DUONEB

AN	+	MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	May	CAHN
----	---	--------------	------------------------	---------	-----	--------------	-----	------

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL
VALTURNA

@	NOVARTIS	EQ 150MG BASE; 160MG	N022217	001	Sep 16, 2009	May	DISC
@		EQ 300MG BASE; 320MG	N022217	002	Sep 16, 2009	May	DISC

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

>D>	AB	CARACO	100MG	A078390	001	Aug 30, 2007	Jul	CAHN
>D>	AB		300MG	A078390	002	Aug 30, 2007	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007	Jul	CAHN
>A>	AB		300MG	A078390	002	Aug 30, 2007	Jul	CAHN

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb	CAHN
AB		0.5MG	A090248	002	Sep 17, 2010	Feb	CAHN
AB		1MG	A090248	003	Sep 17, 2010	Feb	CAHN
AB		2MG	A090248	004	Sep 17, 2010	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

AB	ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan	CAHN
@		0.5MG	A077979	001	Feb 28, 2007	Jan	CAHN
AB		1MG	A077725	002	Jul 31, 2006	Jan	CAHN
@		1MG	A077979	002	Feb 28, 2007	Jan	CAHN
AB		2MG	A077725	004	Jul 31, 2006	Jan	CAHN
@		2MG	A077979	003	Feb 28, 2007	Jan	CAHN
AB		3MG	A077725	003	Jul 31, 2006	Jan	CAHN
@		3MG	A077979	004	Feb 28, 2007	Jan	CAHN

ALPROSTADIL

INJECTABLE; INJECTION
EDEX

	@	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP			0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
	+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP			0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP			0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb	CRLD
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb	CRLD

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

@ SANOFI AVENTIS US

10MG

N010155 002

Jun DISC

AMINO ACIDS

INJECTABLE; INJECTION

>D>		HEPATASOL 8%						
>D>		BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996	Jul	DISC
>A>	@		8% (8GM/100ML)	A020360	001	Apr 04, 1996	Jul	DISC
>D>		RENAMIN W/O ELECTROLYTES						
>D>		BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982	Jul	DISC
>A>	@		6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982	Jul	DISC
>D>		TRAVASOL 10% W/O ELECTROLYTES						
>D>		BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006		Jul	DISC
>A>	@		10% (10GM/100ML)	N017493	006		Jul	DISC
>D>		TRAVASOL 5.5% W/O ELECTROLYTES						
>D>		BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004		Jul	DISC
>A>	@		5.5% (5.5GM/100ML)	N017493	004		Jul	DISC
>D>		TRAVASOL 8.5% W/O ELECTROLYTES						
>D>		BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005		Jul	DISC
>A>	@		8.5% (8.5GM/100ML)	N017493	005		Jul	DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

>D>		TRAVASOL 3.5% W/ ELECTROLYTES						
>D>		BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493	003		Jul	DISC
>A>	@		3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493	003		Jul	DISC
>D>		TRAVASOL 5.5% W/ ELECTROLYTES						
>D>		BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001		Jul	DISC
>A>	@		5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001		Jul	DISC
>D>		TRAVASOL 8.5% W/ ELECTROLYTES						
>D>		BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493	002		Jul	DISC
>A>	@		8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493	002		Jul	DISC

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

@ MERCK

20%

N005619 001

Jun DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ PAR STERILE PRODUCTS

50MG/ML

A076394 001

Apr 25, 2003

May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

>D>	AB	CARACO	10MG	A040816	002	Jun 27, 2008	Jul	CAHN
>D>	AB		25MG	A040816	001	Jun 27, 2008	Jul	CAHN
>D>	AB		50MG	A040816	003	Jun 27, 2008	Jul	CAHN
>D>	AB		75MG	A040816	004	Jun 27, 2008	Jul	CAHN
>D>	AB		100MG	A040816	005	Jun 27, 2008	Jul	CAHN
>D>	AB		150MG	A040816	006	Jun 27, 2008	Jul	CAHN
	AB	MUTUAL PHARM	10MG	A089399	002	Jul 14, 1987	Jun	CMS1
	AB		50MG	A089399	003	Jul 14, 1987	Jun	CMS1
	AB		75MG	A089399	004	Jul 14, 1987	Jun	CMS1
	AB		100MG	A089399	005	Jul 14, 1987	Jun	CMS1
>D>	AB		100MG	A089399	006	Jul 14, 1987	Jul	CPOT
	AB		100MG	A089399	006	Jul 14, 1987	Jun	CMS1

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A>	AB		150MG	A089399	006	Jul 14, 1987	Jul CPOT
>A>	AB	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Jul CAHN
>A>	AB		25MG	A040816	001	Jun 27, 2008	Jul CAHN
>A>	AB		50MG	A040816	003	Jun 27, 2008	Jul CAHN
>A>	AB		75MG	A040816	004	Jun 27, 2008	Jul CAHN
>A>	AB		100MG	A040816	005	Jun 27, 2008	Jul CAHN
>A>	AB		150MG	A040816	006	Jun 27, 2008	Jul CAHN

AMITRIPTYLINE HYDROCHORIDE

AB		ACCORD HLTHCARE	10MG	A202446	001	Jun 04, 2014	May NEWA
AB			25MG	A202446	002	Jun 04, 2014	May NEWA
AB			50MG	A202446	003	Jun 04, 2014	May NEWA
AB			75MG	A202446	004	Jun 04, 2014	May NEWA
AB			100MG	A202446	005	Jun 04, 2014	May NEWA
AB			150MG	A202446	006	Jun 04, 2014	May NEWA

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

>D>	AB	CARACO	EQ 2.5MG BASE	A078231	001	Nov 30, 2007	Jul CAHN
>D>	AB		EQ 5MG BASE	A078231	002	Nov 30, 2007	Jul CAHN
>D>	AB		EQ 10MG BASE	A078231	003	Nov 30, 2007	Jul CAHN
		@ PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb DISC
		@	EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb DISC
		@	EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb DISC
>A>	AB	SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007	Jul CAHN
>A>	AB		EQ 5MG BASE	A078231	002	Nov 30, 2007	Jul CAHN
>A>	AB		EQ 10MG BASE	A078231	003	Nov 30, 2007	Jul CAHN
	AB	VIVIMED LABS	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr CAHN
	AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr CAHN
	AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb NEWA
AB			EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb NEWA
AB			EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar NEWA
AP		UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun NEWA
AP		WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan NEWA

AMOXICILLIN

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+		PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008	Apr CAHN
---	--	-------------------	-------	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB		SANDOZ	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A202588	001	Mar 04, 2014	Feb NEWA
----	--	--------	--	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+		GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Mar CDFR
---	--	--------------	--	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	A 040456	001	May 06, 2003	Apr	CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 040456	002	May 06, 2003	Apr	CMFD
AB		5MG;5MG;5MG;5MG	A 040456	003	May 06, 2003	Apr	CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 040456	004	May 06, 2003	Apr	CMFD

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A 202198	001	Apr 07, 2014	Mar	NEWA
AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A 090354	003	Dec 28, 2009	Jun	CMFD
AP		EQ 2GM BASE/VIAL	A 090354	004	Dec 28, 2009	Jun	CMFD
AP		EQ 250MG BASE/VIAL	A 090354	001	Dec 28, 2009	Jun	CMFD
AP		EQ 500MG BASE/VIAL	A 090354	002	Dec 28, 2009	Jun	CMFD
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A 062719	002	May 12, 1987	Feb	CAHN
AP		EQ 2GM BASE/VIAL	A 062797	002	Jul 12, 1993	Feb	CAHN
AP		EQ 10GM BASE/VIAL	A 201404	001	Dec 20, 2013	Jan	CPOT
AP		EQ 125MG BASE/VIAL	A 062797	001	Jul 12, 1993	Feb	CAHN
AP		EQ 250MG BASE/VIAL	A 062719	001	May 12, 1987	Feb	CAHN
AP		EQ 500MG BASE/VIAL	A 062719	003	May 12, 1987	Feb	CAHN
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A 201025	003	Apr 09, 2014	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A 201025	004	Apr 09, 2014	Mar	NEWA
AP		EQ 250MG BASE/VIAL	A 201025	001	Apr 09, 2014	Mar	NEWA
AP		EQ 500MG BASE/VIAL	A 201025	002	Apr 09, 2014	Mar	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 201024	001	Apr 07, 2014	Mar	NEWA
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 201024	002	Apr 07, 2014	Mar	NEWA
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 202197	001	Apr 07, 2014	Mar	NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065222	001	Nov 29, 2005	Feb	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065222	002	Nov 29, 2005	Feb	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 065314	001	Nov 27, 2006	Feb	CAHN
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065316	001	Jun 29, 2007	May	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065316	002	Jun 29, 2007	May	CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

@ WATSON LABS

1MG

A 078984 001 Jun 28, 2010 May DISC

APREMILAST

TABLET; ORAL

OTEZLA

CELGENE CORP

10MG

N 205437 001 Mar 21, 2014 Mar NEWA

20MG

N 205437 002 Mar 21, 2014 Mar NEWA

+

30MG

N 205437 003 Mar 21, 2014 Mar NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A 202626	001	Jun 30, 2014	Jun	NEWA
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A 091665	001	Jun 30, 2014	Jun	NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB	WATSON LABS INC	200MG	A 200156	004	Aug 29, 2012	May	CTEC
AB	NUVIGIL						
AB	CEPHALON	200MG	N 021875	005	Mar 26, 2009	May	CMFD

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRIS

	FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CAHN
+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@	WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995	Mar	DISC
---	-------------	----------------------	---------	-----	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

@	STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999	Mar	DISC
---	-----------	-----------------	---------	-----	--------------	-----	------

@		770MG;60MG;50MG	A074988	002	Apr 30, 1999	Mar	DISC
---	--	-----------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@	MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	DISC
---	---------------	------------------	---------	-----	--------------	-----	------

@	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Mar	DISC
---	-------------	------------------	---------	-----	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@	WATSON LABS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998	May	DISC
---	-------------	--------------------	---------	-----	--------------	-----	------

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Apr	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

AB		EQ 150MG BASE	A091673	002	Apr 22, 2014	Apr	NEWA
----	--	---------------	---------	-----	--------------	-----	------

AB		EQ 200MG BASE	A091673	003	Apr 22, 2014	Apr	NEWA
----	--	---------------	---------	-----	--------------	-----	------

AB		EQ 300MG BASE	A091673	004	Apr 22, 2014	Apr	NEWA
----	--	---------------	---------	-----	--------------	-----	------

REYATAZ

AB	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N021567	001	Jun 20, 2003	Apr	CFTG
----	----------------------	---------------	---------	-----	--------------	-----	------

AB		EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr	CFTG
----	--	---------------	---------	-----	--------------	-----	------

AB		EQ 200MG BASE	N021567	003	Jun 20, 2003	Apr	CFTG
----	--	---------------	---------	-----	--------------	-----	------

AB	+	EQ 300MG BASE	N021567	004	Oct 16, 2006	Apr	CFTG
----	---	---------------	---------	-----	--------------	-----	------

POWDER;ORAL

REYATAZ

+	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014	Jun	NEWA
---	----------------------	---------------------	---------	-----	--------------	-----	------

ATENOLOL

TABLET;ORAL

ATENOLOL

>D>	AB	CARACO	25MG	A078210	001	Jul 10, 2007	Jul	CAHN
-----	----	--------	------	---------	-----	--------------	-----	------

>D>	AB		50MG	A078210	002	Jul 10, 2007	Jul	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>D>	AB		100MG	A078210	003	Jul 10, 2007	Jul	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

AB	MYLAN	50MG	A073457	003	Jan 24, 1992	Apr	CMS1
----	-------	------	---------	-----	--------------	-----	------

>A>	AB	SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007	Jul	CAHN
-----	----	--------------------	------	---------	-----	--------------	-----	------

>A>	AB		50MG	A078210	002	Jul 10, 2007	Jul	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB		100MG	A078210	003	Jul 10, 2007	Jul	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	AMNEAL PHARMS	750MG/5ML	A202960	001	Mar 18, 2014	Mar	NEWA
----	---------------	-----------	---------	-----	--------------	-----	------

AB	+	GLAXOSMITHKLINE LLC	750MG/5ML	N020500	001	Feb 08, 1995	Mar	CFTG
----	---	---------------------	-----------	---------	-----	--------------	-----	------

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	MYLAN PHARMS INC	62.5MG;25MG	A202362	001	May 27, 2014	May	NEWA
----	------------------	-------------	---------	-----	--------------	-----	------

AB		250MG;100MG	A202362	002	May 27, 2014	May	NEWA
----	--	-------------	---------	-----	--------------	-----	------

MALARONE PEDIATRIC

AB	GLAXOSMITHKLINE	62.5MG;25MG	N021078	002	Jul 14, 2000	May	CTEC
----	-----------------	-------------	---------	-----	--------------	-----	------

ATROPINE SULFATE

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE
 + HOSPIRA 0.05MG/ML N021146 002 Jul 09, 2001 May CRLD
 >A> SOLUTION/DROPS;OPHTHALMIC
 >A> ATROPINE SULFATE
 >A> AKORN 1% N206289 001 Jul 18, 2014 Jul NEWA

AZELASTINE HYDROCHLORIDE

SPRAY;NASAL
 AZELASTINE HYDROCHLORIDE
 AB PERRIGO ISRAEL EQ 0.1876MG BASE/SPRAY A202743 001 May 08, 2014 Apr NEWA
 SPRAY, METERED;NASAL
 AZELASTINE HYDROCHLORIDE
 AB PERRIGO ISRAEL EQ 0.1876MG BASE/SPRAY A202743 001 May 08, 2014 Jun CDFR

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL
 EDARBI
 ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL N200796 001 Feb 25, 2011 Feb CAHN
 + EQ 80MG MEDOXOMIL N200796 002 Feb 25, 2011 Feb CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL
 EDARBYCLOR
 ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL;12.5MG N202331 001 Dec 20, 2011 Feb CAHN
 + EQ 40MG MEDOXOMIL;25MG N202331 002 Dec 20, 2011 Feb CAHN

BACITRACIN

OINTMENT;OPHTHALMIC
 BACITRACIN
 + PERRIGO CO TENNESSEE 500 UNITS/GM A061212 001 Feb CTEC

BACLOFEN

TABLET;ORAL
 BACLOFEN
 >D> AB CARACO 20MG A077862 002 Aug 14, 2006 Jul CAHN
 >A> AB SUN PHARM INDS INC 20MG A077862 002 Aug 14, 2006 Jul CAHN

BELINOSTAT

>A> POWDER; IV (INFUSION)
 >A> BELEODAQ
 >A> + SPECTRUM PHARMS 500MG/VIAL N206256 001 Jul 03, 2014 Jul NEWA

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL
 NADOLOL AND BENDROFLUMETHIAZIDE
 AB MYLAN 5MG;40MG A078688 001 Feb 15, 2008 Jan CTNA
 AB 5MG;80MG A078688 002 Feb 15, 2008 Jan CTNA

BENZONATATE

CAPSULE;ORAL
 BENZONATATE
 AA SUN PHARM INDS INC 100MG A040587 001 Mar 19, 2008 Jun CAHN
 AA 200MG A040587 002 Mar 19, 2008 Jun CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL
 BENZACLIN
 AB + VALEANT BERMUDA 5%;EQ 1% BASE N050756 001 Dec 21, 2000 Mar CRLD
 >D> + 5%;EQ 1% BASE N050756 002 Apr 20, 2007 Jul DISC
 >A> @ 5%;EQ 1% BASE N050756 002 Apr 20, 2007 Jul DISC
 + 5%;EQ 1% BASE N050756 002 Apr 20, 2007 Mar CTEC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC
 BEPREVE
 + BAUSCH AND LOMB INC 1.5% N022288 001 Sep 08, 2009 Apr CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL
LOTRISONE

AB	+	MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N020010	001	Dec 08, 2000	Jan	CAHN
----	---	-------------------	-------------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

>A>	@	ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004	Jul	CAHN
>A>	@		10MG	A040553	001	Oct 28, 2004	Jul	CAHN
>A>	@		25MG	A040554	001	Oct 28, 2004	Jul	CAHN
>A>	@		50MG	A040551	001	Oct 28, 2004	Jul	CAHN
>D>	@	ACTAVIS TOTOWA	5MG	A040552	001	Oct 28, 2004	Jul	CAHN
>D>	@		10MG	A040553	001	Oct 28, 2004	Jul	CAHN
>D>	@		25MG	A040554	001	Oct 28, 2004	Jul	CAHN
>D>	@		50MG	A040551	001	Oct 28, 2004	Jul	CAHN
AA		SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009	Jun	CAHN
AA			10MG	A040897	002	Apr 22, 2009	Jun	CAHN
AA			25MG	A040897	003	Apr 22, 2009	Jun	CAHN
AA			50MG	A040897	004	Apr 22, 2009	Jun	CAHN
		DUVOID						
	@	WELLSPRING PHARM	10MG	A086262	001		Mar	DISC
	@		25MG	A086263	001		Mar	DISC
	@		50MG	A085882	003		Mar	DISC

BEXAROTENE

CAPSULE; ORAL
BEXAROTENE

>A>	AB	BANNER PHARMACAPS	75MG	A203174	001	Aug 12, 2014	Jul	NEWA
		TARGRETIN						
>D>	+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jul	CFTG
>A>	AB	+	75MG	N021055	001	Dec 29, 1999	Jul	CFTG

BICALUTAMIDE

TABLET; ORAL
BICALUTAMIDE

@	ROXANE	50MG	A078285	001	Mar 24, 2011	Jun	DISC
---	--------	------	---------	-----	--------------	-----	------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC
LUMIGAN

@	ALLERGAN	0.03%	N021275	001	Mar 16, 2001	May	DISC
---	----------	-------	---------	-----	--------------	-----	------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL
PYLERA

+	FOREST LABS INC	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006	Apr	CAHN
+	FOREST RES INST INC	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006	Mar	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@	WATSON LABS	2.5MG; 6.25MG	A075469	001	Sep 25, 2000	May	DISC
@		5MG; 6.25MG	A075469	002	Sep 25, 2000	May	DISC
@		10MG; 6.25MG	A075469	003	Sep 25, 2000	May	DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMDAY

AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr	CAHN
AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan	CFTG
		BROMFENAC SODIUM						
AT1		APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun	NEWA
AT			EQ 0.09% ACID	A202620	001	Jun 23, 2014	Jun	NEWA
AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan	CTEC
AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan	NEWA
AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan	CTEC
		XIBROM						
	@	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr	CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

		SYRUP; ORAL							
		BROMFED-DM							
AA	+	WOCKHARDT	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Jun	CTEC	
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE									
AA		PADDOCK LLC	2MG/5ML; 10MG/5ML; 30MG/5ML	A205292	001	Jul 15, 2014	Jun	NEWA	
>A>	AA	VINTAGE PHARMS	2MG/5ML; 10MG/5ML; 30MG/5ML	A202940	001	Jul 21, 2014	Jul	NEWA	

BUDESONIDE

		CAPSULE; ORAL							
		BUDESONIDE							
AB		BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar	NEWA	
SPRAY, METERED; NASAL									
BUDESONIDE									
AB		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Apr	NEWA	
RHINOCORT									
AB	+	ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999	Apr	CFTG	
TABLET, EXTENDED RELEASE; ORAL									
UCERIS									
	+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb	CAHN	
	+	SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar	CAHN	

BUPIVACAINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		BUPIVACAINE HYDROCHLORIDE							
>D>	AP	HOSPIRA	0.75%	A070587	001	Mar 03, 1987	Jul	DISC	
>A>		@	0.75%	A070587	001	Mar 03, 1987	Jul	DISC	

BUPRENORPHINE

		FILM, EXTENDED RELEASE; TRANSDERMAL							
		BUTRANS							
		PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Jun	NEWA	

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

		FILM; BUCCAL							
		BUNAVAIL							
		BIODELIVERY SCI INTL	EQ 2.1MG BASE; EQ 0.3MG BASE	N205637	001	Jun 06, 2014	Jun	NEWA	
			EQ 4.2MG BASE; EQ 0.7MG BASE	N205637	002	Jun 06, 2014	Jun	NEWA	
		+	EQ 6.3MG BASE; EQ 1MG BASE	N205637	003	Jun 06, 2014	Jun	NEWA	
TABLET; SUBLINGUAL									
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE									
AB		ROXANE	EQ 2MG BASE; EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Jun	NEWA	
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDRODHCLORIDE									
AB		ROXANE	EQ 8MG BASE; EQ 2MG BASE	A203326	002	Jun 27, 2014	Jun	NEWA	

BUPROPION HYDROCHLORIDE

		TABLET, EXTENDED RELEASE; ORAL							
		BUPROPION HYDROCHLORIDE							
>A>	AB1	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Jul	CAHN	
>A>	AB1		150MG	A202774	002	Oct 11, 2013	Jul	CAHN	
>A>	AB1		200MG	A202774	003	Oct 11, 2013	Jul	CAHN	
>D>	AB1	JUBILANT LIFE	100MG	A202774	001	Oct 11, 2013	Jul	CAHN	
>D>	AB1		150MG	A202774	002	Oct 11, 2013	Jul	CAHN	
>D>	AB1		200MG	A202774	003	Oct 11, 2013	Jul	CAHN	
	AB3	ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan	NEWA	

BUSPIRONE HYDROCHLORIDE

		TABLET; ORAL							
		BUSPIRONE HYDROCHLORIDE							
AB		ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan	NEWA	
AB			10MG	A078888	002	Feb 07, 2014	Jan	NEWA	
AB			15MG	A078888	003	Feb 07, 2014	Jan	NEWA	
AB			30MG	A078888	004	Feb 07, 2014	Jan	NEWA	

BUTENAFINE HYDROCHLORIDE

		CREAM; TOPICAL							
		MENTAX-TC							
		@ MYLAN	1%	N021408	001	Oct 17, 2002	Jun	DISC	

BUTOCONAZOLE NITRATECREAM;VAGINAL
GYNAZOLE-1

@ LUMARA HEALTH INC	2%	N019881	001	Feb 07, 1997	May CAHN
---------------------	----	---------	-----	--------------	----------

BUTORPHANOL TARTRATEINJECTABLE; INJECTION
BUTORPHANOL TARTRATE

@ HIKMA FARMACEUTICA	2MG/ML	A078247	001	Apr 29, 2009	May DISC
----------------------	--------	---------	-----	--------------	----------

CAFFEINE CITRATESOLUTION; INTRAVENOUS
CAFFEINE CITRATE

AP	EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb CAHN
----	----------------------	------------------------------------	---------	-----	--------------	----------

SOLUTION; ORAL
CAFFEINE CITRATE

AA	EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb CAHN
----	----------------------	------------------------------------	---------	-----	--------------	----------

CALCIPOTRIENESOLUTION; TOPICAL
CALCIPOTRIENE

AT	+ HI TECH PHARMA	0.005%	A077579	001	Nov 19, 2009	May DISC
----	------------------	--------	---------	-----	--------------	----------

+ TOLMAR

A077029	001	Nov 20, 2009	Apr CRLD
---------	-----	--------------	----------

DOVONEX

@ LEO PHARM	0.005%	N020611	001	Mar 03, 1997	Apr DISC
-------------	--------	---------	-----	--------------	----------

CALCITRIOLINJECTABLE; INJECTION
CALCITRIOL

@ TEVA PARENTERAL	0.002MG/ML	A075823	002	Mar 31, 2003	Feb DISC
-------------------	------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

>D> AP	BAXTER HLTHCARE	33MG/100ML; 5GM/100ML; 30MG/100ML; 86	N016695	001		Jul DISC
--------	-----------------	---------------------------------------	---------	-----	--	----------

>A>	@	0MG/100ML	N016695	001		Jul DISC
-----	---	-----------	---------	-----	--	----------

CAPECITABINETABLET; ORAL
CAPECITABINE

>A> AB	MYLAN PHARMS INC	150MG	A090943	001	Aug 08, 2014	Jul NEWA
--------	------------------	-------	---------	-----	--------------	----------

>A> AB		500MG	A090943	002	Aug 08, 2014	Jul NEWA
--------	--	-------	---------	-----	--------------	----------

CAPTOPRILTABLET; ORAL
CAPTOPRIL

@ DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996	May CAHN
-------------------	--------	---------	-----	--------------	----------

@	25MG	A074423	002	Feb 13, 1996	May CAHN
---	------	---------	-----	--------------	----------

@	50MG	A074423	003	Feb 13, 1996	May CAHN
---	------	---------	-----	--------------	----------

@	100MG	A074423	004	Feb 13, 1996	May CAHN
---	-------	---------	-----	--------------	----------

@ WATSON LABS	12.5MG	A074451	001	Feb 13, 1996	Mar DISC
---------------	--------	---------	-----	--------------	----------

@	25MG	A074451	002	Feb 13, 1996	Mar DISC
---	------	---------	-----	--------------	----------

@	50MG	A074451	003	Feb 13, 1996	Mar DISC
---	------	---------	-----	--------------	----------

@	100MG	A074451	004	Feb 13, 1996	Mar DISC
---	-------	---------	-----	--------------	----------

CAPTOPRIL; HYDROCHLOROTHIAZIDETABLET; ORAL
CAPOZIDE 25/15

@ APOTHECON	25MG; 15MG	N018709	001	Oct 12, 1984	Mar DISC
-------------	------------	---------	-----	--------------	----------

@ APOTHECON	25MG; 25MG	N018709	002	Oct 12, 1984	Mar DISC
-------------	------------	---------	-----	--------------	----------

@ APOTHECON	50MG; 15MG	N018709	004	Oct 12, 1984	Mar DISC
-------------	------------	---------	-----	--------------	----------

@ APOTHECON	50MG; 25MG	N018709	003	Oct 12, 1984	Mar DISC
-------------	------------	---------	-----	--------------	----------

AB	+ MYLAN	25MG; 25MG	A074896	002	Dec 29, 1997	Mar CRLD
----	---------	------------	---------	-----	--------------	----------

AB	+ MYLAN	50MG; 15MG	A074896	004	Dec 29, 1997	Mar CRLD
----	---------	------------	---------	-----	--------------	----------

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA
AB	+	ATON	25MG	N017830	001		Feb CFTG

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

AA		VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
AA		VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	@	BEDFORD	50MG/VIAL	A076099	001	Oct 14, 2004	May DISC
	@		150MG/VIAL	A076099	002	Oct 14, 2004	May DISC
	@		450MG/VIAL	A076099	003	Oct 14, 2004	May DISC
	@	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	May DISC
	@		150MG/VIAL	A077383	002	Jan 27, 2006	May DISC
	@		450MG/VIAL	A077383	003	Jan 27, 2006	May DISC
	@	FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004	May DISC
	@		150MG/VIAL	A076235	002	Oct 14, 2004	May DISC
	@		450MG/VIAL	A076235	003	Oct 14, 2004	May DISC
	@	ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May DISC
	@		150MG/VIAL	A091510	002	May 29, 2012	May DISC
	@		450MG/VIAL	A091510	003	May 29, 2012	May DISC
	@	SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005	May DISC
	@		150MG/VIAL	A076959	002	Mar 18, 2005	May DISC
	@		450MG/VIAL	A076959	003	Mar 18, 2005	May DISC
	@	WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004	May DISC
	@		150MG/VIAL	A076162	002	Oct 14, 2004	May DISC
	@		450MG/VIAL	A076162	003	Oct 14, 2004	May DISC

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA		SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA
----	--	--------------------	-------	---------	-----	--------------	----------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

>D>	AB	CARACO	3.125MG	A077346	004	Sep 05, 2007	Jul CAHN
>D>	AB		6.25MG	A077346	001	Sep 05, 2007	Jul CAHN
>D>	AB		12.5MG	A077346	002	Sep 05, 2007	Jul CAHN
>D>	AB		25MG	A077346	003	Sep 05, 2007	Jul CAHN
>A>	AB	SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Jul CAHN
>A>	AB		6.25MG	A077346	001	Sep 05, 2007	Jul CAHN
>A>	AB		12.5MG	A077346	002	Sep 05, 2007	Jul CAHN
>A>	AB		25MG	A077346	003	Sep 05, 2007	Jul CAHN

CEFACTOR

FOR SUSPENSION; ORAL

CEFACTOR

AB	+	YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD
----	---	-----------------	-------------------	---------	-----	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

	@	ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN
	@		EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN
	@		EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN

FOR SUSPENSION;ORAL							
CEFADROXIL							
	@	EQ 500MG BASE/5ML		A062698	003	Mar 01, 1989	Jan CAHN
	@	EQ 500MG BASE/5ML		A065278	002	Jan 20, 2006	Jan CAHN
<u>CEFAZOLIN SODIUM</u>							
INJECTABLE;INJECTION							
CEFAZOLIN SODIUM							
	@	STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC
<u>CEFTAZIDIME</u>							
INJECTABLE;INJECTION							
FORTAZ							
AP	+	COVIS INJECTABLES	1GM/VIAL	N050578	002	Jul 19, 1985	May CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	May CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	May CAHN
AP	+		500MG/VIAL	N050578	001	Jul 19, 1985	May CAHN
<u>CEFTAZIDIME SODIUM</u>							
INJECTABLE;INJECTION							
FORTAZ IN PLASTIC CONTAINER							
	@	COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr CAHN
<u>CEFTRIAXONE SODIUM</u>							
INJECTABLE;INJECTION							
CEFTRIAXONE							
AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb CAHN
		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014	Apr NEWA
<u>CEFUROXIME SODIUM</u>							
INJECTABLE;IM-IV							
ZINACEF							
AB	+	COVIS INJECTABLES	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr CAHN
INJECTABLE;INJECTION							
ZINACEF							
AP	+	COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr CAHN
ZINACEF IN PLASTIC CONTAINER							
	@	COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN
<u>CELECOXIB</u>							
CAPSULE;ORAL							
CELEBREX							
AB		GD SEARLE	50MG	N020998	004	Dec 15, 2006	May CFTG
AB			100MG	N020998	001	Dec 31, 1998	May CFTG
AB			200MG	N020998	002	Dec 31, 1998	May CFTG
AB	+		400MG	N020998	003	Aug 29, 2002	May CFTG
CELECOXIB							
AB		MYLAN PHARMS INC	50MG	A078857	001	May 30, 2014	May NEWA
AB		TEVA	50MG	A076898	001	May 30, 2014	May NEWA
AB			100MG	A076898	002	May 30, 2014	May NEWA
AB			200MG	A076898	003	May 30, 2014	May NEWA
AB			400MG	A076898	004	May 30, 2014	May NEWA
<u>CEPHALEXIN</u>							
CAPSULE;ORAL							
CEPHALEXIN							
	@	FACTA FARMA	EQ 250MG BASE	A062118	001		Jun DISC
	@		EQ 500MG BASE	A062118	002		Jun DISC
	@	STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar DISC
FOR SUSPENSION;ORAL							
CEPHALEXIN							
	@	FACTA FARMA	EQ 125MG BASE/5ML	A062117	002		Jun DISC
	@		EQ 250MG BASE/5ML	A062117	003		Jun DISC

CERITINIBCAPSULE;ORAL
ZYKADIA

+ NOVARTIS PHARMS CORP 150MG N205755 001 Apr 29, 2014 Apr NEWA

CEVIMELINE HYDROCHLORIDECAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

AB PACK PHARMS LLC 30MG A203775 001 Jun 04, 2014 May NEWA

CHLORDIAZEPOXIDE HYDROCHLORIDECAPSULE;ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE

@	WATSON LABS	5MG	A086383	001			May	DISC
@		10MG	A086294	001			May	DISC
@		25MG	A086382	001			May	DISC

CHLOROTHIAZIDE SODIUMINJECTABLE;INJECTION
CHLOROTHIAZIDE SODIUM

AP MYLAN INSTITUTIONAL EQ 500MG BASE/VIAL A202493 001 Jun 18, 2014 Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION;ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA PADDOCK LLC 4MG/5ML;5MG/5ML;60MG/5ML A204627 001 Apr 29, 2014 Apr NEWA

AA + ZUTRIPRO CYPRESS PHARM 4MG/5ML;5MG/5ML;60MG/5ML N022439 001 Jun 08, 2011 Apr CFTG

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREXCAPSULE, EXTENDED RELEASE;ORAL
TUSSICAPS

>A>		ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007	Jul	CAHN
>A>	+		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007	Jul	CAHN
>D>		HI TECH PHARMA CO	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007	Jul	CAHN
>D>	+		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007	Jul	CAHN

CHLORPROPAMIDETABLET;ORAL
CHLORPROPAMIDE

	@	ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984	Jan	CAHN
	@		100MG	A088812	001	Oct 19, 1984	Jan	CAHN
	@		100MG	A088840	001	Oct 25, 1984	Feb	CAHN
	@		100MG	A088918	001	Oct 16, 1984	Jan	CAHN
AB			100MG	A088921	001	Apr 12, 1985	Jan	CAHN
	@		100MG	A089446	001	Nov 17, 1986	Jan	CAHN
	@		250MG	A088813	001	Oct 19, 1984	Jan	CAHN
	@		250MG	A088919	001	Oct 16, 1984	Jan	CAHN
AB			250MG	A088922	001	Apr 12, 1985	Jan	CAHN
	@		250MG	A089447	001	Nov 17, 1986	Jan	CAHN
	@	TEVA PHARMS USA	250MG	A087353	001		Apr	CAHN
		GLUCAMIDE						
	@	ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jan	CAHN
	@	TEVA PHARMS USA	250MG	A088641	001	Oct 11, 1984	Apr	CAHN

CHLORZOXAZONETABLET;ORAL
CHLORZOXAZONE

@	ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987	Jun	CAHN
@	WATSON LABS	500MG	A040137	001	Aug 09, 1996	May	DISC
@		500MG	A081040	001	Aug 22, 1989	May	DISC

CICLOPIROXCREAM;TOPICAL
CICLOPIROX

AB		TARO	0.77%	A076790	001	Apr 12, 2005	Mar	CMFD
	@		0.77%	A076790	001	Apr 12, 2005	Feb	DISC

GEL;TOPICAL
LOPROX

>A>	AB	+	CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Jul	CAHN
>D>	AB	+	MEDICIS	0.77%	N020519	001	Jul 21, 1997	Jul	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>D>	AB	DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995	Jul	DISC
>A>		@	300MG	A074340	001	Jun 23, 1995	Jul	DISC
>D>	AB		400MG	A074340	002	Jun 23, 1995	Jul	DISC
>A>		@	400MG	A074340	002	Jun 23, 1995	Jul	DISC
>D>	AB	IVAX SUB TEVA PHARMS	200MG	A074424	001	Jul 28, 1995	Jul	DISC
>A>		@	200MG	A074424	001	Jul 28, 1995	Jul	DISC
>D>	AB		300MG	A074424	002	Jul 28, 1995	Jul	DISC
>A>		@	300MG	A074424	002	Jul 28, 1995	Jul	DISC
>D>	AB		400MG	A074424	003	Jul 28, 1995	Jul	DISC
>A>		@	400MG	A074424	003	Jul 28, 1995	Jul	DISC
>D>	AB		800MG	A074424	004	Jul 28, 1995	Jul	DISC
>A>		@	800MG	A074424	004	Jul 28, 1995	Jul	DISC
>D>	AB	MYLAN	800MG	A074246	004	May 17, 1994	Jul	CRLD
>A>	AB	+	800MG	A074246	004	May 17, 1994	Jul	CRLD
>D>	AB	PLIVA	200MG	A074568	001	Feb 27, 1997	Jul	DISC
>A>		@	200MG	A074568	001	Feb 27, 1997	Jul	DISC
>D>	AB		300MG	A074568	002	Feb 27, 1997	Jul	DISC
>A>		@	300MG	A074568	002	Feb 27, 1997	Jul	DISC
>D>	AB		400MG	A074568	003	Feb 27, 1997	Jul	DISC
>A>		@	400MG	A074568	003	Feb 27, 1997	Jul	DISC
>D>		TAGAMET						
>D>	AB	GLAXOSMITHKLINE	200MG	N017920	002		Jul	DISC
>A>		@	200MG	N017920	002		Jul	DISC
>D>	AB		300MG	N017920	003		Jul	DISC
>A>		@	300MG	N017920	003		Jul	DISC
>D>	AB		400MG	N017920	004	Dec 14, 1983	Jul	DISC
>A>		@	400MG	N017920	004	Dec 14, 1983	Jul	DISC
>D>	AB	+	800MG	N017920	005	Apr 30, 1986	Jul	DISC
>A>		@	800MG	N017920	005	Apr 30, 1986	Jul	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

AA		ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
		@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
		@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

AB		BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
AB	+		500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
		CIPROFLOXACIN						
AB		LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
AB			500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT		WATSON LABS INC	EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr	CAHN
----	--	-----------------	--------------	---------	-----	--------------	-----	------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP		PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN
----	--	-----------------	--------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB	CARACO	EQ 10MG BASE	A077032	001	Nov 12, 2004	Jul	CAHN
>D>	AB		EQ 20MG BASE	A077032	002	Nov 12, 2004	Jul	CAHN
>D>	AB		EQ 40MG BASE	A077032	003	Nov 12, 2004	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004	Jul	CAHN
>A>	AB		EQ 20MG BASE	A077032	002	Nov 12, 2004	Jul	CAHN
>A>	AB		EQ 40MG BASE	A077032	003	Nov 12, 2004	Jul	CAHN
		@ WATSON LABS	EQ 10MG BASE	A077034	001	Jun 30, 2005	May	DISC
		@	EQ 20MG BASE	A077034	002	Jun 30, 2005	May	DISC
		@	EQ 40MG BASE	A077034	003	Jun 30, 2005	May	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb	NEWA
----	---------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLINDESSE

+ LUMARA HEALTH INC EQ 2% BASE

N050793	001	Nov 30, 2004	May	CAHN
---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AB	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Apr	CMFD
AT	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jun	CTEC
AB		EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN
	@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

OLUX

AB1	+ DELCOR ASSET	0.05%	N021142	001	May 26, 2000	Jun	CAHN
-----	----------------	-------	---------	-----	--------------	-----	------

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

>D>	AB	CARACO	0.5MG	A075423	001	Apr 27, 2001	Jul	CAHN
>D>	AB		1MG	A075423	002	Apr 27, 2001	Jul	CAHN
>D>	AB		2MG	A075423	003	Apr 27, 2001	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Jul	CAHN
>A>	AB		1MG	A075423	002	Apr 27, 2001	Jul	CAHN
>A>	AB		2MG	A075423	003	Apr 27, 2001	Jul	CAHN

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB	WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr	NEWA
AB		0.2MG/24HR	A090873	002	May 06, 2014	Apr	NEWA
AB		0.3MG/24HR	A090873	003	May 06, 2014	Apr	NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb	NEWA
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb	NEWA

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

>D>	AB	CARACO	0.1MG	A090329	001	Jul 03, 2014	Jul	CAHN
	AB		0.1MG	A090329	001	Jul 03, 2014	Jun	NEWA
>D>	AB		0.2MG	A090329	002	Jul 03, 2014	Jul	CAHN
	AB		0.2MG	A090329	002	Jul 03, 2014	Jun	NEWA
>D>	AB		0.3MG	A090329	003	Jul 03, 2014	Jul	CAHN
	AB		0.3MG	A090329	003	Jul 03, 2014	Jun	NEWA
>A>	AB	SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014	Jul	CAHN
>A>	AB		0.2MG	A090329	002	Jul 03, 2014	Jul	CAHN
>A>	AB		0.3MG	A090329	003	Jul 03, 2014	Jul	CAHN
	@ WATSON LABS	0.3MG	A070963	001	Jul 08, 1986	May	DISC	

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar	NEWA
AB		0.2MG	A202983	002	Apr 02, 2014	Mar	NEWA

CLOPIDOGREL

TABLET;ORAL

CLOPIDOGREL

AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar	NEWA
----	---------------	------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@	WATSON LABS	3.75MG	A071852	001	Feb 09, 1988	May	DISC
@		7.5MG	A071853	001	Feb 09, 1988	May	DISC
@		15MG	A071854	001	Feb 09, 1988	May	DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

>D>	AB	CARACO	25MG	A075713	001	Nov 15, 2002	Jul	CAHN
>D>	AB		50MG	A075713	003	Aug 19, 2005	Jul	CAHN
>D>	AB		100MG	A075713	002	Nov 15, 2002	Jul	CAHN
	AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
	AB		200MG	A076809	001	Dec 16, 2005	Mar	CTEC
	AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar	NEWA
	AB		50MG	A075417	004	Apr 15, 2010	Mar	NEWA
	AB		200MG	A075417	005	Apr 15, 2010	Mar	NEWA
>A>	AB	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Jul	CAHN
>A>	AB		50MG	A075713	003	Aug 19, 2005	Jul	CAHN
>A>	AB		100MG	A075713	002	Nov 15, 2002	Jul	CAHN

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE

AB		LANNETT HOLDINGS INC	15MG	A203046	001	Jun 13, 2014	Jun	NEWA
AB			30MG	A203046	002	Jun 13, 2014	Jun	NEWA
AB			60MG	A203046	003	Jun 13, 2014	Jun	NEWA
AB		ROXANE	15MG	N022402	001	Jul 16, 2009	Jun	CFTG
AB			30MG	N022402	002	Jul 16, 2009	Jun	CFTG
AB	+		60MG	N022402	003	Jul 16, 2009	Jun	CFTG

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP		SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA
AP	+	PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108	002		Apr	CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+		PAR STERILE PRODUCTS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Apr	CAHN
---	--	----------------------	---	---------	-----	--	-----	------

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL

	@	CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb	CAHN
		VAPRISOL IN 5% DEXTROSE	IN PLASTIC CONTAINER					
+		CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb	CAHN

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN		MYLAN SPECLT	10MG/ML	A074209	001	Apr 26, 1994	May	CAHN
	@	WATSON LABS	10MG/ML	A076469	001	Jun 17, 2005	May	DISC
		SOLUTION/DROPS; OPHTHALMIC						
		CROMOLYN SODIUM						
AT	+	AKORN	4%	A074706	001	Apr 29, 1998	Jun	CRLD
		OPTICROM						
	@	ALLERGAN	4%	N018155	001	Oct 03, 1984	Jun	DISC

DALBAVANCIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

DALVANCE

+		DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	May	NEWA
---	--	---------------------	--------------------	---------	-----	--------------	-----	------

DANTROLENE SODIUMCAPSULE; ORAL
DANTRIUM

AB	PAR STERILE PRODUCTS	25MG	N017443	001		Mar	CAHN
AB		50MG	N017443	003		Mar	CAHN
AB	+	100MG	N017443	002		Mar	CAHN
>A>	FOR SUSPENSION; INTRAVENOUS						
>A>	RYANODEX						
>A>	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jul	NEWA
	INJECTABLE; INJECTION						
	DANTRIUM						
AP	+	PAR STERILE PRODUCTS	20MG/VIAL	N018264	001	Apr	CAHN
	REVONTO						
AP	US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA

DAPAGLIFLOZINTABLET; ORAL
FARXIGA

ASTRAZENECA AB

+ 5MG

N202293 001 Jan 08, 2014 Feb CAHN

+ 10MG

N202293 002 Jan 08, 2014 Feb CAHN

BRISTOL MYERS SQUIBB

+ 5MG

N202293 001 Jan 08, 2014 Jan NEWA

+ 10MG

N202293 002 Jan 08, 2014 Jan NEWA

DECITABINE

POWDER; INTRAVENOUS

DECITABINE

+ SUN PHARMA GLOBAL 50MG/VIAL

N205582 001 Jan 28, 2014 Jan NEWA

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

@ WATSON LABS 2GM/VIAL

A076806 002 Mar 31, 2006 May DISC

@ 500MG/VIAL

A076806 001 Mar 31, 2006 May DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

@ ANI PHARMS INC 25MG

A071800 001 Dec 08, 1987 Jan CAHN

@ 50MG

A071801 001 Dec 08, 1987 Jan CAHN

@ 75MG

A071802 001 Dec 08, 1987 Jan CAHN

@ 100MG

A071803 001 May 29, 1997 Feb CAHN

@ 150MG

A071804 001 May 29, 1997 Feb CAHN

DESLORATADINE

SOLUTION; ORAL

CLARINEX

+ MERCK SHARP DOHME 0.5MG/ML

N021300 001 Sep 01, 2004 May CDFR

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB SUN PHARMA GLOBAL 0.01MG/SPRAY

A078271 001 Dec 23, 2013 Jan CMS2

TABLET; ORAL

DESMOPRESSIN ACETATE

AB MYLAN PHARMS INC 0.1MG

A200653 001 Jun 27, 2014 Jun NEWA

AB 0.2MG

A200653 002 Jun 27, 2014 Jun NEWA

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

+ AQUA PHARMS 0.05%

N021978 001 Sep 19, 2006 May CAHN

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

AB VERSAPHARM INC 0.25%

A201005 001 Apr 24, 2014 Apr NEWA

DESVENLAFAXINE

		TABLET, EXTENDED RELEASE;ORAL		DESVENLAFAXINE					
BC		SUN PHARMA GLOBAL	50MG	N205583	001	Jan 28, 2014	Jan	NEWA	
BC	+		100MG	N205583	002	Jan 28, 2014	Jan	NEWA	

DESVENLAFAXINE FUMARATE

		TABLET, EXTENDED RELEASE;ORAL		DESVENLAFAXINE					
	+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun	CTNA	
	+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun	CTNA	
	@	TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun	DISC	
	+		EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun	CTNA	
	@		EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun	DISC	
	+		EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun	CTNA	
		DESVENLAFAXINE FUMARATE							
	+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb	CTEC	
	+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb	CTEC	

DEXCHLORPHENIRAMINE MALEATE

		TABLET;ORAL		DEXCHLORPHENIRAMINE MALEATE					
	@	ANI PHARMS INC	2MG	A088682	001	Jan 17, 1986	Jan	CAHN	

DEXLANSOPRAZOLE

		CAPSULE, DELAYED RELEASE;ORAL		DEXILANT					
		TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun	CAHN	
	+		60MG	N022287	002	Jan 30, 2009	Jun	CAHN	

DEXMETHYLPHENIDATE HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE;ORAL		DEXMETHYLPHENIDATE HYDROCHLORIDE					
AB		TEVA PHARMS USA	15MG	A078908	004	May 19, 2014	May	NEWA	
AB			30MG	A202731	003	May 19, 2014	May	NEWA	
AB		WATSON LABS INC	15MG	A079108	003	May 19, 2014	May	NEWA	

DEXTROAMPHETAMINE SULFATE

		TABLET;ORAL		DEXTROAMPHETAMINE SULFATE					
AA		COREPHARMA	5MG	A090652	001	Mar 07, 2014	Feb	NEWA	
AA			10MG	A090652	002	Mar 07, 2014	Feb	NEWA	

DIAZEPAM

		CONCENTRATE;ORAL		DIAZEPAM					
AA		LANNETT HOLDINGS INC	5MG/ML	A204433	001	Apr 14, 2014	Mar	NEWA	
AA	+	ROXANE	5MG/ML	A071415	001	Apr 03, 1987	Mar	CFTG	
		TABLET;ORAL		DIAZEPAM					
	@	DAVA PHARMS INC	2MG	A070226	001	Sep 26, 1985	Mar	DISC	

DICLOFENAC POTASSIUM

		FOR SOLUTION;ORAL		CAMBIA					
	+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Jan	CAHN	

DICLOFENAC SODIUM

		SOLUTION;TOPICAL		DICLOFENAC SODIUM					
AT		APOTEX INC	1.5%	A202027	001	May 27, 2014	May	NEWA	
AT	+	MALLINCKRODT	1.5%	N020947	001	Nov 04, 2009	May	CFTG	
	+	MALLINCKRODT INC	2%	N204623	001	Jan 16, 2014	Jan	NEWA	

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL
DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	NEWA
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL
BENTYL

AB	+ FOREST LABS INC	10MG	N007409	003	Oct 15, 1984	Apr	CAHN
----	-------------------	------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION
BENTYL

AP	+ FOREST LABS INC	10MG/ML	N008370	001	Oct 15, 1984	Apr	CAHN
----	-------------------	---------	---------	-----	--------------	-----	------

BENTYL PRESERVATIVE FREE

AP	+ FOREST LABS INC	10MG/ML	N008370	002	Oct 15, 1984	Apr	CAHN
----	-------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL
BENTYL

AB	+ FOREST LABS INC	20MG	N007409	001	Oct 15, 1984	Apr	CAHN
----	-------------------	------	---------	-----	--------------	-----	------

DIGOXIN

INJECTABLE;INJECTION
LANOXIN

AP	+ COVIS INJECTABLES	0.25MG/ML	N009330	002		Apr	CAHN
----	---------------------	-----------	---------	-----	--	-----	------

LANOXIN PEDIATRIC

	+ COVIS INJECTABLES	0.1MG/ML	N009330	004		Apr	CAHN
--	---------------------	----------	---------	-----	--	-----	------

TABLET;ORAL

DIGOXIN

>D>	@ CARACO	0.125MG	A076363	001	Jan 31, 2003	Jul	CAHN
-----	----------	---------	---------	-----	--------------	-----	------

>D>	@	0.25MG	A076363	002	Jan 31, 2003	Jul	CAHN
-----	---	--------	---------	-----	--------------	-----	------

>A>	@ SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Jul	CAHN
-----	----------------------	---------	---------	-----	--------------	-----	------

>A>	@	0.25MG	A076363	002	Jan 31, 2003	Jul	CAHN
-----	---	--------	---------	-----	--------------	-----	------

LANOXIN

	COVIS PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Jan	CMFD
--	--------------	----------	---------	-----	--------------	-----	------

		0.1875MG	N020405	003	Sep 30, 1997	Jan	CMFD
--	--	----------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

	@ NESHER PHARMS	120MG	A076563	002	Sep 12, 2006	Mar	DISC
--	-----------------	-------	---------	-----	--------------	-----	------

	@	180MG	A076563	003	Sep 12, 2006	Mar	DISC
--	---	-------	---------	-----	--------------	-----	------

	@	240MG	A076563	004	Sep 12, 2006	Mar	DISC
--	---	-------	---------	-----	--------------	-----	------

	@	300MG	A076563	005	Sep 12, 2006	Mar	DISC
--	---	-------	---------	-----	--------------	-----	------

	@	360MG	A076563	006	Sep 12, 2006	Mar	DISC
--	---	-------	---------	-----	--------------	-----	------

	@	420MG	A076563	001	Sep 12, 2006	Mar	DISC
--	---	-------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

	@ AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Feb	CAHN
--	-----------------	--------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

	@ INTL MEDICATION	50MG/ML	A084094	001		Jun	DISC
--	-------------------	---------	---------	-----	--	-----	------

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
AKPRO

	@ AKORN	0.1%	A074382	001	Sep 29, 1995	Jun	DISC
--	---------	------	---------	-----	--------------	-----	------

DIPIVEFRIN HYDROCHLORIDE

	@ FALCON PHARMS	0.1%	A073636	001	Jun 30, 1994	Jun	DISC
--	-----------------	------	---------	-----	--------------	-----	------

PROPINE

	@ ALLERGAN	0.1%	N018239	001		Jun	DISC
--	------------	------	---------	-----	--	-----	------

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

	@ GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991	Mar	DISC
--	---------------------	------	---------	-----	--------------	-----	------

	@	50MG	A089000	001	Feb 05, 1991	Mar	DISC
--	---	------	---------	-----	--------------	-----	------

	@	75MG	A089001	001	Feb 05, 1991	Mar	DISC
--	---	------	---------	-----	--------------	-----	------

	@ WATSON LABS	50MG	A087160	001	Jun 07, 1996	May	DISC
--	---------------	------	---------	-----	--------------	-----	------

DISULFIRAMTABLET; ORAL
DISULFIRAM

AB	ROXANE	250MG	A202652	001	Feb 05, 2014	Jan	NEWA
AB		500MG	A202652	002	Feb 05, 2014	Jan	NEWA

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

AB	AUROBINDO PHARMA LTD	EQ 250MG VALPROIC ACID	A202419	001	Jun 02, 2014	May	NEWA
AB		EQ 500MG VALPROIC ACID	A202419	002	Jun 02, 2014	May	NEWA

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

	@ WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993	May	DISC
--	---------------	-------------------	---------	-----	--------------	-----	------

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

>D>	AP	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jul	CTEC
>A>			20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jul	CTEC
>D>	AP		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jul	CTEC
>A>			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jul	CTEC
		PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar	NEWA
			80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar	NEWA
			130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar	NEWA
			200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Mar	NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL
DONEPEZIL HYDROCHLORIDE

>A>	AB	JUBILANT GENERICS	5MG	A090768	001	May 31, 2011	Jul	CAHN
>A>	AB		10MG	A090768	002	May 31, 2011	Jul	CAHN
>D>	AB	JUBILANT LIFE	5MG	A090768	001	May 31, 2011	Jul	CAHN
>D>	AB		10MG	A090768	002	May 31, 2011	Jul	CAHN
	AB	MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan	NEWA

DOXAPRAM HYDROCHLORIDEINJECTABLE; INJECTION
DOXAPRAM HYDROCHLORIDE

	@ WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992	May	DISC
--	---------------	---------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATETABLET; ORAL
DOXAZOSIN MESYLATE

AB	ACCORD HLTHCARE	EQ 1MG BASE	A202824	001	Jun 11, 2014	May	NEWA
AB		EQ 2MG BASE	A202824	002	Jun 11, 2014	May	NEWA
AB		EQ 4MG BASE	A202824	003	Jun 11, 2014	May	NEWA
AB		EQ 8MG BASE	A202824	004	Jun 11, 2014	May	NEWA

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

AP	SANDOZ	4MCG/2ML (2MCG/ML)	A091333	001	May 05, 2014	Apr	NEWA
AP		4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan	NEWA

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	Jun	NEWA
AP	PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Feb	CAHN
AP		10MG/VIAL	A063097	001	May 21, 1990	Feb	CAHN
AP		20MG/VIAL	A063097	002	May 21, 1990	Feb	CAHN
AP		50MG/VIAL	A063097	003	May 21, 1990	Feb	CAHN
AP		200MG/100ML	A063336	004	Feb 28, 1995	Feb	CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014	Feb	NEWA
AB		EQ 75MG BASE	A204234	002	Mar 05, 2014	Feb	NEWA
AB		EQ 100MG BASE	A204234	003	Mar 05, 2014	Feb	NEWA
	@ WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000	May	DISC
	@	EQ 100MG BASE	A065041	002	Apr 28, 2000	May	DISC
	ORACEA						
>D>	AB + GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Jul	CTEC
>A>	+	40MG	N050805	001	May 26, 2006	Jul	CTEC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

>D>	@ MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul	CMFD
>A>	AB	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul	CMFD
>D>	@	EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul	CMFD
>A>	AB	EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul	CMFD
	TABLET;ORAL						
>A>	ACTICLATE						
>A>	AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jul	NEWA
>A>		EQ 150MG BASE	N205931	002	Jul 25, 2014	Jul	NEWA
	DOXYCYCLINE HYCLATE						
>D>	@ MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul	CMFD
>A>	AB	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul	CMFD
	TABLET, DELAYED RELEASE;ORAL						
	DORYX						
AB	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	CRLD
	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb	CRLD

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB	AKORN INC	2.5MG	A079217	001	Jun 20, 2014	Jun	NEWA
AB		5MG	A079217	002	Jun 20, 2014	Jun	NEWA
AB		10MG	A079217	003	Jun 20, 2014	Jun	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

NIKKI

AB	LUPIN LTD	3MG;0.02MG	A201661	001	May 27, 2014	May	NEWA
----	-----------	------------	---------	-----	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

>D>	+ BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Jul	CRLD
>A>		3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Jul	CRLD
	SAFYRAL						
>D>	BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Jul	CRLD
>A>	+	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Jul	CRLD

DROXIDOPA

CAPSULE;ORAL

NORTHERA

	CHELSEA THERAPS INC	100MG	N203202	001	Feb 18, 2014	Feb	NEWA
		200MG	N203202	002	Feb 18, 2014	Feb	NEWA
	+	300MG	N203202	003	Feb 18, 2014	Feb	NEWA
	LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014	Jun	CAHN
		200MG	N203202	002	Feb 18, 2014	Jun	CAHN
	+	300MG	N203202	003	Feb 18, 2014	Jun	CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A202949	001	Jun 09, 2014	May	NEWA
AB		EQ 30MG BASE	A202949	002	Jun 09, 2014	May	NEWA
AB		EQ 60MG BASE	A202949	003	Jun 09, 2014	May	NEWA
AB	APOTEX INC	EQ 20MG BASE	A202045	001	Jun 11, 2014	May	NEWA
AB		EQ 30MG BASE	A202045	002	Jun 11, 2014	May	NEWA
AB		EQ 60MG BASE	A202045	003	Jun 11, 2014	May	NEWA

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A203088	001	Jun 11, 2014	May NEWA
AB		EQ 30MG BASE	A203088	002	Jun 11, 2014	May NEWA
AB		EQ 60MG BASE	A203088	003	Jun 11, 2014	May NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE						
AB	ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb NEWA
	JALYN					
AB	+ GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

+	VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb CAHN
---	--------------------	----	---------	-----	--------------	----------

CREAM;TOPICAL

SPECTAZOLE

@	MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan CAHN
---	-----------------	----	---------	-----	--------------	----------

EFINACONAZOLE

SOLUTION;TOPICAL

JUBLIA

+	DOW PHARM	10%	N203567	001	Jun 06, 2014	Jun NEWA
---	-----------	-----	---------	-----	--------------	----------

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

@	WATSON LABS	2.5MG	A075501	001	Aug 22, 2000	May DISC
@		5MG	A075501	002	Aug 22, 2000	May DISC
@		10MG	A075501	003	Aug 22, 2000	May DISC
@		20MG	A075501	004	Aug 22, 2000	May DISC

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	TEVA	30MG/0.3ML (100MG/ML)	A076726	001	Jun 23, 2014	Jun NEWA
AP		40MG/0.4ML (100MG/ML)	A076726	002	Jun 23, 2014	Jun NEWA
AP		60MG/0.6ML (100MG/ML)	A076726	003	Jun 23, 2014	Jun NEWA
AP		80MG/0.8ML (100MG/ML)	A076726	004	Jun 23, 2014	Jun NEWA
AP		100MG/ML (100MG/ML)	A076726	005	Jun 23, 2014	Jun NEWA
AP		120MG/0.8ML (150MG/ML)	A076726	006	Jun 23, 2014	Jun NEWA
AP		150MG/ML (150MG/ML)	A076726	007	Jun 23, 2014	Jun NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>D>	AT	LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Jul CAHN
>A>	AT	TESA PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Jul CAHN

>D> EPINEPHRINE

>D> INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

>D> ADRENALIN

>D>	+	PAR STERILE PRODUCTS	1MG/ML	N204200	001	Dec 07, 2012	Jul CAIN
	+		1MG/ML	N204200	001	Dec 07, 2012	Apr CAHN

>D> INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

>D> ADRENALIN

>D>	+	PAR STERILE PRODUCTS	30MG/30ML (1MG/ML)	N204640	001	Dec 18, 2013	Jul CAIN
	+		30MG/30ML (1MG/ML)	N204640	001	Dec 18, 2013	Apr CAHN

>A> EPINEPHRINE HYDROCHLORIDE

>A> INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

>A> ADRENALIN

>A>	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN
-----	---	----------------------	---------------------------------	---------	-----	--------------	----------

>A> INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

>A> ADRENALIN

>A>	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN
-----	---	----------------------	------------------------------------	---------	-----	--------------	----------

>A> SOLUTION;IV (INFUSION)

>A> EPINEPHRINE

>A>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul NEWA
-----	--	--------------------	---------------------------------	---------	-----	--------------	----------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

@ HOSPIRA	50MG/25ML (2MG/ML)	A 065343	002	Apr 19, 2007	May	DISC
@ MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A 090266	001	Apr 15, 2011	Mar	DISC
@	200MG/100ML (2MG/ML)	A 090266	002	Apr 15, 2011	Mar	DISC

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

@ HOSPIRA	50MG/VIAL	N 050807	001	Sep 15, 2006	Jun	DISC
-----------	-----------	----------	-----	--------------	-----	------

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

@ WATSON LABS	0.5MG	A 087233	001		May	DISC
---------------	-------	----------	-----	--	-----	------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 25MG BASE	A 091002	001	Jun 11, 2014	May	NEWA
AB		EQ 100MG BASE	A 091002	002	Jun 11, 2014	May	NEWA
AB		EQ 150MG BASE	A 091002	003	Jun 11, 2014	May	NEWA
	TARCEVA						
AB	OSI PHARMS	EQ 25MG BASE	N 021743	001	Nov 18, 2004	May	CFTG
AB		EQ 100MG BASE	N 021743	002	Nov 18, 2004	May	CFTG
AB	+	EQ 150MG BASE	N 021743	003	Nov 18, 2004	May	CFTG

ERYTHROMYCIN

SWAB; TOPICAL

ERYTHROMYCIN

@ FOUGERA PHARMS	2%	A 065320	001	Jul 25, 2006	May	DISC
------------------	----	----------	-----	--------------	-----	------

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

+	HOSPIRA	EQ 1GM BASE/VIAL	A 062638	002	Oct 31, 1986	May	CTEC
---	---------	------------------	----------	-----	--------------	-----	------

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROMYCIN STEARATE

@ ANI PHARMS INC	EQ 250MG BASE	A 061461	001		Feb	CAHN
@	EQ 250MG BASE	A 061591	001		Jan	CAHN
@	EQ 500MG BASE	A 061461	002		Feb	CAHN
@	EQ 500MG BASE	A 063179	001	May 15, 1990	Feb	CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	TEVA PHARMS USA	EQ 5MG BASE	A 076765	001	Mar 14, 2012	Feb	CAHN
AB		EQ 10MG BASE	A 076765	002	Mar 14, 2012	Feb	CAHN
AB		EQ 20MG BASE	A 076765	003	Mar 14, 2012	Feb	CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

NEXIUM

ASTRAZENECA LP	EQ 20MG BASE	N 204655	001	Mar 28, 2014	Mar	NEWA
----------------	--------------	----------	-----	--------------	-----	------

ESTRADIOL

GEL; TOPICAL

ESTROGEL

@ ASCEND THERAPS US	0.06%	N 021166	001	Feb 09, 2004	May	CAHN
---------------------	-------	----------	-----	--------------	-----	------

GEL; TRANSDERMAL

DIVIGEL

VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N 022038	001	Jun 04, 2007	Apr	CAHN
	0.1% (0.5GM/PACKET)	N 022038	002	Jun 04, 2007	Apr	CAHN
+	0.1% (1GM/PACKET)	N 022038	003	Jun 04, 2007	Apr	CAHN

GEL, METERED; TRANSDERMAL

ESTROGEL

+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N 021166	002	Feb 09, 2004	May	CAHN
---	-------------------	---------------------------	----------	-----	--------------	-----	------

	SPRAY; TRANSDERMAL							
	EVAMIST							
	+	LUMARA HEALTH INC	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN
	<u>ESTRADIOL CYPIONATE</u>							
	INJECTABLE; INJECTION							
	DEPO-ESTRADIOL							
	+	PHARMACIA AND UPJOHN	5MG/ML	A085470	003		May	CTEC
	ESTRADIOL CYPIONATE							
	@	WATSON LABS	5MG/ML	A085620	001		May	DISC
	<u>ESTRADIOL VALERATE</u>							
	INJECTABLE; INJECTION							
	DELESTROGEN							
AO	+	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr	CAHN
AO	+		20MG/ML	N009402	004		Apr	CAHN
AO	+		40MG/ML	N009402	003		Apr	CAHN
	<u>ESTRADIOL; NORETHINDRONE ACETATE</u>							
	TABLET; ORAL							
	ACTIVELLA							
AB		AMNEAL PHARMS LLC	0.5MG; 0.1MG	N020907	002	Dec 28, 2006	Jun	CAHN
AB	+		1MG; 0.5MG	N020907	001	Nov 18, 1998	Jun	CAHN
	<u>ESTROPIPATE</u>							
	TABLET; ORAL							
	ESTROPIPATE							
	@	WATSON LABS	6MG	A081216	001	Sep 23, 1993	May	DISC
	OGEN 5							
		PHARMACIA AND UPJOHN	6MG	A083220	004		May	CTEC
	ORTHO-EST							
	@	SUN PHARM INDS INC	0.75MG	A089567	001	Feb 27, 1991	Jun	CAHN
	@		1.5MG	A089582	001	Jul 17, 1991	Jun	CAHN
	<u>ESZOPICLONE</u>							
	TABLET; ORAL							
	ESZOPICLONE							
AB		DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014	Mar	NEWA
AB			2MG	A091024	002	Apr 15, 2014	Mar	NEWA
AB			3MG	A091024	003	Apr 15, 2014	Mar	NEWA
AB		GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014	Mar	NEWA
AB			2MG	A091166	002	Apr 15, 2014	Mar	NEWA
AB			3MG	A091166	003	Apr 15, 2014	Mar	NEWA
AB		LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Mar	CMFD
AB			2MG	A091124	002	Sep 13, 2011	Mar	CMFD
AB			3MG	A091124	003	Sep 13, 2011	Mar	CMFD
AB		ORCHID HLTHCARE	1MG	A091113	001	Jun 10, 2014	May	NEWA
AB			2MG	A091113	002	Jun 10, 2014	May	NEWA
AB			3MG	A091113	003	Jun 10, 2014	May	NEWA
AB		ROXANE	1MG	A091153	001	Apr 15, 2014	Mar	NEWA
AB			2MG	A091153	002	Apr 15, 2014	Mar	NEWA
AB			3MG	A091153	003	Apr 15, 2014	Mar	NEWA
AB		TEVA	1MG	A091169	001	May 23, 2011	Jan	CMFD
AB			2MG	A091169	002	May 23, 2011	Jan	CMFD
AB			3MG	A091169	003	May 23, 2011	Jan	CMFD
	<u>ETHINYL ESTRADIOL; ETNOGESTREL</u>							
	RING; VAGINAL							
	NUVARING							
	+	ORGANON USA INC	0.015MG/24HR; 0.12MG/24HR	N021187	001	Oct 03, 2001	Apr	CPOT
	<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>							
	TABLET; ORAL-28							
	LEVONORGESTREL AND ETHINYL ESTRADIOL							
AB1		HAUPT PHARMA	0.02MG; 0.1MG	A201108	001	Feb 05, 2014	Jan	NEWA
	<u>ETHINYL ESTRADIOL; NORELGESTROMIN</u>							
	FILM, EXTENDED RELEASE; TRANSDERMAL							
	ORTHO EVRA							
AB	+	JANSSEN PHARMS	0.035MG/24HR; 0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CFTG
	+		0.035MG/24HR; 0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CPOT

FILM, EXTENDED RELEASE;TRANSDERMAL						
XULANE						
AB	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar NEWA
<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>						
TABLET;ORAL-21						
NORETHIN 1/35E-21						
	@ WATSON LABS	0.035MG;1MG	A071480	001	Apr 12, 1988	May DISC
NORETHINDRONE AND ETHINYL ESTRADIOL						
	@ WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010	May DISC
	@	0.035MG;1MG	A070685	001	Jan 29, 1987	May DISC
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)						
	@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988	May DISC
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)						
	@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991	May DISC
TABLET;ORAL-28						
NORETHIN 1/35E-28						
	@ WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988	May DISC
NORETHINDRONE AND ETHINYL ESTRADIOL						
	@ WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75	A076393	001	Feb 04, 2010	May DISC
		MG,1MG				
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)						
	@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991	May DISC
TABLET, CHEWABLE;ORAL						
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	FAMY CARE LTD	0.025MG;0.8MG	A203371	001	Apr 23, 2014	Apr NEWA
AB	+ WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr CFTG
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>						
TABLET;ORAL-21						
GILDESS 1.5/30						
AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Mar NEWA
GILDESS 1/20						
AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Mar NEWA
LARIN 1.5/30						
AB	NOVAST LABS LTD	0.03MG;1.5MG	A202996	001	Mar 20, 2014	Mar NEWA
LOESTRIN 21 1.5/30						
	@ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		May DISC
LOESTRIN 21 1/20						
	@ WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		May DISC
TABLET;ORAL-28						
LOESTRIN FE 1.5/30						
	@ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		May DISC
LOESTRIN FE 1/20						
	@ WARNER CHILCOTT	0.02MG;1MG	N017354	001		May DISC
MICROGESTIN FE 1.5/30						
AB	+ WATSON LABS	0.03MG;1.5MG	A075548	001	Feb 05, 2001	May CRLD
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>						
TABLET;ORAL-28						
NORGESTIMATE AND ETHINYL ESTRADIOL						
	@ WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A090479	001	Mar 09, 2011	May DISC
		15MG,0.25MG				
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A076626	001	Aug 17, 2006	May DISC
		15MG,0.25MG				
	@	0.035MG;0.25MG	A076627	001	Aug 17, 2006	May DISC
<u>ETHINYL ESTRADIOL; NORGESTREL</u>						
TABLET;ORAL-21						
LOW-OGESTREL-21						
	@ WATSON LABS	0.03MG;0.3MG	A075288	001	Jul 28, 1999	May DISC
TABLET;ORAL-28						
LOW-OGESTREL-28						
	@ WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	May DISC
<u>ETHIODIZED OIL</u>						
OIL;INTRALYMPHATIC, INTRAUTERINE						
ETHIODOL						
+	GUERBET	99%	N009190	001		Apr CMFD
LIPIODOL						
+	GUERBET	99%	N009190	001		Apr CTNA

ETODOLAC

CAPSULE;ORAL		ETODOLAC							
	@ ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb	CAHN		
	@	200MG	A075126	001	Sep 16, 1999	Jan	CAHN		
	@	300MG	A074899	002	Jul 08, 1997	Feb	CAHN		
AB		300MG	A075126	002	Sep 16, 1999	Jan	CAHN		
TABLET, EXTENDED RELEASE;ORAL		ETODOLAC							
AB	ZYDUS PHARMS USA INC	400MG	A091134	001	Jan 23, 2014	May	NEWA		
AB		500MG	A091134	002	Jan 23, 2014	May	NEWA		
AB		600MG	A091134	003	Jan 23, 2014	May	NEWA		

ETOMIDATE

INJECTABLE;INJECTION		ETOMIDATE							
AP	AGILA SPECLTS	2MG/ML	A078289	001	Jan 02, 2009	Feb	CAHN		
>D>	AP	JHP PHARMS LLC	A091297	001	Jun 20, 2012	Jul	CAHN		
>A>	AP	PAR STERILE PRODUCTS	A091297	001	Jun 20, 2012	Jul	CAHN		
>A>	AP	ZYDUS PHARMS USA INC	A202360	001	Jul 18, 2014	Jul	NEWA		

ETOPOSIDE

INJECTABLE;INJECTION		ETOPOSIDE							
	@ PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996	Feb	CAHN		
	@ TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May	DISC		

EXEMESTANE

TABLET;ORAL		EXEMESTANE							
>A>	AB	EIRGEN PHARMA LTD	A200898	001	Jul 28, 2014	Jul	NEWA		

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS		BYDUREON							
+	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Jun	CAHN		
INJECTABLE;SUBCUTANEOUS		BYETTA							
+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar	CAHN		
+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar	CAHN		

FAMOTIDINE

FOR SUSPENSION;ORAL		FAMOTIDINE							
AB	HI-TECH PHARMA CO	40MG/5ML	A201995	001	May 30, 2014	May	NEWA		
INJECTABLE;INJECTION		FAMOTIDINE PRESERVATIVE FREE							
AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Feb	CAHN		

FENOFIBRATE

TABLET;ORAL		FENOGLIDE							
	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb	CAHN		
+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN		
TRIGLIDE		@ SKYEPHARMA AG							
		50MG	N021350	001	May 07, 2005	May	DISC		

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL		FENTANYL-100							
	@ NOVEN	100MCG/HR	A077775	004	Oct 16, 2009	Apr	DISC		
FENTANYL-25		@ NOVEN							
		25MCG/HR	A077775	001	Oct 16, 2009	Apr	DISC		
FENTANYL-50		@ NOVEN							
		50MCG/HR	A077775	002	Oct 16, 2009	Apr	DISC		
FENTANYL-75		@ NOVEN							
		75MCG/HR	A077775	003	Oct 16, 2009	Apr	DISC		

FENTANYL CITRATE

TABLET;BUCCAL

FENTANYL CITRATE

@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	May	DISC
@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	May	DISC
@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	May	DISC
@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	May	DISC
@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	May	DISC

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	Jun	CDFR
@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	Jun	CDFR
@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	Jun	CDFR
@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	Jun	CDFR
@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	Jun	CDFR

FENTORA

CEPHALON

		EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Jun	CTEC
		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Jun	CTEC
+		EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Jun	CTEC
		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Jun	CTEC
		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Jun	CTEC

TABLET;SUBLINGUAL

FENTANYL CITRATE

@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	May	CDFR
@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	May	CDFR
@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	May	CDFR
@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	May	CDFR
@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	May	CDFR

FIDAXOMICIN

TABLET;ORAL

DIFICID

>A>	+	CUBIST PHARMS	200MG	N201699	001	May 27, 2011	Jul	CAHN
>D>	+	OPTIMER PHARMS	200MG	N201699	001	May 27, 2011	Jul	CAHN

FLECAINIDE ACETATE

TABLET;ORAL

TAMBOCOR

>A>	@	CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jul	CAHN
>A>	@		100MG	N018830	001	Oct 31, 1985	Jul	CAHN
>A>	@		150MG	N018830	003	Jun 03, 1988	Jul	CAHN
>A>	@		200MG	N018830	002	Oct 31, 1985	Jul	CAHN
>D>	@	MEDICIS	50MG	N018830	004	Aug 23, 1988	Jul	CAHN
>D>	@		100MG	N018830	001	Oct 31, 1985	Jul	CAHN
>D>	@		150MG	N018830	003	Jun 03, 1988	Jul	CAHN
>D>	@		200MG	N018830	002	Oct 31, 1985	Jul	CAHN

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

+	PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Mar	NEWA
---	-----------------	----------------------	---------	-----	--------------	-----	------

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Apr	DISC
@		400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP	MUSTAFA NEVZAT ILAC	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	May	CAHN
----	---------------------	--------------------	---------	-----	--------------	-----	------

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan	NEWA
AP	LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan	NEWA
AP	UCSF RODIOPHARM	20-300mCi/ML	A203902	001	May 09, 2014	Apr	NEWA
>A>	AP	UIHC PET IMAGING	A203990	001	Aug 06, 2014	Jul	NEWA
	@	WEILL MEDCL COLL	N021768	001	Aug 05, 2004	Feb	DISC

	INJECTABLE; INTRAVENOUS							
	FLUDEOXYGLUCOSE F18							
AP	WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan	NEWA	
	<u>FLUDROCORTISONE ACETATE</u>							
	TABLET; ORAL							
	FLUDROCORTISONE ACETATE							
AB	HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN	
	<u>FLUNISOLIDE</u>							
	AEROSOL, METERED; INHALATION							
	AEROSPAN HFA							
	+	MEDA PHARMS INC	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar	CAHN
	<u>FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE</u>							
	CREAM; TOPICAL							
	NEO-SYNALAR							
	+	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001		Apr	CMFD
	<u>FLUOCINONIDE</u>							
	CREAM; TOPICAL							
	FLUOCINONIDE							
AB	FOUGERA PHARMS INC	0.1%	A200735	001	Jul 14, 2014	Jun	NEWA	
AB	GLENMARK GENERICS	0.1%	A091282	001	Jul 14, 2014	Jun	NEWA	
AB	TARO	0.1%	A200734	001	Jul 14, 2014	Jun	NEWA	
	SOLUTION; TOPICAL							
	FLUOCINONIDE							
AT	G AND W LABS INC	0.05%	A071535	001	Dec 02, 1988	May	CAHN	
	LIDEX							
AT	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Apr	CMFD	
	<u>FLUOXETINE HYDROCHLORIDE</u>							
	CAPSULE; ORAL							
	FLUOXETINE HYDROCHLORIDE							
AB2	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Jan	CAHN	
AB2		EQ 20MG BASE	A076287	002	May 20, 2008	Jan	CAHN	
	TABLET; ORAL							
	SARAFEM							
AB1	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CFTG	
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CFTG	
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CFTG	
	SELFEMRA							
AB1	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan	NEWA	
AB1		EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan	NEWA	
AB1		EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan	NEWA	
	<u>FLUPHENAZINE DECANOATE</u>							
	INJECTABLE; INJECTION							
	FLUPHENAZINE DECANOATE							
AO	PAR STERILE PRODUCTS	25MG/ML	A203732	001	Jul 03, 2014	Jun	NEWA	
	<u>FLUPHENAZINE HYDROCHLORIDE</u>							
	ELIXIR; ORAL							
	FLUPHENAZINE HYDROCHLORIDE							
	@	ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb	CAHN
	<u>FLURAZEPAM HYDROCHLORIDE</u>							
	CAPSULE; ORAL							
	FLURAZEPAM HYDROCHLORIDE							
		MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985	May	CTEC
	+		30MG	A070345	001	Nov 27, 1985	May	CTEC
	@	WATSON LABS	15MG	A071205	001	Nov 25, 1986	May	DISC
	@		30MG	A071068	001	Nov 25, 1986	May	DISC
	@		30MG	A072369	001	Mar 30, 1989	May	DISC
	<u>FLURBIPROFEN</u>							
	TABLET; ORAL							
	FLURBIPROFEN							
>D>	AB	CARACO	50MG	A075058	001	Apr 27, 2001	Jul	CAHN
>D>	AB		100MG	A075058	002	Apr 27, 2001	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001	Jul	CAHN

	TABLET;ORAL						
	FLURBIPROFEN						
>A>	AB	100MG	A075058	002	Apr 27, 2001	Jul	CAHN
	<u>FLUVOXAMINE MALEATE</u>						
	TABLET;ORAL						
	FLUVOXAMINE MALEATE						
>D>	@ CARACO	25MG	A075900	001	Feb 23, 2006	Jul	CAHN
>D>	@	50MG	A075900	002	Feb 23, 2006	Jul	CAHN
>D>	@	100MG	A075900	003	Feb 23, 2006	Jul	CAHN
>A>	@ SUN PHARM INDS INC	25MG	A075900	001	Feb 23, 2006	Jul	CAHN
>A>	@	50MG	A075900	002	Feb 23, 2006	Jul	CAHN
>A>	@	100MG	A075900	003	Feb 23, 2006	Jul	CAHN
	<u>FOLIC ACID</u>						
	TABLET;ORAL						
	FOLIC ACID						
AA	CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan	NEWA
	<u>FOLLITROPIN ALFA/BETA</u>						
	INJECTABLE;SUBCUTANEOUS						
	GONAL-F RFF REDI-JECT						
+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004	May	CTNA
+		450 IU/0.75ML	N021684	002	May 25, 2004	May	CTNA
+		900 IU/1.5ML	N021684	003	May 25, 2004	May	CTNA
	<u>FOMEPIZOLE</u>						
	INJECTABLE;INJECTION						
	FOMEPIZOLE						
	@ MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Jun	DISC
	<u>FONDAPARINUX SODIUM</u>						
	INJECTABLE;SUBCUTANEOUS						
	ARIXTRA						
AP	+ AGI	2.5MG/0.5ML	N021345	001	Dec 07, 2001	May	CAHN
AP	+	5MG/0.4ML	N021345	002	May 28, 2004	May	CAHN
AP	+	7.5MG/0.6ML	N021345	003	May 28, 2004	May	CAHN
AP	+	10MG/0.8ML	N021345	004	May 28, 2004	May	CAHN
	<u>FOSINOPRIL SODIUM</u>						
	TABLET;ORAL						
	FOSINOPRIL SODIUM						
	@ WATSON LABS	10MG	A077531	001	Aug 31, 2006	May	DISC
	@	20MG	A077531	002	Aug 31, 2006	May	DISC
	@	40MG	A077531	003	Aug 31, 2006	May	DISC
	<u>FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE</u>						
	TABLET;ORAL						
	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb	CAIN
AB	+	20MG;12.5MG	A079025	002	Sep 17, 2010	Feb	CAIN
	<u>FOSINOPRIL; HYDROCHLOROTHIAZIDE</u>						
	TABLET;ORAL						
	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
AB	+ EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CRLD
	<u>FOSPHENYTOIN SODIUM</u>						
	INJECTABLE;INJECTION						
	CEREBYX						
AP	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb	CMFD
	FOSPHENYTOIN SODIUM						
AP	AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb	CAHN
AP	AMNEAL PHARMS CO	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Jun	CAHN
	<u>FUROSEMIDE</u>						
	INJECTABLE;INJECTION						
	FUROSEMIDE						
AP	CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan	NEWA

TABLET;ORAL
FUROSEMIDE

>D>	AB	CARACO	20MG	A091258	001	Apr 01, 2014	Jul	CAHN
	AB		20MG	A091258	001	Apr 01, 2014	Mar	NEWA
>D>	AB		40MG	A091258	002	Apr 01, 2014	Jul	CAHN
	AB		40MG	A091258	002	Apr 01, 2014	Mar	NEWA
>D>	AB		80MG	A091258	003	Apr 01, 2014	Jul	CAHN
	AB		80MG	A091258	003	Apr 01, 2014	Mar	NEWA
>A>	AB	SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	Jul	CAHN
>A>	AB		40MG	A091258	002	Apr 01, 2014	Jul	CAHN
>A>	AB		80MG	A091258	003	Apr 01, 2014	Jul	CAHN
		@ WATSON LABS	20MG	A070412	001	Feb 26, 1986	May	DISC
		@	20MG	A070449	001	Nov 22, 1985	May	DISC
		@	20MG	A071379	001	Jan 02, 1987	May	DISC
		@	40MG	A070450	001	Nov 22, 1985	May	DISC
		@	80MG	A070528	001	Jan 07, 1986	May	DISC
		@	80MG	A071594	001	Feb 09, 1988	May	DISC

GABAPENTIN

CAPSULE;ORAL
GABAPENTIN

		@ WATSON LABS	100MG	A075485	003	May 11, 2007	May	DISC
		@	300MG	A075485	002	May 11, 2007	May	DISC
		@	400MG	A075485	001	May 11, 2007	May	DISC

TABLET;ORAL
GABAPENTIN

AB		ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb	CAHN
AB			800MG	A203244	001	Jul 12, 2013	Feb	CAHN

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

		@ YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May	CAHN
		@	EQ 8MG BASE	A077604	002	Feb 06, 2009	May	CAHN
		@	EQ 12MG BASE	A077604	003	Feb 06, 2009	May	CAHN

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Jun	CAHN
		@ WATSON LABS	600MG	A074442	001	Apr 28, 1995	May	DISC

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS
COPAXONE

+		TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan	NEWA
---	--	-----------------	---------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

		@ WATSON LABS	1MG	A077280	001	Feb 03, 2006	May	DISC
		@	2MG	A077280	002	Feb 03, 2006	May	DISC
		@	4MG	A077280	003	Feb 03, 2006	May	DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

>D>	AB	CARACO	5MG	A077820	001	Jul 11, 2006	Jul	CAHN
>D>	AB		10MG	A077820	002	Jul 11, 2006	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	5MG	A077820	001	Jul 11, 2006	Jul	CAHN
>A>	AB		10MG	A077820	002	Jul 11, 2006	Jul	CAHN
		@ WATSON LABS	5MG	A074370	001	Nov 22, 1994	May	DISC
		@	10MG	A074370	002	Nov 22, 1994	May	DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	CARACO	2.5MG;250MG	A077620	001	Jan 11, 2008	Jul	CAHN
>D>	AB		2.5MG;500MG	A077620	002	Jan 11, 2008	Jul	CAHN
>D>	AB		5MG;500MG	A077620	003	Jan 11, 2008	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	2.5MG;250MG	A077620	001	Jan 11, 2008	Jul	CAHN
>A>	AB		2.5MG;500MG	A077620	002	Jan 11, 2008	Jul	CAHN

TABLET;ORAL		GLIPIZIDE AND METFORMIN HYDROCHLORIDE						
>A>	AB	5MG;500MG		A 077620	003	Jan 11, 2008	Jul	CAHN
<u>GLYCOPYRROLATE</u>								
TABLET;ORAL		GLYCOPYRROLATE						
AA	STASON PHARMS	1MG		A 091182	001	Feb 03, 2014	Jan	NEWA
AA		2MG		A 091182	002	Feb 03, 2014	Jan	NEWA
AA	VINTAGE PHARMS	1MG		A 090020	001	Oct 19, 2011	Feb	CAHN
AA		2MG		A 090020	002	Oct 19, 2011	Feb	CAHN
<u>GRANISETRON HYDROCHLORIDE</u>								
INJECTABLE;INJECTION		GRANISETRON HYDROCHLORIDE						
	@ SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A 078808	001	Apr 29, 2008	Jun	CAHN
AP	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A 078835	001	Jun 30, 2008	Jun	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A 078835	002	Jun 30, 2008	Jun	CAHN
>D>	SOLUTION;ORAL							
>D>	GRANISETRON HYDROCHLORIDE							
>D>	+	PEDIATR	EQ 2MG BASE/10ML	A 078334	001	Feb 28, 2008	Jul	CTNA
		GRANISOL						
>A>	@	PEDIATR	EQ 2MG BASE/10ML	A 078334	001	Feb 28, 2008	Jul	DISC
>A>	+		EQ 2MG BASE/10ML	A 078334	001	Feb 28, 2008	Jul	CTNA
<u>GUANABENZ ACETATE</u>								
TABLET;ORAL		GUANABENZ ACETATE						
	ANI PHARMS INC	EQ 4MG BASE		A 074149	001	Apr 07, 1995	Jan	CAHN
	@	EQ 4MG BASE		A 074267	001	Jun 01, 1994	Mar	CAHN
	+	EQ 8MG BASE		A 074149	002	Apr 07, 1995	Jan	CAHN
	@	EQ 8MG BASE		A 074267	002	Jun 01, 1994	Mar	CAHN
<u>HALOBETASOL PROPIONATE</u>								
OINTMENT;TOPICAL		HALOBETASOL PROPIONATE						
AB	TARO	0.05%		A 076994	001	Dec 16, 2004	Apr	CMFD
<u>HALOPERIDOL DECANOATE</u>								
INJECTABLE;INJECTION		HALOPERIDOL DECANOATE						
AO	AGILA SPECLTS	EQ 50MG BASE/ML		A 075440	001	Feb 28, 2000	Feb	CMFD
AO		EQ 100MG BASE/ML		A 075440	002	Feb 28, 2000	Feb	CMFD
<u>HEPARIN SODIUM</u>								
INJECTABLE;INJECTION		HEPARIN SODIUM						
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N 017029	020	Mar 31, 2011	Mar	NEWA
	+	HOSPIRA	5,000 UNITS/ML	A 088100	001	Apr 28, 1983	Mar	CRLD
	+	PFIZER	1,000 UNITS/ML	N 201370	001	Jul 21, 2011	Mar	CRLD
	+		5,000 UNITS/ML	N 201370	002	Jul 21, 2011	Mar	CRLD
	+		10,000 UNITS/ML	N 201370	003	Jul 21, 2011	Mar	CRLD
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A 202957	001	Jun 12, 2014	Jun	NEWA
AP			5,000 UNITS/ML	A 202733	001	Jun 12, 2014	Jun	NEWA
AP			5,000 UNITS/ML	A 202957	002	Jun 12, 2014	Jun	NEWA
AP			10,000 UNITS/ML	A 203198	001	Jun 12, 2014	Jun	NEWA
AP			20,000 UNITS/ML	A 203198	002	Jun 12, 2014	Jun	NEWA
		HEPARIN SODIUM IN PLASTIC CONTAINER						
AP	+	FRESENIUS KABI USA	1,000 UNITS/ML	N 017029	013	Dec 05, 1985	Jun	CTEC
	+		1,000 UNITS/ML	N 017029	013	Dec 05, 1985	Mar	CTEC
AP	+		10,000 UNITS/ML	N 017029	015	Dec 05, 1985	Jun	CTEC
	+		10,000 UNITS/ML	N 017029	015	Dec 05, 1985	Mar	CTEC
AP	+		20,000 UNITS/ML	N 017029	016	Dec 05, 1985	Jun	CTEC
	+		20,000 UNITS/ML	N 017029	016	Dec 05, 1985	Mar	CTEC
		HEPARIN SODIUM PRESERVATIVE FREE						
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N 017029	019	Nov 22, 2010	Mar	NEWA
	+	HOSPIRA	10,000 UNITS/ML	A 089522	001	May 04, 1987	Mar	CTEC
	+	PFIZER	1,000 UNITS/ML	N 201370	004	Jul 21, 2011	Mar	CRLD
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A 202732	001	Jun 12, 2014	Jun	NEWA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@ WATSON LABS	25MG	A 084504	001		May	DISC
@	50MG	A 084503	001		May	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	CARACO	12.5MG	A 090651	001	Apr 07, 2014	Jul	CAHN
	AB		12.5MG	A 090651	001	Apr 07, 2014	Mar	NEWA
>A>	AB	SUN PHARM INDS INC	12.5MG	A 090651	001	Apr 07, 2014	Jul	CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	CARACO	12.5MG	A 040857	001	May 30, 2008	Jul	CAHN
>D>	AB		25MG	A 040810	001	Mar 27, 2007	Jul	CAHN
>D>	AB		50MG	A 040810	002	Mar 27, 2007	Jul	CAHN
>A>	AB	SCIEGEN PHARMS INC	25MG	A 203018	001	Jul 23, 2014	Jul	NEWA
>A>	AB		50MG	A 203018	002	Jul 23, 2014	Jul	NEWA
>A>	AB	SUN PHARM INDS INC	12.5MG	A 040857	001	May 30, 2008	Jul	CAHN
>A>	AB		25MG	A 040810	001	Mar 27, 2007	Jul	CAHN
>A>	AB		50MG	A 040810	002	Mar 27, 2007	Jul	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;150MG	A 203072	001	May 09, 2014	Apr	NEWA
AB		12.5MG;300MG	A 203072	002	May 09, 2014	Apr	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@ WATSON LABS	12.5MG;50MG	A 200180	001	Jan 12, 2011	May	DISC
@	12.5MG;100MG	A 200180	002	Jan 12, 2011	May	DISC
@	25MG;100MG	A 200180	003	Jan 12, 2011	May	DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN	15MG;250MG	A 070265	002	Jan 23, 1986	Mar	CMS1
-------	------------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPIROL

COVIS PHARMA SARL	12.5MG;EQ 25MG TARTRATE	N 021956	001	Aug 28, 2006	Jun	CAHN
	12.5MG;EQ 50MG TARTRATE	N 021956	002	Aug 28, 2006	Jun	CAHN
+	12.5MG;EQ 100MG TARTRATE	N 021956	003	Aug 28, 2006	Jun	CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	HERITAGE PHARMS INC	12.5MG;7.5MG	A 202150	001	Mar 07, 2014	Apr	CAHN
AB		12.5MG;15MG	A 202150	002	Mar 07, 2014	Apr	CAHN
AB		25MG;15MG	A 202150	003	Mar 07, 2014	Apr	CAHN
AB	INDICUS PHARMA	12.5MG;7.5MG	A 202150	001	Mar 07, 2014	Feb	NEWA
AB		12.5MG;15MG	A 202150	002	Mar 07, 2014	Feb	NEWA
AB		25MG;15MG	A 202150	003	Mar 07, 2014	Feb	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;40MG	A 070947	002	Mar 04, 1987	Mar	CMS1
----	-------	-----------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS	25MG;25MG	A 087398	001		May	DISC
---------------	-----------	----------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB	BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000	Feb	CFTG
AB		12.5MG;80MG	N021162	002	Nov 17, 2000	Feb	CFTG
AB	+	25MG;80MG	N021162	003	Apr 19, 2004	Feb	CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;40MG	A203010	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG;80MG	A203010	002	Feb 25, 2014	Feb	NEWA
AB		25MG;80MG	A203010	003	Feb 25, 2014	Feb	NEWA
>A>	AB	LUPIN LTD	A091351	001	Aug 07, 2014	Jul	NEWA
>A>	AB		A091351	002	Aug 07, 2014	Jul	NEWA
>A>	AB		A091351	003	Aug 07, 2014	Jul	NEWA
AB	MYLAN PHARMS INC	12.5MG;40MG	A091648	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG;80MG	A091648	002	Feb 25, 2014	Feb	NEWA
AB		25MG;80MG	A091648	003	Feb 25, 2014	Feb	NEWA
AB	TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG;80MG	A201192	002	Feb 25, 2014	Feb	NEWA
AB		25MG;80MG	A201192	003	Feb 25, 2014	Feb	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	PADDOCK LLC	5MG/5ML; 60MG/5ML	A204658	001	Apr 29, 2014	Apr	NEWA
AA	+	CYPRESS PHARM	N022442	001	Jun 08, 2011	Apr	CFTG

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

@ TARO

1%

A086155 001

Mar DISC

LOTION; TOPICAL

ALA-CORT

@ CROWN LABS

1%

A083201 001

Mar DISC

NUTRACORT

@ DOW PHARM

1%

A080443 003

Mar DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

@ VINTAGE PHARMS 1%;1%

A089440 001 May 17, 1988 Feb CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

AB	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Apr	CFTG
AB		12MG	N021217	002	Mar 01, 2010	Apr	CFTG
AB		16MG	N021217	003	Mar 01, 2010	Apr	CFTG

HYDROMORPHONE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014	Apr	NEWA
AB		12MG	A202144	002	May 12, 2014	Apr	NEWA
AB		16MG	A202144	003	May 12, 2014	Apr	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

@ WATSON LABS 200MG

A040133 001 Nov 30, 1995 May DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+	LUMARA HEALTH INC	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	May	CAHN
---	-------------------	-----------------------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Jun	CAHN
AB		25MG	A040899	002	Jun 10, 2008	Jun	CAHN
AB		50MG	A040899	003	Jun 10, 2008	Jun	CAHN
	@ WATSON LABS	10MG	A081149	001	Mar 18, 1994	May	DISC
	@	25MG	A081150	001	Mar 18, 1994	May	DISC

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@	50MG	A081151	001	Mar 18, 1994	May DISC
---	------	---------	-----	--------------	----------

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	EMCURE PHARMS USA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Jun CPOT
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jun CPOT
	@ WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991	May DISC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

AP	+ ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG
AP		IBANDRONATE SODIUM				
	SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

IBUPROFEN

TABLET;ORAL

IBUPROFEN

@ WATSON LABS	400MG	A070436	001	Aug 21, 1985	May DISC
@	600MG	A070437	001	Aug 21, 1985	May DISC

>A> IDELALISIB

>A> TABLET;ORAL

>A> ZYDELIG

>A>	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Jul NEWA
>A>	+	150MG	N205858	002	Jul 23, 2014	Jul NEWA

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

AB	STRIDES ARCOLAB LTD	5%	A202002	001	Jun 24, 2014	Jun NEWA
----	---------------------	----	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

>A>	@ AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Jul CAHN
>A>	@	2.5MG	A075201	002	Dec 04, 1998	Jul CAHN
>D>	@ CADISTA PHARMS	1.25MG	A075201	001	Dec 04, 1998	Jul CAHN
>D>	@	2.5MG	A075201	002	Dec 04, 1998	Jul CAHN
	@ WATSON LABS	1.25MG	A074585	001	Sep 26, 1996	May DISC
	@	2.5MG	A074585	002	Sep 26, 1996	May DISC

INDOMETHACIN

CAPSULE;ORAL

INDOCIN

@ IROKO PHARMS LLC	25MG	N016059	001		May CAHN
@	50MG	N016059	002		May CAHN

INDOMETHACIN

AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Jun CAHN
AB		50MG	A091401	002	Mar 28, 2013	Jun CAHN

TIVORBEX

	IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb NEWA
+		40MG	N204768	002	Feb 24, 2014	Feb NEWA

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

AB	MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar NEWA
----	------------------	------	---------	-----	--------------	----------

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMANPOWDER; INHALATION
AFREZZAMANNKIND 4 UNITS/INH
+ 8 UNITS/INHN022472 001 Jun 27, 2014 Jun NEWA
N022472 002 Jun 27, 2014 Jun NEWAIPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDEAN + MYLAN SPECLT 0.02%
SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

A074755 001 Jan 10, 1997 Mar CAHN

AB MYLAN SPECLT 0.021MG/SPRAY
AB 0.042MG/SPRAYA075552 001 Mar 31, 2003 May CAHN
A075553 001 Mar 31, 2003 May CAHNIRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDEAP MUSTAFA NEVZAT ILAC 40MG/2ML (20MG/ML)
AP 100MG/5ML (20MG/ML)A090393 002 May 13, 2011 May CAHN
A090393 003 May 13, 2011 May CAHNISOFLURANELIQUID; INHALATION
ISOFLURANE

AN PIRAMAL ENT 99.9%

A074502 001 Jun 27, 1995 Feb CAHN

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR+ AUXILIUM PHARMS LLC 40MG
TABLET; ORAL
ISOSORBIDE DINITRATE

N019790 001 Sep 02, 1988 Apr CAHN

>A> AB HIKMA INTL PHARMS 5MG
>A> AB 10MG
>A> AB 20MG
>A> AB 30MG
>D> AB HIKMA PHARMS LLC 5MG
>D> AB 10MG
>D> AB 20MG
>D> AB 30MGA086067 001 Oct 29, 1987 Jul CAHN
A086066 001 Oct 29, 1987 Jul CAHN
A088088 001 Nov 02, 1987 Jul CAHN
A040591 001 Jan 10, 2007 Jul CAHN
A086067 001 Oct 29, 1987 Jul CAHN
A086066 001 Oct 29, 1987 Jul CAHN
A088088 001 Nov 02, 1987 Jul CAHN
A040591 001 Jan 10, 2007 Jul CAHNTABLET; SUBLINGUAL
ISOSORBIDE DINITRATE>A> @ HIKMA INTL PHARMS 2.5MG
>A> @ 5MG
>D> @ HIKMA PHARMS LLC 2.5MG
>D> @ 5MGA086054 001 Oct 29, 1987 Jul CAHN
A086055 001 Nov 02, 1987 Jul CAHN
A086054 001 Oct 29, 1987 Jul CAHN
A086055 001 Nov 02, 1987 Jul CAHNTABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE DINITRATE>D> AB + CARACO 40MG
>A> AB + SUN PHARM INDS INC 40MGA040009 001 Dec 30, 1998 Jul CAHN
A040009 001 Dec 30, 1998 Jul CAHNISOSORBIDE MONONITRATETABLET; ORAL
ISOSORBIDE MONONITRATE

AB ANI PHARMS INC 20MG

A075147 001 Nov 27, 1998 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE@ ACTAVIS ELIZABETH 30MG
@ 60MGA075306 001 Dec 31, 1998 May DISC
A075306 002 Dec 31, 1998 May DISCISRADIPINECAPSULE; ORAL
ISRADIPINEAB MIKAH PHARMA 2.5MG
@ 2.5MG
AB 5MG
@ 5MG
AB WATSON LABS 2.5MG
2.5MG
AB + 5MG
+ 5MGA077169 001 Apr 24, 2006 May CMFD
A077169 001 Apr 24, 2006 Feb DISC
A077169 002 Apr 24, 2006 May CMFD
A077169 002 Apr 24, 2006 Feb DISC
A077317 001 Jan 05, 2006 May CTEC
A077317 001 Jan 05, 2006 Feb CTEC
A077317 002 Jan 05, 2006 May CTEC
A077317 002 Jan 05, 2006 Feb CTEC

KETAMINE HYDROCHLORIDEINJECTABLE; INJECTION
KETALAR

AP	+	PAR STERILE PRODUCTS	EQ 10MG BASE/ML	N016812	001		Apr	CAHN
AP	+		EQ 50MG BASE/ML	N016812	002		Apr	CAHN
AP	+		EQ 100MG BASE/ML	N016812	003		Apr	CAHN

KETOCONAZOLEAEROSOL, FOAM; TOPICAL
EXTINA

AT	+	DELCOR ASSET CORP	2%	N021738	001	Jun 12, 2007	Jun	CAHN
AB	+	JANSSEN PHARMS	200MG	N018533	001		Mar	CAHN

KETOROLAC TROMETHAMINEINJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

>A>	AP	AGILA SPECLTS	15MG/ML	A201155	001	Aug 04, 2014	Jul	NEWA
>A>	AP		30MG/ML	A201155	002	Aug 04, 2014	Jul	NEWA
>D>	AP	+ BEDFORD	15MG/ML	A075222	001	Apr 26, 1999	Jul	DISC
>A>		@	15MG/ML	A075222	001	Apr 26, 1999	Jul	DISC
>D>	AP	+	30MG/ML	A075222	002	Apr 26, 1999	Jul	DISC
>A>		@	30MG/ML	A075222	002	Apr 26, 1999	Jul	DISC
>D>	AP	+	30MG/ML	A075228	001	Apr 26, 1999	Jul	DISC
>A>		@	30MG/ML	A075228	001	Apr 26, 1999	Jul	DISC
		@ HIKMA MAPLE	15MG/ML	A075299	001	Nov 03, 1999	Jun	DISC
		@	15MG/ML	A075772	001	Jul 21, 2004	Jun	DISC
		@	30MG/ML	A075299	002	Nov 03, 1999	Jun	DISC
		@	30MG/ML	A075772	002	Jul 21, 2004	Jun	DISC
>D>	AP	HOSPIRA	15MG/ML	A074802	001	Jun 05, 1997	Jul	CRLD
>A>	AP	+	15MG/ML	A074802	001	Jun 05, 1997	Jul	CRLD
>D>	AP		30MG/ML	A074802	002	Jun 05, 1997	Jul	CRLD
>A>	AP	+	30MG/ML	A074802	002	Jun 05, 1997	Jul	CRLD
>D>	AP	SANDOZ	15MG/ML	A076271	001	Oct 06, 2004	Jul	DISC
>A>		@	15MG/ML	A076271	001	Oct 06, 2004	Jul	DISC
>D>	AP	SUN PHARMA GLOBAL	15MG/ML	A078737	001	Oct 06, 2008	Jul	DISC
>A>		@	15MG/ML	A078737	001	Oct 06, 2008	Jul	DISC
>D>	AP		30MG/ML	A078737	002	Oct 06, 2008	Jul	DISC
>A>		@	30MG/ML	A078737	002	Oct 06, 2008	Jul	DISC
		@ WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007	Jun	DISC

SOLUTION/DROPS; OPHTHALMIC
ACUVAIL

AT	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Jan	CFTG
AT		@ AKORN	0.45%	A203376	001	Feb 10, 2014	Feb	DISC
AT			0.45%	A203376	001	Feb 10, 2014	Jan	NEWA

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDESOLUTION; IRRIGATION
OMIDRIA

+	OMEROS	EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388	001	May 30, 2014	Jun	CPOT
+		EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	May	NEWA

LAMIVUDINE; ZIDOVUDINETABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

AB		HETERO LABS LTD V	150MG; 300MG	A203259	001	Feb 03, 2014	Jan	NEWA
----	--	-------------------	--------------	---------	-----	--------------	-----	------

LAMOTRIGINETABLET; ORAL
LAMOTRIGINE

		@ ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	May	DISC
		@	100MG	A078669	002	Apr 08, 2011	May	DISC
		@	150MG	A078669	003	Apr 08, 2011	May	DISC
		@	200MG	A078669	004	Apr 08, 2011	May	DISC
>A>		@ PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009	Jul	DISC
>A>	BX		25MG	A078310	001	Feb 04, 2009	Jul	CAHN
>A>		@	100MG	A078310	002	Feb 04, 2009	Jul	DISC
>A>	BX		100MG	A078310	002	Feb 04, 2009	Jul	CAHN

TABLET;ORAL

LAMOTRIGINE

>A>	@	150MG	A078310	003	Feb 04, 2009	Jul	DISC	
>A>	BX	150MG	A078310	003	Feb 04, 2009	Jul	CAHN	
>A>	@	200MG	A078310	004	Feb 04, 2009	Jul	DISC	
>A>	BX	200MG	A078310	004	Feb 04, 2009	Jul	CAHN	
>D>	BX	UPSHER SMITH	25MG	A078310	001	Feb 04, 2009	Jul	CAHN
>D>	BX		100MG	A078310	002	Feb 04, 2009	Jul	CAHN
>D>	BX		150MG	A078310	003	Feb 04, 2009	Jul	CAHN
>D>	BX		200MG	A078310	004	Feb 04, 2009	Jul	CAHN

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

AB	ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	May	NEWA	
AB		25MG	A201168	002	Jun 12, 2014	May	NEWA	
>A>	AB	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jul	CAHN
>A>	AB		25MG	A200220	002	Feb 28, 2011	Jul	CAHN
>D>	AB	JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Jul	CAHN
>D>	AB		25MG	A200220	002	Feb 28, 2011	Jul	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

>A>	AB	IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jul	CAHN
>A>	AB		50MG	A200828	002	Jul 15, 2013	Jul	CAHN
>A>	AB		100MG	A200828	003	Jul 15, 2013	Jul	CAHN
>A>	AB		200MG	A200828	004	Jul 15, 2013	Jul	CAHN
>D>	AB	WATSON LABS INC	25MG	A200828	001	Jul 15, 2013	Jul	CAHN
>D>	AB		50MG	A200828	002	Jul 15, 2013	Jul	CAHN
>D>	AB		100MG	A200828	003	Jul 15, 2013	Jul	CAHN
>D>	AB		200MG	A200828	004	Jul 15, 2013	Jul	CAHN

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL

LANSOPRAZOLE

@	ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Jan	CAHN
@		30MG	A078730	002	Oct 15, 2010	Jan	CAHN

LETROZOLE

TABLET;ORAL

LETROZOLE

@	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	May	DISC
---	----------------	-------	---------	-----	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE;INJECTION

LUPRON DEPOT

@	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	May	DISC
+		3.75MG	N020011	002	Oct 26, 1995	May	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	MYLAN SPECLT	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	May	CAHN
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	May	CAHN
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	May	CAHN
AN	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Jun	CMFD
	@	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	May	DISC
AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Jun	CMFD
	@	EQ 0.021% BASE	A077756	001	Apr 09, 2008	May	DISC
AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Jun	CMFD
	@	EQ 0.042% BASE	A077756	002	Apr 09, 2008	May	DISC

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

@	SANDOZ	1GM	A077324	004	Jan 15, 2009	Jun	DISC
@		250MG	A077324	001	Jan 15, 2009	Jun	DISC
@		500MG	A077324	002	Jan 15, 2009	Jun	DISC
@		750MG	A077324	003	Jan 15, 2009	Jun	DISC
AB	VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Feb	CAHN
AB		500MG	A077319	002	Mar 20, 2009	Feb	CAHN
AB		750MG	A077319	003	Mar 20, 2009	Feb	CAHN
@	WATSON LABS INC	1GM	A078797	001	Jan 15, 2009	May	DISC

	TABLET, EXTENDED RELEASE;ORAL							
	LEVETIRACETAM							
AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Feb	CAHN	
AB		750MG	A201464	002	May 25, 2012	Feb	CAHN	
	<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>							
	SOLUTION;ORAL							
	LEVOCETIRIZINE DIHYDROCHLORIDE							
AA	L PERRIGO CO	2.5MG/5ML	A091263	001	Nov 07, 2011	Jan	CAHN	
	TABLET;ORAL							
	LEVOCETIRIZINE DIHYDROCHLORIDE							
	@ SANDOZ	5MG	A090486	001	Mar 26, 2013	May	DISC	
	<u>LEVOFLOXACIN</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	IQUIX							
	@ SANTEN	1.5%	N021571	001	Mar 01, 2004	Jun	DISC	
	LEVOFLOXACIN							
AT	WATSON LABS INC	0.5%	A076826	001	Feb 10, 2011	May	CAHN	
	<u>LEVOLEUCOVORIN CALCIUM</u>							
	SOLUTION;IV (INFUSION)							
	FUSILEV							
	@ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Jun	DISC	
	<u>LEVONORGESTREL</u>							
	IMPLANT;IMPLANTATION							
	JADELLE							
	@ POPULATION COUNCIL	75MG/IMPLANT	N020544	001	Nov 01, 1996	Jun	CTNA	
	<u>LEVORPHANOL TARTRATE</u>							
	TABLET;ORAL							
	LEVORPHANOL TARTRATE							
	+ ROXANE	2MG	A074278	001	Mar 31, 2000	Feb	CRLD	
	<u>LIDOCAINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	LIDOCAINE HYDROCHLORIDE							
AP	AGILA SPECLTS	2%	A202242	001	Apr 11, 2014	Mar	NEWA	
	LIDOPEN							
	@ MERIDIAN MEDCL TECHN	10%	N017549	001		Mar	DISC	
	XYLOCAINE PRESERVATIVE FREE							
	@ FRESENIUS KABI USA	10%	N016801	003		Jun	DISC	
	+	10%	N016801	003		Mar	CTEC	
	JELLY;TOPICAL							
	ANESTACON							
	@ BANNER PHARMACAPS	2%	A080429	001		Jun	CAHN	
	@ DSM PHARMS INC	2%	A080429	001		Jan	CAHN	
	GLYDO							
AT	SAGENT PHARMS	2%	A201094	001	Apr 28, 2014	Apr	NEWA	
	LIDOCAINE HYDROCHLORIDE							
AT	WATSON LABS INC	2%	A040837	001	Mar 23, 2011	May	CAHN	
	SOLUTION;TOPICAL							
	LIDOCAINE HYDROCHLORIDE							
AT	IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb	NEWA	
	SYSTEM;INTRADERMAL							
	ZINGO							
	POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Mar	CMFD	
	<u>LIDOCAINE; PRILOCAINE</u>							
	CREAM;TOPICAL							
	EMLA							
AB	+ WATSON LABS INC	2.5%;2.5%	N019941	001	Dec 30, 1992	May	CAHN	
	<u>LIOTHYRONINE SODIUM</u>							
	INJECTABLE;INJECTION							
	TRIOSTAT							
AP	+ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr	CAHN	

LISINOPRILTABLET; ORAL
LISINOPRIL

>A>	AB	HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002	Jul	CAHN
>A>	AB		5MG	A076063	002	Jul 01, 2002	Jul	CAHN
>A>	AB		10MG	A076063	003	Jul 01, 2002	Jul	CAHN
>A>	AB		20MG	A076063	004	Jul 01, 2002	Jul	CAHN
>A>	AB		30MG	A076063	006	Jun 27, 2003	Jul	CAHN
>A>	AB		40MG	A076063	005	Jul 01, 2002	Jul	CAHN
>D>	AB	HIKMA PHARMS	2.5MG	A076063	001	Jul 01, 2002	Jul	CAHN
>D>	AB		5MG	A076063	002	Jul 01, 2002	Jul	CAHN
>D>	AB		10MG	A076063	003	Jul 01, 2002	Jul	CAHN
>D>	AB		20MG	A076063	004	Jul 01, 2002	Jul	CAHN
>D>	AB		30MG	A076063	006	Jun 27, 2003	Jul	CAHN
>D>	AB		40MG	A076063	005	Jul 01, 2002	Jul	CAHN

LITHIUM CARBONATETABLET, EXTENDED RELEASE; ORAL
LITHOBID

AB	+	ANI PHARMS INC	300MG	N018027	001		Jun	CAHN
----	---	----------------	-------	---------	-----	--	-----	------

LORAZEPAMINJECTABLE; INJECTION
ATIVAN

AP	+	HIKMA MAPLE	2MG/ML	N018140	001		Jun	CAHN
AP	+		4MG/ML	N018140	002		Jun	CAHN

TABLET; ORAL
LORAZEPAM

		@ WATSON LABS	1MG	A071118	001	Jul 24, 1986	May	DISC
--	--	---------------	-----	---------	-----	--------------	-----	------

LOTEPREDNOL ETABONATEGEL; OPHTHALMIC
LOTEMAX

	+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb	CAHN
--	---	---------------------	------	---------	-----	--------------	-----	------

LULICONAZOLECREAM; TOPICAL
LUZU

	+	MEDICIS	1%	N204153	001	Nov 14, 2013	Jan	CRLD
--	---	---------	----	---------	-----	--------------	-----	------

MAGNESIUM SULFATEINJECTABLE; INJECTION
MAGNESIUM SULFATE

AP	+	HOSPIRA	500MG/ML	A075151	001	Apr 25, 2000	Jun	CRLD
----	---	---------	----------	---------	-----	--------------	-----	------

MALATHIONLOTION; TOPICAL
MALATHION

		@ MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Mar	DISC
--	--	--------------------	------	---------	-----	--------------	-----	------

MEBENDAZOLETABLET, CHEWABLE; ORAL
MEBENDAZOLE

	+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Jun	CAHN
--	---	-------------------	-------	---------	-----	--------------	-----	------

MECHLORETHAMINE HYDROCHLORIDEGEL; TOPICAL
VALCHLOR

	+	ACELION PHARMS LTD	EQ 0.016% BASE	N202317	001	Aug 23, 2013	Jun	CPOT
--	---	--------------------	----------------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDETABLET; ORAL
MECLIZINE HYDROCHLORIDE

		@ WATSON LABS	25MG	A085740	001		May	DISC
--	--	---------------	------	---------	-----	--	-----	------

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

@ USL PHARMA	10MG	A 088484	001	Jul 26, 1984	Mar	DISC
--------------	------	----------	-----	--------------	-----	------

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	VINTAGE PHARMS LLC	250MG	A 091608	001	Jun 02, 2014	May	NEWA
----	--------------------	-------	----------	-----	--------------	-----	------

MELOXICAM

TABLET; ORAL

MELOXICAM

>D>	AB	CARACO	7.5MG	A 077937	001	Jul 19, 2006	Jul	CAHN
>D>	AB		15MG	A 077937	002	Jul 19, 2006	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	7.5MG	A 077937	001	Jul 19, 2006	Jul	CAHN
>A>	AB		15MG	A 077937	002	Jul 19, 2006	Jul	CAHN
		@ YABAO PHARM	7.5MG	A 077933	001	Jul 19, 2006	May	CAHN
		@	15MG	A 077933	002	Jul 19, 2006	May	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

>D>	AB	DR REDDYS LABS LTD	5MG	A 090048	001	Apr 14, 2010	Jul	DISC
>A>		@	5MG	A 090048	001	Apr 14, 2010	Jul	DISC
	AB		5MG	A 090048	001	Apr 14, 2010	Jun	CMFD
>D>	AB		10MG	A 090048	002	Apr 14, 2010	Jul	DISC
>A>		@	10MG	A 090048	002	Apr 14, 2010	Jul	DISC
	AB		10MG	A 090048	002	Apr 14, 2010	Jun	CMFD
		NAMENDA						
>D>	AB	FOREST LABS	5MG	N 021487	001	Oct 16, 2003	Jul	CTEC
>A>			5MG	N 021487	001	Oct 16, 2003	Jul	CTEC
	AB		5MG	N 021487	001	Oct 16, 2003	Jun	CTEC
>D>	AB	+	10MG	N 021487	002	Oct 16, 2003	Jul	CTEC
>A>		+	10MG	N 021487	002	Oct 16, 2003	Jul	CTEC
	AB	+	10MG	N 021487	002	Oct 16, 2003	Jun	CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

@ WATSON LABS	50MG/ML	A 073444	001	Mar 17, 1992	May	DISC
---------------	---------	----------	-----	--------------	-----	------

@	100MG/ML	A 073445	001	Mar 17, 1992	May	DISC
---	----------	----------	-----	--------------	-----	------

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

@ INTL MEDICATION	10MG/ML	A 081309	001	Aug 30, 1993	Mar	DISC
-------------------	---------	----------	-----	--------------	-----	------

@ WATSON LABS	10MG/ML	A 073443	001	Mar 17, 1992	May	DISC
---------------	---------	----------	-----	--------------	-----	------

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

>D>	AA	CARACO	50MG	A 040446	001	Aug 08, 2002	Jul	CAHN
>D>	AA		100MG	A 040446	002	Aug 08, 2002	Jul	CAHN
>A>	AA	SUN PHARM INDS INC	50MG	A 040446	001	Aug 08, 2002	Jul	CAHN
>A>	AA		100MG	A 040446	002	Aug 08, 2002	Jul	CAHN
		@ WATSON LABS	50MG	A 040186	001	Jun 30, 1997	May	DISC
		@	100MG	A 040186	002	Jun 30, 1997	May	DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPIVACAINE HYDROCHLORIDE

@ WATSON LABS	1%	A 088769	001	Nov 20, 1984	May	DISC
---------------	----	----------	-----	--------------	-----	------

@	2%	A 088770	001	Nov 20, 1984	May	DISC
---	----	----------	-----	--------------	-----	------

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIXAN

+	NOVA LABS LTD	20MG/ML	N 205919	001	Apr 28, 2014	Apr	NEWA
---	---------------	---------	----------	-----	--------------	-----	------

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

+	FOREST LABS INC	1GM	N 021252	002	Nov 05, 2004	Apr	CAHN
@		500MG	N 021252	001	Jan 05, 2001	Apr	CAHN

MESNAINJECTABLE; INTRAVENOUS
MESNA

>A>	AP	AGILA SPECLTS	100MG/ML	A203364	001	Jul 18, 2014	Jul	NEWA
-----	----	---------------	----------	---------	-----	--------------	-----	------

METAPROTERENOL SULFATESOLUTION; INHALATION
METAPROTERENOL SULFATE

AN	+	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	May	CAHN
AN	+		0.6%	A070804	001	Aug 17, 1987	May	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		ATLAS PHARMS LLC	1GM	A076033	003	Jan 24, 2002	May	CAHN
AB			500MG	A076033	001	Jan 24, 2002	May	CAHN
AB			850MG	A076033	002	Jan 24, 2002	May	CAHN
>D>	AB	CARACO	1GM	A075967	003	Jan 29, 2002	Jul	CAHN
>D>	AB		500MG	A075967	001	Jan 29, 2002	Jul	CAHN
>D>	AB		850MG	A075967	002	Jan 29, 2002	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	1GM	A075967	003	Jan 29, 2002	Jul	CAHN
>A>	AB		500MG	A075967	001	Jan 29, 2002	Jul	CAHN
>A>	AB		850MG	A075967	002	Jan 29, 2002	Jul	CAHN
		@ WATSON LABS	1GM	A075979	003	Jan 24, 2002	May	DISC
		@	500MG	A075979	001	Jan 24, 2002	May	DISC
		@	850MG	A075979	002	Jan 24, 2002	May	DISC

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

+		SALIX PHARMS INC	1GM	N021748	002	Jun 03, 2005	Feb	CTEC
			500MG	N021748	001	Jun 03, 2005	Feb	CTEC
+		SANTARUS INC	1GM	N021748	002	Jun 03, 2005	Mar	CAHN
			500MG	N021748	001	Jun 03, 2005	Mar	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb	NEWA
AB			850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB		SB PHARMCO	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	Apr	CFTG
AB	+		1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	Apr	CFTG
AB			500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	Apr	CFTG
AB			500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	Apr	CFTG

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

AB		TEVA	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr	NEWA
AB			1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr	NEWA
AB			500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr	NEWA
AB			500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr	NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

		ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr	CAHN
+			1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr	CAHN
			500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr	CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB		ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan	CAHN
AB			50MG	A040001	002	Jun 30, 1993	Jan	CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

>D>	AB	CARACO	5MG	A040870	001	Sep 25, 2007	Jul	CAHN
>D>	AB		10MG	A040870	002	Sep 25, 2007	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007	Jul	CAHN

TABLET; ORAL
METHIMAZOLE

>A>	AB		10MG	A040870	002	Sep 25, 2007	Jul	CAHN
	AB	VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb	CAHN
	AB		10MG	A202068	002	Mar 07, 2012	Feb	CAHN

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

>A>	AA	HIKMA INTL PHARMS	500MG	A085159	001		Jul	CAHN
>A>	AA		750MG	A085123	001		Jul	CAHN
>D>	AA	HIKMA PHARMS	750MG	A085123	001		Jul	CAHN
>D>	AA	HIKMA PHARMS LLC	500MG	A085159	001		Jul	CAHN
		@ WATSON LABS	500MG	A085180	001		May	DISC
		@	750MG	A085192	001		May	DISC
		ROBAXIN						
AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004		Apr	CAHN
		ROBAXIN-750						
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Apr	CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION
BREVITAL SODIUM

+	PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002		Apr	CAHN
	@	5GM/VIAL	N011559	003		Apr	CAHN
+		200MG/VIAL	N011559	004	Dec 21, 2012	Apr	CAHN
+		500MG/VIAL	N011559	001		Apr	CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS
RASUVO

>A>		MEDAC PHARMA INC	7.5MG/0.15ML	N205776	001	Jul 10, 2014	Jul	NEWA
>A>			10MG/0.20ML	N205776	002	Jul 10, 2014	Jul	NEWA
>A>			12.5MG/0.25ML	N205776	003	Jul 10, 2014	Jul	NEWA
>A>			15MG/0.30ML	N205776	004	Jul 10, 2014	Jul	NEWA
>A>			17.5MG/0.35ML	N205776	005	Jul 10, 2014	Jul	NEWA
>A>			20MG/0.4ML	N205776	006	Jul 10, 2014	Jul	NEWA
>A>			22.5MG/0.45ML	N205776	007	Jul 10, 2014	Jul	NEWA
>A>			25MG/0.5ML	N205776	008	Jul 10, 2014	Jul	NEWA
>A>			27.5MG/0.55ML	N205776	009	Jul 10, 2014	Jul	NEWA
>A>			30MG/0.6ML	N205776	010	Jul 10, 2014	Jul	NEWA

METHOXSALLEN

CAPSULE; ORAL
METHOXSALLEN

AB		STRIDES ARCOLAB LTD	10MG	A202687	001	Jun 05, 2014	May	NEWA
		OXSORALEN-ULTRA						
AB	+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	May	CTEC

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
METHSCOPOLAMINE BROMIDE

AA		VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb	CAHN
AA			5MG	A040624	002	Dec 28, 2006	Feb	CAHN

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB		MYLAN	250MG	A070076	002	Apr 18, 1985	Apr	CMS1
----	--	-------	-------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION
METHERGINE

AP	+	EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb	CAHN
AB	+	EDISON THERAPS LLC	0.2MG	N006035	003		Feb	CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb	NEWA
AB		10MG	A091159	002	Mar 12, 2014	Feb	NEWA
AB		20MG	A091159	003	Mar 12, 2014	Feb	NEWA
AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Jun	CAHN
AB		10MG	A090710	002	Mar 15, 2012	Jun	CAHN
AB		20MG	A090710	003	Mar 15, 2012	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	WATSON LABS	20MG	A040410	001	Feb 09, 2001	May	DISC
---	-------------	------	---------	-----	--------------	-----	------

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

>D>	AB	CARACO	25MG	A076670	001	Jan 15, 2004	Jul	CAHN
>D>	AB		50MG	A074644	001	Dec 10, 1996	Jul	CAHN
>D>	AB		100MG	A074644	002	Dec 10, 1996	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Jul	CAHN
>A>	AB		50MG	A074644	001	Dec 10, 1996	Jul	CAHN
>A>	AB		100MG	A074644	002	Dec 10, 1996	Jul	CAHN

METRONIDAZOLE

GEL; VAGINAL

METRONIDAZOLE

	VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar	NEWA
	WATSON LABS INC	1.3%	N205223	001	Mar 24, 2014	Jun	CAHN

TABLET; ORAL

METRONIDAZOLE

AB	UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan	NEWA
AB		500MG	A203458	002	Jan 22, 2014	Jan	NEWA
	@ VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
	@	500MG	A070039	001	Jan 29, 1985	Apr	CAHN
	@ WATSON LABS	250MG	N018764	001	Sep 17, 1982	May	DISC
	@	500MG	N018764	002	Dec 20, 1982	May	DISC
AB	WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar	CAHN

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+	BIOALLIANCE PHARMA	50MG	N022404	001	Apr 16, 2010	Apr	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	DELCOR ASSET	0.25%; 81.35%; 15%	N021026	001	Feb 16, 2006	Jun	CAHN
---	--------------	--------------------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	BEDFORD LABS	EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr	CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr	CAHN

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

	PALADIN THERAP	50MG	N204684	001	Mar 19, 2014	Mar	NEWA
--	----------------	------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

>A>	AB	CNTY LINE PHARMS	EQ 75MG BASE	A063067	002	Sep 15, 1999	Jul	CAHN
>A>	AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jul	CAHN
>D>	AB	MEDICIS	EQ 75MG BASE	A063067	002	Sep 15, 1999	Jul	CAHN
	AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	May	CAHN
>D>	AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jul	CAHN
	AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	May	CAHN
		MINOCYCLINE HYDROCHLORIDE						
>D>	AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Jul	CAHN
>D>	AB		EQ 75MG BASE	A090867	002	May 13, 2013	Jul	CAHN

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB		EQ 100MG BASE	A090867	003	May 13, 2013	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	EQ 50MG BASE	A090867	001	May 13, 2013	Jul	CAHN
>A>	AB		EQ 75MG BASE	A090867	002	May 13, 2013	Jul	CAHN
>A>	AB		EQ 100MG BASE	A090867	003	May 13, 2013	Jul	CAHN

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

>D>	AB	CARACO	7.5MG	A076541	004	Apr 22, 2004	Jul	CAHN
>D>	AB		15MG	A076541	001	Apr 22, 2004	Jul	CAHN
>D>	AB		30MG	A076541	002	Apr 22, 2004	Jul	CAHN
>D>	AB		45MG	A076541	003	Apr 22, 2004	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	7.5MG	A076541	004	Apr 22, 2004	Jul	CAHN
>A>	AB		15MG	A076541	001	Apr 22, 2004	Jul	CAHN
>A>	AB		30MG	A076541	002	Apr 22, 2004	Jul	CAHN
>A>	AB		45MG	A076541	003	Apr 22, 2004	Jul	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

@ ACTAVIS ELIZABETH

15MG

A076689 001 Aug 31, 2005 Jun CAHN

@

30MG

A076689 002 Aug 31, 2005 Jun CAHN

@

45MG

A076689 003 Aug 31, 2005 Jun CAHN

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION

MIVACURIUM CHLORIDE

@ AGILA SPECLTS

EQ 2MG BASE/ML

A078562 001 Apr 30, 2009 Feb CAHN

MODAFINIL

TABLET;ORAL

MODAFINIL

AB APOTEX INC

100MG

A077667 001 Feb 03, 2014 Jan NEWA

AB

200MG

A077667 002 Feb 03, 2014 Jan NEWA

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

ASMANEX HFA

MERCK SHARP DOHME

0.10MG/INH

N205641 001 Apr 25, 2014 Apr NEWA

+

0.20MG/INH

N205641 002 Apr 25, 2014 Apr NEWA

POWDER;INHALATION

ASMANEX TWISTHALER

MERCK SHARP DOHME

0.11MG/INH

N021067 002 Feb 01, 2008 Mar CAHN

+

0.22MG/INH

N021067 001 Mar 30, 2005 Mar CAHN

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED;NASAL

NASONEX

+ MERCK SHARP DOHME

EQ 0.05MG BASE/SPRAY

N020762 001 Oct 01, 1997 May CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AVINZA

AB2 KING PHARMS LLC

30MG

N021260 001 Mar 20, 2002 Mar CAHN

AB2

45MG

N021260 005 Dec 18, 2008 Mar CAHN

AB2

60MG

N021260 002 Mar 20, 2002 Mar CAHN

AB2

75MG

N021260 006 Dec 18, 2008 Mar CAHN

AB2

90MG

N021260 003 Mar 20, 2002 Mar CAHN

AB2 +

120MG

N021260 004 Mar 20, 2002 Mar CAHN

INJECTABLE;INJECTION

MORPHINE SULFATE

@ WATSON LABS

0.5MG/ML

A073373 001 Sep 30, 1991 May DISC

@

0.5MG/ML

A073375 001 Sep 30, 1991 May DISC

@

1MG/ML

A073374 001 Sep 30, 1991 May DISC

@

1MG/ML

A073376 001 Sep 30, 1991 May DISC

SOLUTION;ORAL

MORPHINE SULFATE

AA CARACO

10MG/5ML

A201011 001 Feb 05, 2014 Jan NEWA

AA

20MG/5ML

A201011 002 Feb 05, 2014 Jan NEWA

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
EMBEDA

	ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009	Mar	CAHN
		30MG;1.2MG	N022321	002	Aug 13, 2009	Mar	CAHN
		50MG;2MG	N022321	003	Aug 13, 2009	Mar	CAHN
+		60MG;2.4MG	N022321	004	Aug 13, 2009	Mar	CAHN
		80MG;3.2MG	N022321	005	Aug 13, 2009	Mar	CAHN
		100MG;4MG	N022321	006	Aug 13, 2009	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

AVELOX

AB	+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb	CFTG
		MOXIFLOXACIN HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb	NEWA
AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb	NEWA
AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb	NEWA
AB		TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar	NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar	NEWA
AP			EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar	NEWA
AP		ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan	CPOT
AP			EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan	CPOT
AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb	CAHN
AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb	CAHN
AP			EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb	NEWA
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS						
		EVZIO						
+		KALEO INC	0.4MG/0.4ML	N205787	001	Apr 03, 2014	Apr	NEWA

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARGINIQ

>A>		@ PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014	Jul	DISC
>A>		@	10MG;20MG	N205777	002	Jul 23, 2014	Jul	DISC
>A>		@	20MG;40MG	N205777	003	Jul 23, 2014	Jul	DISC

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALBALON

		@ ALLERGAN	0.1%	A080248	001		Jun	DISC
		NAPHAZOLINE HYDROCHLORIDE						
+		AKORN INC	0.1%	A083590	001		Jun	CRLD

NAPROXEN

TABLET;ORAL

NAPROXEN

		@ DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb	DISC
		@	375MG	A074410	002	Apr 28, 1995	Feb	DISC
		@	500MG	A074410	003	Apr 28, 1995	Feb	DISC
		@ WATSON LABS	250MG	A074457	001	May 31, 1995	May	DISC
		@	375MG	A074457	002	May 31, 1995	May	DISC
		@	500MG	A074457	003	May 31, 1995	May	DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

		@ WATSON LABS	EQ 250MG BASE	A074455	001	May 31, 1995	May	DISC
		@	EQ 500MG BASE	A074455	002	May 31, 1995	May	DISC

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan	CAIN
AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan	CAIN
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	CAIN

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

AB	STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan	CAHN
TABLET, EXTENDED RELEASE; ORAL							
NEVIRAPINE							
AB	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar	NEWA
AB	SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar	NEWA
VIRAMUNE XR							
AB	+ BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	CFTG

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB	LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar	NEWA
AB		500MG	A090860	001	Mar 20, 2014	Mar	NEWA
AB		750MG	A090892	001	Mar 20, 2014	Mar	NEWA
AB	SUN PHARMA GLOBAL	1GM	A200484	002	Apr 23, 2014	Apr	NEWA
AB		500MG	A200484	001	Apr 23, 2014	Apr	NEWA
AB		750MG	A201273	001	Apr 23, 2014	Apr	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

AB	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	Apr	CAHN
AB	+	30MG	N019488	002	Dec 21, 1988	Apr	CAHN
NICARDIPINE HYDROCHLORIDE							
AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan	CAHN
AB		20MG	A074540	001	Oct 28, 1996	Jan	CAHN
AB		30MG	A074439	002	Dec 10, 1996	Jan	CAHN
AB		30MG	A074540	002	Oct 28, 1996	Jan	CAHN
	@ WATSON LABS	20MG	A074670	001	Oct 28, 1996	May	DISC
	@	30MG	A074670	002	Oct 28, 1996	May	DISC
CAPSULE, EXTENDED RELEASE; ORAL							
CARDENE SR							
+	CHIESI USA INC	30MG	N020005	001	Feb 21, 1992	Apr	CAHN
	@	45MG	N020005	002	Feb 21, 1992	Apr	CAHN
+		60MG	N020005	003	Feb 21, 1992	Apr	CAHN

INJECTABLE; INJECTION

CARDENE

AP	+ CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr	CAHN
NICARDIPINE HYDROCHLORIDE							
AP	LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan	CAHN
INJECTABLE; INTRAVENOUS							
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER							
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CAHN
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER							
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CAHN
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER							
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr	CAHN
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER							
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2	TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar	NEWA
AB2		60MG	A203126	002	Apr 03, 2014	Mar	NEWA
AB2		90MG	A203126	003	Apr 03, 2014	Mar	NEWA

NIMODIPINE

	CAPSULE;ORAL							
	NIMODIPINE							
AB	THEPHARMANETWORK LLC	30MG		A090103	001	Apr 07, 2014	Mar	NEWA

NITROGLYCERIN

	FILM, EXTENDED RELEASE;TRANSDERMAL							
	NITROGLYCERIN							
	@ KREMERS URBAN PHARMS	0.2MG/HR		A075115	001	Aug 10, 2004	May	DISC
	@	0.4MG/HR		A075115	002	Aug 10, 2004	May	DISC
	OINTMENT;INTRA-ANAL							
	RECTIV							
+	FOREST LABS INC	0.4%		N021359	001	Jun 21, 2011	Apr	CAHN

NIZATIDINE

	CAPSULE;ORAL							
	NIZATIDINE							
	@ ANI PHARMS INC	150MG		A075461	001	Jul 08, 2002	Jan	CAHN
AB		150MG		A075668	001	Sep 12, 2002	Jan	CAHN
	@	300MG		A075461	002	Jul 08, 2002	Jan	CAHN
AB		300MG		A075668	002	Sep 12, 2002	Jan	CAHN

>D> NORFLOXACIN

>D>	TABLET;ORAL							
>D>	NOROXIN							
>D>	+ MERCK	400MG		N019384	002	Oct 31, 1986	Jul	DISC
>A>	@	400MG		N019384	002	Oct 31, 1986	Jul	DISC

NORTRIPTYLINE HYDROCHLORIDE

	SOLUTION;ORAL							
	AVENTYL							
	@ RANBAXY	EQ 10MG BASE/5ML		N014685	001		Apr	CTNA
	AVENTYL HYDROCHLORIDE							
	@ RANBAXY	EQ 10MG BASE/5ML		N014685	001		Apr	DISC
	NORTRIPTYLINE HYDROCHLORIDE							
AA	+ PHARM ASSOC	EQ 10MG BASE/5ML		A075606	001	Aug 28, 2000	Apr	CRLD

NYSTATIN

	CREAM;TOPICAL							
	MYCOSTATIN							
>D>	@ BRISTOL MYERS SQUIBB	100,000 UNITS/GM		A060575	001		Jul	CAHN
>A>	@ DELCOR ASSET CORP	100,000 UNITS/GM		A060575	001		Jul	CAHN
	OINTMENT;TOPICAL							
	MYCOSTATIN							
>A>	@ DELCOR ASSET CORP	100,000 UNITS/GM		A060571	001		Jul	CAHN
>D>	@ WESTWOOD SQUIBB	100,000 UNITS/GM		A060571	001		Jul	CAHN
	POWDER;TOPICAL							
	MYCOSTATIN							
>D>	@ BRISTOL MYERS SQUIBB	100,000 UNITS/GM		A060578	001		Jul	CAHN
>A>	@ DELCOR ASSET CORP	100,000 UNITS/GM		A060578	001		Jul	CAHN
	SUSPENSION;ORAL							
	MYCOSTATIN							
>D>	@ APOTHECON	100,000 UNITS/ML		A061533	001		Jul	CAHN
>A>	@ DELCOR ASSET CORP	100,000 UNITS/ML		A061533	001		Jul	CAHN
	TABLET;ORAL							
	MYCOSTATIN							
>D>	@ BRISTOL MYERS SQUIBB	500,000 UNITS		A060574	001		Jul	CAHN
>A>	@ DELCOR ASSET CORP	500,000 UNITS		A060574	001		Jul	CAHN
	TABLET;VAGINAL							
	MYCOSTATIN							
>D>	@ BRISTOL MYERS SQUIBB	100,000 UNITS		A060577	001		Jul	CAHN
>A>	@ DELCOR ASSET CORP	100,000 UNITS		A060577	001		Jul	CAHN

OLANZAPINE

	TABLET, ORALLY DISINTEGRATING;ORAL							
	OLANZAPINE							
AB	AUROBINDO PHARMA LTD	5MG		A203708	001	May 15, 2014	Apr	NEWA
AB		10MG		A203708	002	May 15, 2014	Apr	NEWA
AB		15MG		A203708	003	May 15, 2014	Apr	NEWA
AB		20MG		A203708	004	May 15, 2014	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>A>	AB	JUBILANT GENERICS	5MG	A200221	001	Sep 12, 2012	Jul CAHN
>A>	AB		10MG	A200221	002	Sep 12, 2012	Jul CAHN
>A>	AB		15MG	A200221	003	Sep 12, 2012	Jul CAHN
>A>	AB		20MG	A200221	004	Sep 12, 2012	Jul CAHN
>D>	AB	JUBILANT ORGANOSYS	5MG	A200221	001	Sep 12, 2012	Jul CAHN
>D>	AB		10MG	A200221	002	Sep 12, 2012	Jul CAHN
>D>	AB		15MG	A200221	003	Sep 12, 2012	Jul CAHN
>D>	AB		20MG	A200221	004	Sep 12, 2012	Jul CAHN
	AB	MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr NEWA
	AB		10MG	A202285	002	May 12, 2014	Apr NEWA
	AB		15MG	A202285	003	May 12, 2014	Apr NEWA
	AB		20MG	A202285	004	May 12, 2014	Apr NEWA

>A> OLODATEROL HYDROCHLORIDE

>A>		SPRAY, METERED;INHALATION					
>A>		STRIVERDI RESPIMAT					
>A>	+	BOEHRINGER INGELHEIM	EQ 2.5MG BASE/INH	N203108	001	Jul 31, 2014	Jul NEWA

OMEGA-3-ACID ETHYL ESTERS

		CAPSULE;ORAL					
		LOVAZA					
AB	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar CFTG
		OMEGA-3-ACID ETHYL ESTERS					
AB		PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun NEWA
AB		TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar NEWA
		OMTRYG					
	+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Apr NEWA

OMEGA-3-CARBOXYLIC ACIDS

		CAPSULE;ORAL					
		EPANOVA					
	+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

		CAPSULE;ORAL					
		ZEGERID					
AB		SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb CAHN
AB	+		40MG;1.1GM	N021849	002	Feb 27, 2006	Feb CAHN
		FOR SUSPENSION;ORAL					
		OMEPRAZOLE AND SODIUM BICARBONATE					
		@ PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jun DISC
		@	40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jun DISC
		ZEGERID					
AB		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
			20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jun CTEC
	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN

ONDANSETRON HYDROCHLORIDE

		INJECTABLE;INJECTION					
		ONDANSETRON HYDROCHLORIDE					
		@ LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan DISC
		TABLET;ORAL					
		ONDANSETRON HYDROCHLORIDE					
AB		IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan NEWA
AB			EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION
ORPHENADRINE CITRATE
@ WATSON LABS

30MG/ML

A 087062 001

May DISC

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

@ ISTITUTO BIO ITA SPA EQ 1GM BASE/VIAL
@ EQ 2GM BASE/VIAL
@ EQ 125MG BASE/VIAL
@ EQ 250MG BASE/VIAL
@ EQ 500MG BASE/VIAL

A 062798 001 Dec 11, 1995 Feb CAHN
A 062798 002 Dec 11, 1995 Feb CAHN
A 062798 003 Dec 11, 1995 Feb CAHN
A 062798 004 Dec 11, 1995 Feb CAHN
A 062798 005 Dec 11, 1995 Feb CAHN

OXALIPLATIN

INJECTABLE; IV (INFUSION)
OXALIPLATIN

AP JIANGSU HENGRUI MED 50MG/10ML (5MG/ML)
AP 100MG/20ML (5MG/ML)
AP SUN PHARMA GLOBAL 50MG/10ML (5MG/ML)
AP 100MG/20ML (5MG/ML)

A 203869 001 Jun 18, 2014 Jun NEWA
A 203869 002 Jun 18, 2014 Jun NEWA
A 202922 001 Apr 08, 2014 Mar NEWA
A 202922 002 Apr 08, 2014 Mar NEWA

OXANDROLONE

TABLET; ORAL
OXANDRIN

AB CREALTA PHARMS LLC 2.5MG
AB + 10MG

N 013718 001 Jan CAHN
N 013718 002 Nov 05, 2001 Jan CAHN

OXAPROZIN

TABLET; ORAL
OXAPROZIN

>D> AB CARACO 600MG
>A> AB SUN PHARM INDS INC 600MG
@ WATSON LABS 600MG

A 075844 001 Jan 03, 2002 Jul CAHN
A 075844 001 Jan 03, 2002 Jul CAHN
A 075848 001 Feb 09, 2001 May DISC

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

@ IVAX SUB TEVA PHARMS 10MG
@ 15MG
@ 30MG
@ WATSON LABS 10MG
@ 15MG
@ 30MG

A 070943 001 Aug 03, 1987 Apr DISC
A 070944 001 Aug 03, 1987 Apr DISC
A 070945 001 Aug 03, 1987 Apr DISC
A 072952 001 Sep 28, 1990 May DISC
A 072953 001 Sep 28, 1990 May DISC
A 072954 001 Sep 28, 1990 May DISC

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

@ ANI PHARMS INC 150MG
@ 300MG
@ 600MG

A 078005 001 Dec 11, 2007 Jan CAHN
A 078005 002 Dec 11, 2007 Jan CAHN
A 078005 003 Dec 11, 2007 Jan CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL
OXYBUTYNIN

AB BARR LABS DIV TEVA 3.9MG/24HR
OXYTROL
AB + WATSON LABS (UTAH) 3.9MG/24HR

A 090526 001 Mar 04, 2014 Feb NEWA
N 021351 002 Feb 26, 2003 Feb CFTG

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

>A> AB LANNETT HOLDINGS INC 5MG

A 203823 001 Aug 01, 2014 Jul NEWA

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA COASTAL PHARMS 100MG/5ML
AA LEHIGH VALLEY 5MG/5ML

A 204092 001 Jun 05, 2014 May NEWA
N 200535 002 Aug 22, 2013 Jun NEWA

TABLET; ORAL

OXECTA

ACURA PHARMS INC 5MG
7.5MG

N 202080 001 Jun 17, 2011 May CAHN
N 202080 002 Jun 17, 2011 May CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	15MG	A076636	001	Feb 06, 2004	Jul	CAHN
>A>	AB		30MG	A076636	002	Feb 06, 2004	Jul	CAHN
>D>	AB	ACTAVIS TOTOWA	15MG	A076636	001	Feb 06, 2004	Jul	CAHN
>D>	AB		30MG	A076636	002	Feb 06, 2004	Jul	CAHN
	AB	AMNEAL PHARMS	5MG	A203638	001	Jun 03, 2014	May	NEWA
	AB		10MG	A203638	002	Jun 03, 2014	May	NEWA
	AB		15MG	A203638	003	Jun 03, 2014	May	NEWA
	AB		20MG	A203638	004	Jun 03, 2014	May	NEWA
	AB		30MG	A203638	005	Jun 03, 2014	May	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A202946	001	Jun 27, 2014	Jun	NEWA
AB			7.5MG	A202946	002	Jun 27, 2014	Jun	NEWA
AB			10MG	A202946	003	Jun 27, 2014	Jun	NEWA
AB			15MG	A202946	004	Jun 27, 2014	Jun	NEWA
AB			20MG	A202946	005	Jun 27, 2014	Jun	NEWA
AB			30MG	A202946	006	Jun 27, 2014	Jun	NEWA
AB			40MG	A202946	007	Jun 27, 2014	Jun	NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	+	HIKMA MAPLE	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		May	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	May	CAHN
		PITOCIN						
AP	+	PAR STERILE PRODUCTS	10USP UNITS/ML (10USP UNITS/ML)	N018261	001		Apr	CAHN
AP			100USP UNITS/10ML (10USP UNITS/ML)	N018261	002	Jul 27, 2007	Apr	CAHN
			500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012	Apr	CAHN

SOLUTION;NASAL

SYNTOCINON

@ RETROPHIN INC

40USP UNITS/ML

N012285 001

Feb CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

@ MYLAN

6MG/ML

A075278 001 Jan 25, 2002 Jun DISC

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

@ MN PHARMS

30MG/VIAL

A078300 001 Mar 10, 2009 Jan DISC

@

90MG/VIAL

A078300 002 Mar 10, 2009 Jan DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

PANCREAZE

JANSSEN PHARMS

10,850USP UNITS;2,600USP UNITS;6,200USP UNITS

N022523 005 Mar 07, 2014 Jun NEWA

ULTRESA

FOREST LABS INC

27,600USP UNITS;13,800USP UNITS;27,600USP UNITS

N022222 001 Mar 01, 2012 May CAHN

41,400USP UNITS;20,700USP UNITS;41,400USP UNITS

N022222 002 Mar 01, 2012 May CAHN

+

46,000USP UNITS;23,000USP UNITS;46,000USP UNITS

N022222 003 Mar 01, 2012 May CAHN

ZENPEP

APTALIS PHARMA US

218,000USP UNITS; 40,000USP UNITS; 136,000 USP UNITS

N022210 007 Mar 25, 2014 Mar NEWA

FOREST LABS INC

218,000USP UNITS; 40,000USP UNITS; 136,000 USP UNITS

N022210 007 Mar 25, 2014 Apr CAHN

16,000USP UNITS;3,000USP UNITS;10,000USP UNITS

N022210 005 Jun 15, 2011 Apr CAHN

55,000USP UNITS;10,000USP UNITS;34,000USP UNITS

N022210 002 Aug 27, 2009 Apr CAHN

82,000USP UNITS;15,000USP UNITS;51,000USP UNITS

N022210 003 Aug 27, 2009 Apr CAHN

27,000USP UNITS;5,000USP UNITS;17,000USP UNITS

N022210 001 Aug 27, 2009 Apr CAHN

109,000USP UNITS;20,000USP UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009 Apr CAHN

+

136,000USP UNITS;25,000USP UNITS;

N022210 006 Jul 13, 2011 Apr CAHN

CAPSULE, DELAYED RELEASE;ORAL
ZENPEP

85,000USP UNITS

TABLET;ORAL
VIOKACE

	FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Apr	CAHN
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Apr	CAHN
	FOREST RES INST INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar	CAHN
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar	CAHN

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

>A>	AB	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jul	CAHN
>A>	AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jul	CAHN
>D>	AB	JUBILANT ORGANOSYS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jul	CAHN
>D>	AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jul	CAHN
	AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr	NEWA

PARICALCITOLCAPSULE;ORAL
PARICALCITOL

AB		ANCHEN PHARMS	1MCG	A202124	001	Jun 24, 2014	Jun	NEWA
AB			2MCG	A202124	002	Jun 24, 2014	Jun	NEWA
AB			4MCG	A202124	003	Jun 24, 2014	Jun	NEWA
AB		BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar	NEWA
AB			2MCG	A202539	002	Mar 27, 2014	Mar	NEWA
AB			4MCG	A202539	003	Mar 27, 2014	Mar	NEWA
AB		DR REDDYS LABS LTD	1MCG	A091412	001	Jun 24, 2014	Jun	NEWA
AB			2MCG	A091412	002	Jun 24, 2014	Jun	NEWA
AB			4MCG	A091412	003	Jun 24, 2014	Jun	NEWA

PAROMOMYCIN SULFATECAPSULE;ORAL
PAROMOMYCIN SULFATE

>D>	AA	+ CARACO	EQ 250MG BASE	A064171	001	Jun 30, 1997	Jul	CAHN
>A>	AA	+ SUN PHARM INDS INC	EQ 250MG BASE	A064171	001	Jun 30, 1997	Jul	CAHN

PAROXETINE HYDROCHLORIDECAPSULE;ORAL
PAXIL

	@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb	CAHN
	@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb	CAHN
	@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb	CAHN
	@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb	CAHN

SUSPENSION;ORAL

PAXIL

AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb	CAHN
----	---	---------------------	------------------	---------	-----	--------------	-----	------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

>D>	AB	CARACO	EQ 10MG BASE	A078194	001	Jun 29, 2007	Jul	CAHN
>D>	AB		EQ 20MG BASE	A078194	002	Jun 29, 2007	Jul	CAHN
>D>	AB		EQ 30MG BASE	A078194	003	Jun 29, 2007	Jul	CAHN
>D>	AB		EQ 40MG BASE	A078194	004	Jun 29, 2007	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Jul	CAHN
>A>	AB		EQ 20MG BASE	A078194	002	Jun 29, 2007	Jul	CAHN
>A>	AB		EQ 30MG BASE	A078194	003	Jun 29, 2007	Jul	CAHN
>A>	AB		EQ 40MG BASE	A078194	004	Jun 29, 2007	Jul	CAHN

PAXIL

AB		APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan	CAHN
AB			EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan	CAHN
AB			EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan	CAHN
AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan	CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

PAXIL CR

AB		APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb	CAHN
AB			EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb	CAHN
AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb	CAHN

PEGVISOMANTINJECTABLE;SUBCUTANEOUS
SOMAVERT

>A>	+	PHARMACIA AND UPJOHN	25MG/VIAL	N021106	004	Jul 31, 2014	Jul NEWA
>A>	+		30MG/VIAL	N021106	005	Jul 31, 2014	Jul NEWA

PEMIROLAST POTASSIUMSOLUTION/DROPS;OPHTHALMIC
ALAMAST

	@	SANTEN	0.1%	N021079	001	Sep 24, 1999	Jun DISC
--	---	--------	------	---------	-----	--------------	----------

PENBUTOLOL SULFATETABLET;ORAL
LEVATOL

	@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Apr CAHN
	+		20MG	N018976	004	Jan 05, 1989	Apr CAHN

PENICILLIN G POTASSIUMINJECTABLE;INJECTION
PENICILLIN G POTASSIUM

AP		ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
AP			20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN

PENTAMIDINE ISETHIONATEINJECTABLE;INJECTION
PENTAM

	+	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	May CTEC
		PENTAMIDINE ISETHIONATE					
	@	WATSON LABS	300MG/VIAL	A074303	001	Aug 17, 1995	May DISC

PENTOXIFYLLINETABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

	@	WATSON LABS	400MG	A075107	001	Sep 04, 1998	May DISC
		TRENTAL					
	@	SANOFI AVENTIS US	400MG	N018631	001	Aug 30, 1984	Jun DISC

PERINDOPRIL ERBUMINETABLET;ORAL
ACEON

>A>	AB		2MG	N020184	001	Dec 30, 1993	Jul CAHN
>A>	AB		4MG	N020184	002	Dec 30, 1993	Jul CAHN
>A>	AB	+	8MG	N020184	003	Dec 30, 1993	Jul CAHN
>D>	AB	XOMA	2MG	N020184	001	Dec 30, 1993	Jul CAHN
>D>	AB		4MG	N020184	002	Dec 30, 1993	Jul CAHN
>D>	AB	+	8MG	N020184	003	Dec 30, 1993	Jul CAHN
		PERINDOPRIL ERBUMINE					
	AB	ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan CAHN
	AB		4MG	A078138	002	Nov 10, 2009	Jan CAHN
	AB		8MG	A078138	003	Nov 10, 2009	Jan CAHN

PERPHENAZINETABLET;ORAL
PERPHENAZINE

	@	ANI PHARMS INC	8MG	A089456	001	Sep 10, 1987	Apr CAHN
	@	TEVA PHARMS USA	2MG	A089707	001	Sep 10, 1987	Apr CAHN
	@		4MG	A089708	001	Sep 10, 1987	Apr CAHN
	@		16MG	A089457	001	Sep 10, 1987	Apr CAHN

PHENDIMETRAZINE TARTRATETABLET;ORAL
PHENDIMETRAZINE TARTRATE

AA		ELITE LABS INC	35MG	A040762	001	Jan 28, 2008	Apr CAHN
----	--	----------------	------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDECAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA		INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb NEWA
AA			30MG	A202858	002	Feb 14, 2014	Feb NEWA
AA			30MG	A204414	001	May 05, 2014	Apr NEWA
AA			37.5MG	A202846	001	Feb 05, 2014	Jan NEWA

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA	AUROLIFE PHARMA LLC	37.5MG	A203068	001	Aug 06, 2014	Jul	NEWA
>D>	AA	CARACO	37.5MG	A040790	001	Aug 21, 2007	Jul	CAHN
	AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan	NEWA
	AA	MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	May	CMFD
>A>	AA	SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007	Jul	CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)

VAZCULEP

		ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun	NEWA
			50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun	NEWA
	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun	NEWA

PHENYTOIN

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB		TARO	50MG	A200565	001	Apr 17, 2014	Apr	NEWA
----	--	------	------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

	@	ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003	Apr	CAHN
	@		100MG EXTENDED	A089441	001	Dec 18, 1986	Jan	CAHN
		PROMPT PHENYTOIN SODIUM						
	@	ANI PHARMS INC	100MG PROMPT	A080259	001		Jan	CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb	CMFD
AB			10MG	A074063	002	Jan 27, 1994	Feb	CMFD
AB		MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb	CTEC
AB	+		10MG	A074019	002	Sep 03, 1992	Feb	CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar	NEWA
AB			EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar	NEWA
AB			EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar	NEWA

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

	+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb	CAHN
	+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb	CAHN
	+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb	CAHN
	+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb	CAHN
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb	CAHN
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb	CAHN
AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION

MAXAIR

>D>	@	MEDICIS	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Jul	CAHN
>A>	@	VALEANT PHARM NORTH	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Jul	CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

@	WATSON LABS	10MG	A074287	001	May 16, 1996	May	DISC
@		10MG	A074460	001	Sep 29, 1995	May	DISC
@		20MG	A074287	002	May 16, 1996	May	DISC
@		20MG	A074460	002	Sep 29, 1995	May	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION;ORAL

CO-LAV

@	VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992	Feb	CAHN
---	----------------	--	---------	-----	--------------	-----	------

GO-EVAC

@	VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992	Feb	CAHN
---	----------------	--	---------	-----	--------------	-----	------

PORACTANT ALFA

SUSPENSION;INTRATRACHEAL

CUROSURF

+	CHIESI USA INC	80MG/ML	N020744	001	Nov 18, 1999	Apr	CAHN
---	----------------	---------	---------	-----	--------------	-----	------

POSACONAZOLE

SOLUTION;IV (INFUSION)

NOXAFIL

+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Mar	NEWA
---	-------------------	------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

@	INTL MEDICATION	2MEQ/ML	A083163	001		Mar	DISC
---	-----------------	---------	---------	-----	--	-----	------

POTASSIUM CITRATE

FOR SOLUTION;ORAL

POTASSIUM CITRATE

>D>	@	NOVA K	10MEQ/PACKET	N019647	002	Oct 13, 1988	Jul	CAHN
>D>	@		20MEQ/PACKET	N019647	001	Oct 13, 1988	Jul	CAHN
>A>	@	UT SW MEDCTR	10MEQ/PACKET	N019647	002	Oct 13, 1988	Jul	CAHN
>A>	@		20MEQ/PACKET	N019647	001	Oct 13, 1988	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

>A>	AB	ZYDUS PHARMS USA INC	5MEQ	A203546	001	Aug 06, 2014	Jul	NEWA
>A>	AB		10MEQ	A203546	002	Aug 06, 2014	Jul	NEWA
>A>	AB		15MEQ	A203546	003	Aug 06, 2014	Jul	NEWA

UROCIT-K

>D>	+	MISSION PHARMA	15MEQ	N019071	003	Dec 30, 2009	Jul	CTEC
>A>	AB	+	15MEQ	N019071	003	Dec 30, 2009	Jul	CTEC

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		STRIDES ARCOLAB LTD	0.125MG	A202702	001	Jun 03, 2014	May	NEWA
AB			0.25MG	A202702	002	Jun 03, 2014	May	NEWA
AB			0.5MG	A202702	003	Jun 03, 2014	May	NEWA
AB			0.75MG	A202702	004	Jun 03, 2014	May	NEWA
AB			1MG	A202702	005	Jun 03, 2014	May	NEWA
AB			1.5MG	A202702	006	Jun 03, 2014	May	NEWA

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB	+	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan	CFTG
AB			0.75MG	N022421	002	Feb 19, 2010	Jan	CFTG
AB			1.5MG	N022421	003	Feb 19, 2010	Jan	CFTG
AB			2.25MG	N022421	006	Jun 17, 2011	Jan	CFTG
AB			3MG	N022421	004	Feb 19, 2010	Jan	CFTG
AB			3.75MG	N022421	007	Jun 17, 2011	Jan	CFTG
AB			4.5MG	N022421	005	Feb 19, 2010	Jan	CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan	NEWA
AB			0.75MG	A202206	002	Feb 06, 2014	Jan	NEWA
AB			1.5MG	A202206	003	Feb 06, 2014	Jan	NEWA
AB			2.25MG	A202206	004	Feb 06, 2014	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB		3MG		A202206	005	Feb 06, 2014	Jan NEWA
AB		3.75MG		A202206	006	Feb 06, 2014	Jan NEWA
AB		4.5MG		A202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS
SYMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)		N021332	002	Sep 25, 2007	Feb CAHN
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)		N021332	003	Sep 25, 2007	Feb CAHN
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)		N021332	001	Mar 16, 2005	Feb CAHN

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

AB	SANDOZ	10MG		A076397	003	Oct 23, 2006	Apr CMFD
AB		20MG		A076397	002	Oct 23, 2006	Apr CMFD
AB		40MG		A076397	001	Oct 23, 2006	Apr CMFD

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	+ BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10% VASOCIDIN		A074449	001	Dec 29, 1995	Feb CRLD
@	NOVARTIS	EQ 0.23% PHOSPHATE;10%		N018988	001	Aug 26, 1988	Feb DISC

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE

AB	+ SANOFI AVENTIS US	EQ 15MG BASE		N008316	001		Jan CFTG
	PRIMAQUINE PHOSPHATE						
AB	ALVOGEN INC	EQ 15MG BASE		A203924	001	Feb 03, 2014	Jan NEWA
AB	BAYSHORE PHARMS LLC	EQ 15MG BASE		A204476	001	Feb 25, 2014	Feb NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

>D>	AP	+ HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jul CTEC
>A>			100MG/ML	A089069	001	Feb 12, 1986	Jul CTEC
>D>	AP	+	500MG/ML	A089070	001	Feb 12, 1986	Jul CTEC
>A>			500MG/ML	A089070	001	Feb 12, 1986	Jul CTEC
>D>	AP	INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984	Jul DISC
>A>		@	100MG/ML	A088636	001	Jul 31, 1984	Jul DISC
>D>	AP		500MG/ML	A088637	001	Jul 31, 1984	Jul DISC
>A>		@	500MG/ML	A088637	001	Jul 31, 1984	Jul DISC

TABLET, EXTENDED RELEASE;ORAL
PROCAINAMIDE HYDROCHLORIDE

@	ANI PHARMS INC	1GM		A040111	001	Dec 13, 1996	Jan CAHN
@		250MG		A088958	001	Dec 02, 1985	Jan CAHN
@		500MG		A088959	001	Dec 02, 1985	Jan CAHN
@		500MG		A088974	001	Jul 22, 1985	Mar CAHN
@		750MG		A089438	001	Mar 23, 1987	Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL
PHENERGAN

@	DELCOR ASSET CORP	50MG		N011689	001		Apr CAHN
---	-------------------	------	--	---------	-----	--	----------

TABLET;ORAL
PHENERGAN

>A>	@	DELCOR ASSET CORP	12.5MG	N007935	002		Jul CAHN
	@		12.5MG	N007935	002		Apr CAHN
>A>	@		25MG	N007935	003		Jul CAHN
	@		25MG	N007935	003		Apr CAHN
>A>	@		50MG	N007935	004		Jul CAHN
	@		50MG	N007935	004		Apr CAHN
>D>	@	SHIONOGI INC	12.5MG	N007935	002		Jul CAHN
	@		12.5MG	N007935	002		May CAHN
>D>	@		25MG	N007935	003		Jul CAHN
	@		25MG	N007935	003		May CAHN

	TABLET;ORAL							
	PHENERGAN							
>D>	@	50MG	N007935	004		Jul	CAHN	
	@	50MG	N007935	004		May	CAHN	
	PROMETHAZINE HYDROCHLORIDE							
AB	SANDOZ	25MG	A084176	003		Apr	CMS1	
AB	SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008	Jun	CAHN	
AB		25MG	A040863	002	Dec 30, 2008	Jun	CAHN	
AB		50MG	A040863	003	Dec 30, 2008	Jun	CAHN	
	<u>PROPAFENONE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	PROPAFENONE HYDROCHLORIDE							
AB	ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan	CAHN	
AB		225MG	A076550	002	Apr 23, 2004	Jan	CAHN	
AB		300MG	A076550	003	Apr 23, 2004	Jan	CAHN	
	<u>PROPARACAINE HYDROCHLORIDE</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	ALCAINE							
AT	+ ALCON	0.5%	A080027	001		Jun	CRLD	
	OPHTHAINE							
	@ APOTHECON	0.5%	N008883	001		Jun	DISC	
	OPHTHETIC							
	@ ALLERGAN	0.5%	N012583	001		Jun	DISC	
	<u>PROPRANOLOL HYDROCHLORIDE</u>							
	SOLUTION;ORAL							
	HEMANGEOL							
	+ PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	Mar	NEWA	
	TABLET;ORAL							
	INDERAL							
	@ WYETH PHARMS INC	40MG	N016418	002		Jan	DISC	
	@	60MG	N016418	009	Oct 18, 1982	Jan	DISC	
	@	80MG	N016418	004		Jan	DISC	
	PROPRANOLOL HYDROCHLORIDE							
	@ ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988	Jan	CAHN	
	<u>PROPYLTHIOURACIL</u>							
	TABLET;ORAL							
	PROPYLTHIOURACIL							
	@ ANI PHARMS INC	50MG	A080215	001		Jan	CAHN	
	<u>QUETIAPINE FUMARATE</u>							
	TABLET;ORAL							
	QUETIAPINE FUMARATE							
>A>	AB	JUBILANT GENERICS	EQ 25MG BASE	A203150	001	Nov 26, 2013	Jul	CAHN
>D>	AB	JUBILANT LIFE	EQ 25MG BASE	A203150	001	Nov 26, 2013	Jul	CAHN
	<u>QUINIDINE GLUCONATE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	QUINIDINE GLUCONATE							
	@ WATSON LABS	324MG	A087810	001	Sep 29, 1982	May	DISC	
	<u>RALOXIFENE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	EVISTA							
AB	+ LILLY	60MG	N020815	001	Dec 09, 1997	Feb	CFTG	
	RALOXIFENE HYDROCHLORIDE							
AB	TEVA PHARMS USA	60MG	A078193	001	Mar 04, 2014	Feb	NEWA	
	<u>RAMIPRIL</u>							
	CAPSULE;ORAL							
	RAMIPRIL							
AB	ACCORD HLTHCARE INC	1.25MG	A202392	001	Apr 15, 2014	Mar	NEWA	
AB		2.5MG	A202392	002	Apr 15, 2014	Mar	NEWA	
AB		5MG	A202392	003	Apr 15, 2014	Mar	NEWA	
AB		10MG	A202392	004	Apr 15, 2014	Mar	NEWA	

RANITIDINE HYDROCHLORIDEINJECTABLE; INJECTION
ZANTAC

AP	+	COVIS INJECTABLES	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr	CAHN
		ZANTAC IN PLASTIC CONTAINER						
		@ COVIS INJECTABLES	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Apr	CAHN
		@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Apr	CAHN
		TABLET, EFFERVESCENT; ORAL						
		ZANTAC 25						
		@ GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Feb	DISC

RASAGILINE MESYLATETABLET; ORAL
RASAGILINE MESYLATE

		@ WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	May	DISC
		@	EQ 1MG BASE	A201823	002	Jul 01, 2013	May	DISC

REPAGLINIDETABLET; ORAL
REPAGLINIDE

AB		ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Jan	NEWA
AB			1MG	A090008	002	Jan 22, 2014	Jan	NEWA
AB			2MG	A090008	003	Jan 22, 2014	Jan	NEWA
AB		AUROBINDO PHARMA LTD	0.5MG	A203820	001	Jan 22, 2014	Jan	NEWA
AB			1MG	A203820	002	Jan 22, 2014	Jan	NEWA
AB			2MG	A203820	003	Jan 22, 2014	Jan	NEWA
>D>	AB	CARACO	1MG	A077571	002	Jul 11, 2013	Jul	CAHN
>D>	AB		2MG	A077571	003	Jul 11, 2013	Jul	CAHN
AB		MYLAN PHARMS INC	1MG	A090252	002	Jan 22, 2014	Jan	NEWA
AB			2MG	A090252	003	Jan 22, 2014	Jan	NEWA
AB		PADDOCK LLC	1MG	A201189	002	Jan 22, 2014	Jan	NEWA
AB			2MG	A201189	003	Jan 22, 2014	Jan	NEWA
AB		SANDOZ	1MG	A078555	002	Jan 22, 2014	Jan	NEWA
AB			2MG	A078555	003	Jan 22, 2014	Jan	NEWA
>A>	AB	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Jul	CAHN
>A>	AB		2MG	A077571	003	Jul 11, 2013	Jul	CAHN

RIFABUTINCAPSULE; ORAL
MYCOBUTIN

AB	+	PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb	CFTG
AB		RIFABUTIN						
AB		LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb	NEWA

RISEDRONATE SODIUMTABLET; ORAL
ACTONEL

AB	+	WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008	May	CTEC
		RISEDRONATE SODIUM						
AB		APOTEX INC	75MG	A090877	002	Jun 10, 2014	May	NEWA
AB			150MG	A090877	003	Jun 10, 2014	May	NEWA
AB		MYLAN PHARMS INC	75MG	A200477	004	Jun 10, 2014	May	NEWA
AB			150MG	A200477	005	Jun 10, 2014	May	NEWA
AB		SUN PHARMA GLOBAL	75MG	A090886	004	Jun 10, 2014	May	NEWA
AB			150MG	A090886	005	Jun 10, 2014	May	NEWA
AB		TEVA PHARMS USA	150MG	A079215	001	Jun 13, 2014	Jun	NEWA

RISPERIDONESOLUTION; ORAL
RISPERIDONE

AA		ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan	CAHN
		TABLET; ORAL						
		RISPERIDONE						
>D>	AB	CARACO	0.25MG	A078036	001	Mar 10, 2014	Jul	CAHN
	AB		0.25MG	A078036	001	Mar 10, 2014	Feb	NEWA
>D>	AB		0.5MG	A078036	002	Mar 10, 2014	Jul	CAHN
	AB		0.5MG	A078036	002	Mar 10, 2014	Feb	NEWA
>D>	AB		1MG	A078036	003	Mar 10, 2014	Jul	CAHN
	AB		1MG	A078036	003	Mar 10, 2014	Feb	NEWA
>D>	AB		2MG	A078036	004	Mar 10, 2014	Jul	CAHN
	AB		2MG	A078036	004	Mar 10, 2014	Feb	NEWA

TABLET;ORAL
RISPERIDONE

>D>	AB		3MG	A078036	005	Mar 10, 2014	Jul	CAHN
	AB		3MG	A078036	005	Mar 10, 2014	Feb	NEWA
>D>	AB		4MG	A078036	006	Mar 10, 2014	Jul	CAHN
	AB		4MG	A078036	006	Mar 10, 2014	Feb	NEWA
>A>	AB	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Jul	CAHN
>A>	AB		0.5MG	A078036	002	Mar 10, 2014	Jul	CAHN
>A>	AB		1MG	A078036	003	Mar 10, 2014	Jul	CAHN
>A>	AB		2MG	A078036	004	Mar 10, 2014	Jul	CAHN
>A>	AB		3MG	A078036	005	Mar 10, 2014	Jul	CAHN
>A>	AB		4MG	A078036	006	Mar 10, 2014	Jul	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

>A>	AB	JUBILANT GENERICS	0.5MG	A090839	001	Nov 04, 2011	Jul	CAHN
>A>	AB		1MG	A090839	002	Nov 04, 2011	Jul	CAHN
>A>	AB		2MG	A090839	003	Nov 04, 2011	Jul	CAHN
>A>	AB		3MG	A090839	004	Nov 04, 2011	Jul	CAHN
>A>	AB		4MG	A090839	005	Nov 04, 2011	Jul	CAHN
>D>	AB	JUBILANT ORGANOSYS	0.5MG	A090839	001	Nov 04, 2011	Jul	CAHN
>D>	AB		1MG	A090839	002	Nov 04, 2011	Jul	CAHN
>D>	AB		2MG	A090839	003	Nov 04, 2011	Jul	CAHN
>D>	AB		3MG	A090839	004	Nov 04, 2011	Jul	CAHN
>D>	AB		4MG	A090839	005	Nov 04, 2011	Jul	CAHN

RIVASTIGMINE TARTRATE

SOLUTION;ORAL
EXELON

@	NOVARTIS		EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Jun	DISC
---	----------	--	----------------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan	NEWA
AB			EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan	NEWA

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION
NAROPIN

>D>		FRESENIUS KABI USA	5MG/ML	N020533	003	Sep 24, 1996	Jul	CFTG
>A>	AP		5MG/ML	N020533	003	Sep 24, 1996	Jul	CFTG
>D>		+	10MG/ML	N020533	005	Sep 24, 1996	Jul	CFTG
>A>	AP	+	10MG/ML	N020533	005	Sep 24, 1996	Jul	CFTG
>A>		ROPIVACAINE HYDROCHLORIDE						
>A>	AP	NAVINTA LLC	5MG/ML	A078601	002	Jul 17, 2014	Jul	NEWA
>A>	AP		10MG/ML	A078601	003	Jul 17, 2014	Jul	NEWA

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL
ONGLYZA

		ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	May	CAHN
+			EQ 5MG BASE	N022350	002	Jul 31, 2009	May	CAHN

SIMEPREVIR SODIUM

CAPSULE;ORAL
OLYSIO

+		JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013	Jun	CAHN
+		JANSSEN RES AND DEV	EQ 150MG BASE	N205123	001	Nov 22, 2013	Feb	CAIN

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)
AMMONUL

>A>	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul	CAHN
>D>	+	UCYCLYD	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul	CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

@	MEDEFIL INC		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun	DISC
@			22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun	DISC
@			27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun	DISC
@			45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun	DISC

	INJECTABLE; INJECTION								
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
	@ MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Jun	DISC		
	<u>SODIUM FLUORIDE F-18</u>								
	INJECTABLE; INTRAVENOUS								
	SODIUM FLUORIDE F-18								
AP	UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014	Mar	NEWA		
	<u>SODIUM POLYSTYRENE SULFONATE</u>								
	POWDER; ORAL, RECTAL								
	SODIUM POLYSTYRENE SULFONATE								
AA	EPIC PHARMA LLC	453.6GM/BOT	A202333	001	Mar 19, 2014	Mar	NEWA		
	<u>SOLIFENACIN SUCCINATE</u>								
	TABLET; ORAL								
	SOLIFENACIN SUCCINATE								
AB	TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014	Mar	NEWA		
AB		10MG	A091464	002	Apr 02, 2014	Mar	NEWA		
	VESICARE								
AB	ASTELLAS	5MG	N021518	001	Nov 19, 2004	Mar	CFTG		
AB	+	10MG	N021518	002	Nov 19, 2004	Mar	CFTG		
	<u>SOMATROPIN RECOMBINANT</u>								
	INJECTABLE; INJECTION								
	ACCRETROPIN								
	@ EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Feb	CAHN		
	<u>SPIRONOLACTONE</u>								
	TABLET; ORAL								
	SPIRONOLACTONE								
AB	JUBILANT LIFE	25MG	A203253	001	Apr 23, 2014	Apr	NEWA		
AB		50MG	A203253	002	Apr 23, 2014	Apr	NEWA		
AB		100MG	A203253	003	Apr 23, 2014	Apr	NEWA		
AB	ORION CORP ORION	25MG	A202187	001	Mar 06, 2014	Feb	NEWA		
AB		50MG	A202187	002	Mar 06, 2014	Feb	NEWA		
AB		100MG	A202187	003	Mar 06, 2014	Feb	NEWA		
	<u>SUCRALFATE</u>								
	SUSPENSION; ORAL								
	CARAFATE								
	+ FOREST LABS INC	1GM/10ML	N019183	001	Dec 16, 1993	Apr	CAHN		
	TABLET; ORAL								
	CARAFATE								
AB	+ FOREST LABS INC	1GM	N018333	001		Apr	CAHN		
	<u>SULFASALAZINE</u>								
	TABLET; ORAL								
	SULFASALAZINE								
	@ WATSON LABS	500MG	A087197	001		May	DISC		
	<u>SUMATRIPTAN SUCCINATE</u>								
	INJECTABLE; SUBCUTANEOUS								
	IMITREX STATDOSE								
BX	+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006	May	CTEC		
	SUMATRIPTAN SUCCINATE								
AP	AGILA SPECLTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Mar	NEWA		
AB	DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090495	001	Jan 29, 2014	Jan	NEWA		
AP	PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Jun	CAHN		
	SUMAVEL DOSEPRO								
BX	+ ZOGENIX INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May	NEWA		
	SYSTEM; IONTOPHORESIS								
	ZECUITY								
	+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	May	CAHN		

SUNITINIB MALATE

CAPSULE;ORAL		SUNITINIB MALATE					
AB	MYLAN PHARMS INC	EQ 12.5MG BASE	A201275	001	Jan 30, 2014	Jan	NEWA
AB		EQ 25MG BASE	A201275	002	Jan 30, 2014	Jan	NEWA
AB		EQ 37.5MG BASE	A201275	003	Jan 30, 2014	Jan	NEWA
AB		EQ 50MG BASE	A201275	004	Jan 30, 2014	Jan	NEWA
SUTENT							
AB	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Jan	CFTG
AB		EQ 25MG BASE	N021938	002	Jan 26, 2006	Jan	CFTG
AB		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Jan	CFTG
AB	+	EQ 50MG BASE	N021938	003	Jan 26, 2006	Jan	CFTG

TACROLIMUS

CAPSULE;ORAL		TACROLIMUS						
>A>	AB	STRIDES ARCOLAB LTD	EQ 0.5MG BASE	A090687	001	Jul 22, 2014	Jul	NEWA
>A>	AB		EQ 1MG BASE	A090687	002	Jul 22, 2014	Jul	NEWA
>A>	AB		EQ 5MG BASE	A090687	003	Jul 22, 2014	Jul	NEWA
		@ WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010	May	DISC

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC		ZIOPTAN					
+	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Apr	CAHN

TASIMELTEON

CAPSULE;ORAL		HETLIOZ					
+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan	NEWA

>A>		<u>TAVABOROLE</u>						
>A>		SOLUTION;TOPICAL						
>A>		KERYDIN						
>A>	+	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Jul	NEWA

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INJECTION, ORAL		TECHNELITE					
@	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001		May	DISC
@	MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002		May	DISC
SOLUTION;INTRAVENOUS		TECHNELITE					
+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	May	NEWA
@		0.0083-2.7 CI/GENERATOR	N017771	001		May	CDFR
+	MALLINCKRODT	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	May	NEWA
@		0.25-3 CI/GENERATOR	N017243	002		May	CDFR
SOLUTION;INTRAVENOUS, ORAL		TECHNETIUM TC 99M GENERATOR					
+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	May	NEWA
		830-16600mCi/GENERATOR	N017693	001		May	CDFR

TEDIZOLID PHOSPHATE

POWDER;IV (INFUSION)		SIVEXTRO					
+	CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014	Jun	NEWA
TABLET;ORAL		SIVEXTRO					
+	CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014	Jun	NEWA

TELAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)		VIBATIV					
+	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jun	CAHN
+		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jun	CAHN

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB	ALEMBIC PHARMS LTD	20MG	A202130	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A202130	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A202130	003	Jul 07, 2014	Jun	NEWA
AB	GLENMARK GENERICS	20MG	A090032	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A090032	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A090032	003	Jul 07, 2014	Jun	NEWA
AB	MYLAN PHARMS INC	20MG	A202397	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A202397	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A202397	003	Jul 07, 2014	Jun	NEWA
AB	TORRENT PHARMS LTD	20MG	A203171	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A203171	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A203171	003	Jul 07, 2014	Jun	NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

@ WATSON LABS
@

15MG
30MG

A071446 001 May 21, 1993 May DISC
A071447 001 May 21, 1993 May DISC

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB	SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb	NEWA
AB		20MG	A201742	002	Feb 12, 2014	Feb	NEWA
AB		100MG	A201742	003	Feb 12, 2014	Feb	NEWA
AB		140MG	A201742	004	Feb 12, 2014	Feb	NEWA
AB		180MG	A201742	005	Feb 12, 2014	Feb	NEWA
AB		250MG	A201742	006	Feb 12, 2014	Feb	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

@ ABBOTT
@
@
@

EQ 1MG BASE
EQ 2MG BASE
EQ 5MG BASE
EQ 10MG BASE

N020347 001 Dec 14, 1994 Apr DISC
N020347 002 Dec 14, 1994 Apr DISC
N020347 003 Dec 14, 1994 Apr DISC
N020347 004 Dec 14, 1994 Apr DISC

TERAZOSIN HYDROCHLORIDE

AB	+ SANDOZ	EQ 2MG BASE	A074823	002	Mar 30, 1998	Apr	CRLD
----	----------	-------------	---------	-----	--------------	-----	------

TABLET; ORAL

HYTRIN

@ ABBOTT
@
@
@

EQ 1MG BASE
EQ 2MG BASE
EQ 5MG BASE
EQ 10MG BASE

N019057 001 Aug 07, 1987 Apr DISC
N019057 002 Aug 07, 1987 Apr DISC
N019057 003 Aug 07, 1987 Apr DISC
N019057 004 Aug 07, 1987 Apr DISC

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

@ THERATECHNOLOGIES
+

EQ 1MG BASE/VIAL
EQ 2MG BASE/VIAL

N022505 001 Nov 10, 2010 May CAHN
N022505 002 Nov 29, 2011 May CAHN

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

>D>	ABBVIE	1% (25MG/2.5GM PACKET)	N021015	001	Feb 28, 2000	Jul	CTEC
>D> BX	+	1% (50MG/5GM PACKET)	N021015	002	Feb 28, 2000	Jul	CTEC
>A> AB		25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jul	CTEC
>A> AB	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jul	CTEC
	TESTOSTERONE						
>D>	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jul	CTEC
>A> AB		25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jul	CTEC
>D>		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jul	CTEC
>A> AB		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jul	CTEC
>D>	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jul	CTEC
>A> BX		25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jul	CTEC
>D>		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jul	CTEC
>A> BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jul	CTEC

	GEL; TRANSDERMAL									
	VOGELXO									
	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014			Jun	NEWA	
	GEL, METERED; NASAL									
	NATESTO									
	@ TRIMEL BIOPHARMA SRL	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014			Jun	DISC	
	+	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014			May	NEWA	
	GEL, METERED; TRANSDERMAL									
	ANDROGEL									
>D>	+	ABBVIE	1% (12.5MG/1.25GM ACTUATION)	N021015	003	Sep 26, 2003		Jul	CTEC	
>A>	AB	+	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003		Jul	CTEC	
	TESTOSTERONE									
>D>	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013			Jul	CTEC	
>A>	AB	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013			Jul	CTEC	
	VOGELXO									
	UPSHER SMITH	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014			Jun	NEWA	
	TABLET, EXTENDED RELEASE; BUCCAL									
	STRIANT									
	+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003		Apr	CAHN	
	<u>TESTOSTERONE UNDECANOATE</u>									
	INJECTABLE; INTRAMUSCULAR									
	AVEED									
	+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014		Mar	NEWA	
	<u>THEOPHYLLINE</u>									
	SOLUTION, ELIXIR; ORAL									
	ELIXOPHYLLIN									
>D>	+	CARACO	80MG/15ML	A085186	001			Jul	CAHN	
	+		80MG/15ML	A085186	001			Jun	CDFR	
>A>	+	SUN PHARM INDS INC	80MG/15ML	A085186	001			Jul	CAHN	
	TABLET, EXTENDED RELEASE; ORAL									
	THEOCHRON									
>D>	AB	CARACO	100MG	A088320	001	Feb 21, 1985		Jul	CAHN	
>D>	AB		200MG	A088321	001	Feb 21, 1985		Jul	CAHN	
>D>	@		300MG	A087400	002	Jan 11, 1983		Jul	CAHN	
	@		300MG	A087400	002	Jan 11, 1983		Jan	DISC	
>A>	AB	SUN PHARM INDS INC	100MG	A088320	001	Feb 21, 1985		Jul	CAHN	
>A>	AB		200MG	A088321	001	Feb 21, 1985		Jul	CAHN	
>A>	@		300MG	A087400	002	Jan 11, 1983		Jul	CAHN	
	<u>THIAMINE HYDROCHLORIDE</u>									
	INJECTABLE; INJECTION									
	THIAMINE HYDROCHLORIDE									
	@	WATSON LABS	100MG/ML	A080571	001			May	DISC	
	@		200MG/ML	A080571	002			May	DISC	
	<u>THIORIDAZINE HYDROCHLORIDE</u>									
	CONCENTRATE; ORAL									
	THIORIDAZINE HYDROCHLORIDE									
	@	ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987		Feb	CAHN	
	TABLET; ORAL									
	THIORIDAZINE HYDROCHLORIDE									
	@	ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983		Feb	CAHN	
	@		10MG	A088493	001	May 17, 1985		Feb	CAHN	
	@		15MG	A088271	001	Apr 14, 1983		Feb	CAHN	
	@		25MG	A088272	001	Apr 14, 1983		Feb	CAHN	
	@		50MG	A088194	001	Apr 14, 1983		Feb	CAHN	
	@		100MG	A088273	001	Oct 03, 1983		Feb	CAHN	
	@		100MG	A088456	001	May 17, 1985		Feb	CAHN	
	<u>THIOTHIXENE</u>									
	CAPSULE; ORAL									
	THIOTHIXENE									
	@	WATSON LABS	2MG	A070601	001	Jun 05, 1987		May	DISC	
	@		5MG	A070602	001	Jun 05, 1987		May	DISC	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

>D>	AB	CARACO	250MG	A075526	001	Sep 26, 2002	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002	Jul	CAHN

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+	OAK PHARMS AKORN	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Apr	CAHN
+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Apr	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

>D>	AB	CARACO	EQ 2MG BASE	A076416	001	Sep 29, 2003	Jul	CAHN
>D>	AB		EQ 4MG BASE	A076416	002	Sep 29, 2003	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	EQ 2MG BASE	A076416	001	Sep 29, 2003	Jul	CAHN
>A>	AB		EQ 4MG BASE	A076416	002	Sep 29, 2003	Jul	CAHN

TOBRAMYCIN

SOLUTION; INHALATION

BETHKIS

		CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Apr	CAHN
AN		AKORN INC	300MG/5ML	A201422	001	May 28, 2014	May	NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

@	WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989	May	DISC
---	-----------------	-----------------	---------	-----	--------------	-----	------

TOPIRAMATE

CAPSULE, DELAYED RELEASE; ORAL

QUDEXY XR

	UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Mar	NEWA
		50MG	N205122	002	Mar 11, 2014	Mar	NEWA
		100MG	N205122	003	Mar 11, 2014	Mar	NEWA
		150MG	N205122	004	Mar 11, 2014	Mar	NEWA
+		200MG	N205122	005	Mar 11, 2014	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

QUDEXY XR

	UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Apr	CDFR
		50MG	N205122	002	Mar 11, 2014	Apr	CDFR
		100MG	N205122	003	Mar 11, 2014	Apr	CDFR
		150MG	N205122	004	Mar 11, 2014	Apr	CDFR
+		200MG	N205122	005	Mar 11, 2014	Apr	CDFR

TABLET; ORAL

TOPIRAMATE

@	WATSON LABS	25MG	A077643	001	Mar 27, 2009	May	DISC
@		50MG	A077643	002	Mar 27, 2009	May	DISC
@		100MG	A077643	003	Mar 27, 2009	May	DISC
@		200MG	A077643	004	Mar 27, 2009	May	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP		INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Apr	CAHN
----	--	----------------------	------------------	---------	-----	--------------	-----	------

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB		ALLIED PHARMA INC	50MG	A202075	001	Nov 28, 2011	Apr	CAHN
AB		AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar	NEWA
>D>	AB	CARACO	50MG	A075964	001	Jun 19, 2002	Jul	CAHN
>A>	AB	SUN PHARM INDS INC	50MG	A075964	001	Jun 19, 2002	Jul	CAHN
		@ WATSON LABS	50MG	A075962	001	Jun 24, 2002	May	DISC

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@ COREPHARMA	1MG	A 077256	001	Jun 12, 2007	Jun DISC
@	2MG	A 077256	002	Jun 12, 2007	Jun DISC
@	4MG	A 077256	003	Jun 12, 2007	Jun DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	ACIC FINE CHEMS	100MG/ML	A 202436	001	Feb 11, 2014	Jan NEWA
----	-----------------	----------	----------	-----	--------------	----------

TABLET; ORAL

TRANEXAMIC ACID

AB	APOTEX INC	650 MG	A 202286	001	Jan 27, 2014	Jan NEWA
----	------------	--------	----------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

IZBA

+	ALCON LABS INC	0.003%	N 204822	001	May 15, 2014	May NEWA
---	----------------	--------	----------	-----	--------------	----------

TRAVOPROST

+	PAR PHARM	0.004%	A 091340	001	Mar 01, 2013	Feb CRLD
---	-----------	--------	----------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

@ WATSON LABS	50MG	A 070857	001	Oct 10, 1986	May DISC
@	100MG	A 070858	001	Oct 10, 1986	May DISC

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL

ORENITRAM

	UNITED THERAP	EQ 0.125MG BASE	N 203496	001	Dec 20, 2013	Jun CAIN
		EQ 0.25MG BASE	N 203496	002	Dec 20, 2013	Jun CAIN
		EQ 1MG BASE	N 203496	003	Dec 20, 2013	Jun CAIN
+		EQ 2.5MG BASE	N 203496	004	Dec 20, 2013	Jun CAIN

TRETINOIN

GEL; TOPICAL

RETIN-A-MICRO

+	VALEANT INTL	0.08%	N 020475	003	Jan 28, 2014	Jan NEWA
---	--------------	-------	----------	-----	--------------	----------

SOLUTION; TOPICAL

RETIN-A

+	VALEANT INTL	0.05%	N 016921	001		Feb CTEC
---	--------------	-------	----------	-----	--	----------

TRETINOIN

@ WOCKHARDT	0.05%	A 075260	001	Jan 25, 1999	Feb DISC
-------------	-------	----------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

KENALOG

>D>	@ APOTHECON	0.025%	N 011601	003		Jul CAHN
>D>	@	0.1%	N 011601	006		Jul CAHN
>A>	@ DELCOR ASSET CORP	0.025%	N 011601	003		Jul CAHN
>A>	@	0.1%	N 011601	006		Jul CAHN

INJECTABLE; INJECTION

KENALOG-10

APOTHECON

	APOTHECON	10MG/ML	N 012041	001		May CTEC
--	-----------	---------	----------	-----	--	----------

KENALOG-40

+	APOTHECON	40MG/ML	N 014901	001		May CTEC
---	-----------	---------	----------	-----	--	----------

TRIAMCINOLONE ACETONIDE

@ SANDOZ	10MG/ML	A 090166	001	May 27, 2009	May DISC
----------	---------	----------	-----	--------------	----------

@ SANDOZ CANADA INC	40MG/ML	A 090164	001	Jun 01, 2009	May DISC
---------------------	---------	----------	-----	--------------	----------

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

@ TARO	0.1%	A 089129	001	Aug 14, 1986	Mar DISC
--------	------	----------	-----	--------------	----------

OINTMENT; TOPICAL

KENALOG

>D>	@ APOTHECON	0.025%	N 011600	003		Jul CAHN
>D>	@	0.1%	N 011600	001		Jul CAHN
>A>	@ DELCOR ASSET CORP	0.025%	N 011600	003		Jul CAHN
>A>	@	0.1%	N 011600	001		Jul CAHN

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ WATSON LABS	0.125MG	A074445	001	Oct 20, 1995	May	DISC
@	0.25MG	A074445	002	Oct 20, 1995	May	DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

@ WATSON LABS	2MG	A040184	001	Feb 06, 1998	May	DISC
@	5MG	A040184	002	Feb 06, 1998	May	DISC

TRIMETHOENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN

AP	+	PAR STERILE PRODUCTS	100MG/ML	N017530	001		May	CAHN
----	---	----------------------	----------	---------	-----	--	-----	------

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014	Apr	NEWA
---	-------------------	---------------------	---------	-----	--------------	-----	------

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH; EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013	Apr	CAHN
---	-----------------	---	---------	-----	--------------	-----	------

UREA C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

@ OTSUKA AMERICA	EQ 75MG / POUCH	N020586	002	May 10, 2001	May	DISC
------------------	-----------------	---------	-----	--------------	-----	------

URSODIOL

TABLET; ORAL

URSO 250

AB		FOREST LABS INC	250MG	N020675	001	Dec 10, 1997	Apr	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

URSO FORTE

AB	+	FOREST LABS INC	500MG	N020675	002	Jul 21, 2004	Apr	CAHN
----	---	-----------------	-------	---------	-----	--------------	-----	------

URSODIOL

>A>	AB	IMPAX LABS INC	250MG	A200826	001	Dec 23, 2011	Jul	CAHN
-----	----	----------------	-------	---------	-----	--------------	-----	------

>A>	AB		500MG	A200826	002	Dec 23, 2011	Jul	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>D>	AB	WATSON LABS INC	250MG	A200826	001	Dec 23, 2011	Jul	CAHN
-----	----	-----------------	-------	---------	-----	--------------	-----	------

>D>	AB		500MG	A200826	002	Dec 23, 2011	Jul	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		APOTEX INC	EQ 1GM BASE	A090500	002	Apr 04, 2014	Mar	NEWA
----	--	------------	-------------	---------	-----	--------------	-----	------

AB			EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar	NEWA
----	--	--	---------------	---------	-----	--------------	-----	------

AB		CIPLA LTD	EQ 1GM BASE	A077135	002	May 24, 2010	Jan	CAHN
----	--	-----------	-------------	---------	-----	--------------	-----	------

AB			EQ 500MG BASE	A077135	001	May 24, 2010	Jan	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

AB		WATSON LABS INC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr	CAHN
----	--	-----------------	-------------	---------	-----	--------------	-----	------

AB			EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

AA		ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan	CAHN
----	--	----------------	-----------	---------	-----	--------------	-----	------

VALSARTAN

TABLET; ORAL

DIOVAN

AB		NOVARTIS	40MG	N021283	004	Aug 14, 2002	Jun	CFTG
----	--	----------	------	---------	-----	--------------	-----	------

AB			80MG	N021283	001	Jul 18, 2001	Jun	CFTG
----	--	--	------	---------	-----	--------------	-----	------

AB			160MG	N021283	002	Jul 18, 2001	Jun	CFTG
----	--	--	-------	---------	-----	--------------	-----	------

AB	+		320MG	N021283	003	Jul 18, 2001	Jun	CFTG
----	---	--	-------	---------	-----	--------------	-----	------

VALSARTAN

AB		OHM LABS INC	40MG	A077492	001	Jun 26, 2014	Jun	NEWA
----	--	--------------	------	---------	-----	--------------	-----	------

AB			80MG	A077492	002	Jun 26, 2014	Jun	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			160MG	A077492	003	Jun 26, 2014	Jun	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TABLET;ORAL		VALSARTAN							
AB		320MG		A 077492	004	Jun 26, 2014	Jun	NEWA	
<u>VANCOMYCIN HYDROCHLORIDE</u>									
CAPSULE;ORAL		VANCOCIN HYDROCHLORIDE							
AB	SHIRE VIROPHARM INC	EQ 125MG BASE		N 050606	001	Apr 15, 1986	May	CAHN	
AB	+	EQ 250MG BASE		N 050606	002	Apr 15, 1986	May	CAHN	
INJECTABLE;INJECTION		VANCOMYCIN HYDROCHLORIDE							
AP	AGILA SPECLTS	EQ 10GM BASE/VIAL		A 091554	001	Sep 19, 2011	Feb	CAHN	
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL		A 065401	002	Jun 30, 2008	May	CAHN	
AP		EQ 500MG BASE/VIAL		A 065401	001	Jun 30, 2008	May	CAHN	
<u>VASOPRESSIN</u>									
SOLUTION;IV (INFUSION)		VASOSTRICT							
+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)		N 204485	001	Apr 17, 2014	Apr	NEWA	
<u>VECURONIUM BROMIDE</u>									
INJECTABLE;INJECTION		VECURONIUM BROMIDE							
	@ WATSON LABS	10MG/VIAL		A 074334	001	Aug 31, 1995	May	DISC	
	@	20MG/VIAL		A 074334	002	Aug 31, 1995	May	DISC	
<u>VENLAFAXINE HYDROCHLORIDE</u>									
TABLET;ORAL		VENLAFAXINE HYDROCHLORIDE							
>D>	AB	CARACO	EQ 25MG BASE	A 078627	001	Jun 13, 2008	Jul	CAHN	
>D>	AB		EQ 37.5MG BASE	A 078627	002	Jun 13, 2008	Jul	CAHN	
>D>	AB		EQ 50MG BASE	A 078627	003	Jun 13, 2008	Jul	CAHN	
>D>	AB		EQ 75MG BASE	A 078627	004	Jun 13, 2008	Jul	CAHN	
>D>	AB		EQ 100MG BASE	A 078627	005	Jun 13, 2008	Jul	CAHN	
>A>	AB	SUN PHARM INDS INC	EQ 25MG BASE	A 078627	001	Jun 13, 2008	Jul	CAHN	
>A>	AB		EQ 37.5MG BASE	A 078627	002	Jun 13, 2008	Jul	CAHN	
>A>	AB		EQ 50MG BASE	A 078627	003	Jun 13, 2008	Jul	CAHN	
>A>	AB		EQ 75MG BASE	A 078627	004	Jun 13, 2008	Jul	CAHN	
>A>	AB		EQ 100MG BASE	A 078627	005	Jun 13, 2008	Jul	CAHN	
<u>VERAPAMIL HYDROCHLORIDE</u>									
TABLET;ORAL		VERAPAMIL HYDROCHLORIDE							
AB	MYLAN	80MG		A 071483	002	Feb 15, 1989	Apr	CMS1	
	@ WATSON LABS	40MG		A 072923	001	Jun 29, 1993	May	DISC	
	@	80MG		A 070855	001	Sep 24, 1986	May	DISC	
	@	80MG		A 071366	001	Oct 01, 1986	May	DISC	
	@	120MG		A 070856	001	Sep 24, 1986	May	DISC	
	@	120MG		A 071367	001	Oct 01, 1986	May	DISC	
TABLET, EXTENDED RELEASE;ORAL		VERAPAMIL HYDROCHLORIDE							
>D>	AB	ANI PHARMS INC	120MG	A 090529	001	Dec 30, 2011	Jul	CAHN	
	AB		120MG	A 090529	001	Dec 30, 2011	Jun	CAHN	
>D>	AB		180MG	A 090529	002	Dec 30, 2011	Jul	CAHN	
	AB		180MG	A 090529	002	Dec 30, 2011	Jun	CAHN	
>D>	AB		240MG	A 090529	003	Dec 30, 2011	Jul	CAHN	
	AB		240MG	A 090529	003	Dec 30, 2011	Jun	CAHN	
>A>	AB	SUN PHARM INDS INC	120MG	A 090529	001	Dec 30, 2011	Jul	CAHN	
>A>	AB		180MG	A 090529	002	Dec 30, 2011	Jul	CAHN	
>A>	AB		240MG	A 090529	003	Dec 30, 2011	Jul	CAHN	
<u>VORAPAXAR SULFATE</u>									
TABLET;ORAL		ZONTIVITY							
+	MERCK SHARP DOHME	EQ 2.08MG BASE		N 204886	001	May 08, 2014	Jun	CPOT	
+		EQ 2.5MG BASE		N 204886	001	May 08, 2014	May	NEWA	

WARFARIN SODIUM

		INJECTABLE; INJECTION							
		COUMADIN							
	@	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995	Mar	DISC	
		TABLET; ORAL							
		COUMADIN							
AB		BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Apr	CMFD	
	@		1MG	N009218	022	Mar 01, 1990	Mar	DISC	
AB			2MG	N009218	013		Apr	CMFD	
	@		2MG	N009218	013		Mar	DISC	
AB			2.5MG	N009218	018		Apr	CMFD	
	@		2.5MG	N009218	018		Mar	DISC	
AB			3MG	N009218	025	Nov 18, 1996	Apr	CMFD	
	@		3MG	N009218	025	Nov 18, 1996	Mar	DISC	
AB			4MG	N009218	023	Aug 24, 1993	Apr	CMFD	
	@		4MG	N009218	023	Aug 24, 1993	Mar	DISC	
AB			5MG	N009218	007		Apr	CMFD	
	@		5MG	N009218	007		Mar	DISC	
AB			6MG	N009218	026	Nov 18, 1996	Apr	CMFD	
	@		6MG	N009218	026	Nov 18, 1996	Mar	DISC	
AB			7.5MG	N009218	016		Apr	CMFD	
	@		7.5MG	N009218	016		Mar	DISC	
AB	+		10MG	N009218	005		Apr	CMFD	
	@		10MG	N009218	005		Mar	DISC	

ZICONOTIDE ACETATE

		INJECTABLE; INTRATHECAL							
		PRIALT							
	@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb	CAIN	

ZIDOVUDINE

		INJECTABLE; INJECTION							
		ZIDOVUDINE							
	@	LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013	Mar	DISC	

ZILEUTON

		TABLET; ORAL							
		ZYFLO							
	@	CHIESI USA INC	300MG	N020471	001	Dec 09, 1996	Apr	CAHN	
	+		600MG	N020471	003	Dec 09, 1996	Apr	CAHN	
		TABLET, EXTENDED RELEASE; ORAL							
		ZYFLO CR							
	+	CHIESI USA INC	600MG	N022052	001	May 30, 2007	Apr	CAHN	

ZOLEDRONIC ACID

		INJECTABLE; IV (INFUSION)							
		ZOLEDRONIC ACID							
AP		AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	May	NEWA	

ZOLMITRIPTAN

		TABLET; ORAL							
		ZOLMITRIPTAN							
AB		INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	NEWA	
AB			5MG	A204284	002	Apr 09, 2014	Mar	NEWA	
AB		TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb	NEWA	
AB			5MG	A090861	002	Mar 04, 2014	Feb	NEWA	

ZOLPIDEM TARTRATE

		TABLET; ORAL							
		ZOLPIDEM TARTRATE							
>D>	AB	CARACO	5MG	A077359	001	Apr 23, 2007	Jul	CAHN	
>D>	AB		10MG	A077359	002	Apr 23, 2007	Jul	CAHN	
>A>	AB	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Jul	CAHN	
>A>	AB		10MG	A077359	002	Apr 23, 2007	Jul	CAHN	
	@	VIVIMED LABS	5MG	A076062	001	Apr 23, 2007	Apr	CAHN	
	@		10MG	A076062	002	Apr 23, 2007	Apr	CAHN	
	@	WATSON LABS	5MG	A077773	001	Apr 23, 2007	May	DISC	
	@		10MG	A077773	002	Apr 23, 2007	May	DISC	

ZONISAMIDE

CAPSULE;ORAL		ZONISAMIDE							
AB	ANI PHARMS INC	25MG	A 077639	001	Dec 22, 2005	Jan	CAHN		
	@	25MG	A 077641	003	Dec 22, 2005	Jan	CAHN		
AB		50MG	A 077639	002	Dec 22, 2005	Jan	CAHN		
	@	50MG	A 077641	002	Dec 22, 2005	Jan	CAHN		
AB		100MG	A 077639	003	Dec 22, 2005	Jan	CAHN		
	@	100MG	A 077641	001	Dec 22, 2005	Jan	CAHN		
	@ SANDOZ	25MG	A 077644	001	Dec 22, 2005	Feb	DISC		
	@	50MG	A 077644	002	Dec 22, 2005	Feb	DISC		
	@	100MG	A 077644	003	Dec 22, 2005	Feb	DISC		

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

@ SCHERING PLOUGH 500MG;3MG;60MG N019453 001 May 22, 1987 Feb DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D> CARACO 5MG A077499 001 Dec 27, 2007 Jul CAHN

>D> 10MG A077499 002 Dec 27, 2007 Jul CAHN

IPCA LABS LTD 5MG A202277 002 Mar 11, 2014 Feb NEWA

10MG A202277 004 Mar 11, 2014 Feb NEWA

>A> SUN PHARM INDS INC 5MG A077499 001 Dec 27, 2007 Jul CAHN

>A> 10MG A077499 002 Dec 27, 2007 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES

>D> CARACO 5MG A077499 003 Dec 27, 2007 Jul CAHN

>D> 10MG A077499 004 Dec 27, 2007 Jul CAHN

IPCA LABS LTD 5MG A202277 001 Mar 11, 2014 Feb NEWA

10MG A202277 003 Mar 11, 2014 Feb NEWA

>A> SUN PHARM INDS INC 5MG A077499 003 Dec 27, 2007 Jul CAHN

>A> 10MG A077499 004 Dec 27, 2007 Jul CAHN

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D> @ CARACO 5MG A077631 004 Jan 11, 2008 Jul CAHN

@ 5MG A077631 004 Jan 11, 2008 Feb DISC

>D> @ 10MG A077631 003 Jan 11, 2008 Jul CAHN

@ 10MG A077631 003 Jan 11, 2008 Feb DISC

>A> @ SUN PHARM INDS INC 5MG A077631 004 Jan 11, 2008 Jul CAHN

>A> @ 10MG A077631 003 Jan 11, 2008 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> @ CARACO 5MG A077631 001 Jan 11, 2008 Jul CAHN

@ 5MG A077631 001 Jan 11, 2008 Feb DISC

>D> @ 10MG A077631 002 Jan 11, 2008 Jul CAHN

@ 10MG A077631 002 Jan 11, 2008 Feb DISC

>A> @ SUN PHARM INDS INC 5MG A077631 001 Jan 11, 2008 Jul CAHN

>A> @ 10MG A077631 002 Jan 11, 2008 Jul CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ WATSON LABS 200MG A075425 001 Jul 29, 1999 May DISC

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC 6MG;120MG A078648 001 Feb 27, 2013 Jan CRLD

DISOPHROL

@ SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982 Jan DISC

DRIXORAL

@ SCHERING PLOUGH 6MG;120MG N013483 003 Sep 13, 1982 Jan DISC

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE 25MG;220MG N205352 001 Jan 17, 2014 Jan NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

ASTRAZENECA LP EQ 20MG BASE N204655 001 Mar 28, 2014 Apr CMS2

NEXIUM 24HR

+ ASTRAZENECA LP EQ 20MG BASE N204655 001 Mar 28, 2014 Apr CTNA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

@ WATSON LABS 10MG A075404 001 Nov 28, 2001 May DISC

FLUTICASONE PROPIONATE

	SPRAY, METERED;NASAL						
>A>	FLONASE ALLERGY RELIEF						
>A>	+ GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014	Jul	NEWA

IBUPROFEN

	SUSPENSION;ORAL						
	CHILDREN'S ELIXSURE						
	MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004	May	CAHN
	TABLET;ORAL						
	IBUPROFEN						
	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Mar	NEWA
	@ WATSON LABS	200MG	A070435	001	Mar 05, 1986	May	DISC

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

	TABLET;ORAL						
	IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE						
	PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014	Jun	NEWA

LEVONORGESTREL

	TABLET;ORAL						
	FALLBACK SOLO						
	LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014	Jun	NEWA

MINOXIDIL

	AEROSOL, FOAM;TOPICAL						
	WOMEN'S ROGAINE						
	+ JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014	Feb	NEWA

TRIAMCINOLONE ACETONIDE

	SPRAY, METERED;NASAL						
	NASACORT ALLERGY 24 HOUR						
>D>	SANOFI AVENTIS US	0.055MG/SPRAY	N020468	002	Oct 11, 2013	Jul	CRLD
>A>	+	0.055MG/SPRAY	N020468	002	Oct 11, 2013	Jul	CRLD

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2014

NO JULY 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001	8747896	Jun 03, 2027	DP U-1460			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8709392	Sep 15, 2026	DP U-1078			
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					PC	Mar 22, 2014
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	>A> 7500444	Feb 26, 2026	DP			
	>A> 7500444*PED	Aug 26, 2026				
<u>ALCAFTADINE - LASTACAFT</u>						
N 022134 001	8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTRINA</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTRINA</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8645160	Jun 18, 2029	U-1485			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	>A> 8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866	001				M-137	Jun 09, 2017
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	001	8722679	Oct 19, 2024	DP		
	>A>	8759351	Aug 06, 2023	DP U-1530		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	002	8722679	Oct 19, 2024	DP		
	>A>	8759351	Aug 06, 2023	DP U-1530		
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	001	>A> 8022228	Apr 06, 2026	DS DP		
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	002	>A> 8022228	Apr 06, 2026	DS DP		
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352	001	5849911	Jun 20, 2017	DS DP U-167	NP	Jun 02, 2017
		6087383	Dec 21, 2018	DS DP		
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	001	5686104	Nov 11, 2014	DP U-1400		
		5686104*PED	May 11, 2015			
		5969156	Jul 08, 2016	DS		
		5969156*PED	Jan 08, 2017			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	002	5686104	Nov 11, 2014	DP U-1400		
		5686104*PED	May 11, 2015			
		5969156	Jul 08, 2016	DS		
		5969156*PED	Jan 08, 2017			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	003	5686104	Nov 11, 2014	DP U-1400		
		5686104*PED	May 11, 2015			
		5969156	Jul 08, 2016	DS		
		5969156*PED	Jan 08, 2017			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	004	5686104	Nov 11, 2014	DP U-1400		
		5686104*PED	May 11, 2015			
		5969156	Jul 08, 2016	DS		
		5969156*PED	Jan 08, 2017			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001				NP	Oct 03, 2016
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911	001	5683677	Nov 04, 2014	DP		
		5776432	Jul 07, 2015	DP U-645		
		6446627	Dec 18, 2017	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911	002	5683677	Nov 04, 2014	DP		
		5776432	Jul 07, 2015	DP U-645		
		6446627	Dec 18, 2017	DP		
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384	001	8546428	Mar 19, 2029	DS DP U-1321		
<u>BELINOSTAT - BELEODAO</u>						
N 206256	001	>A> 6888027	Sep 27, 2021	DS DP U-1544	>A> NCE	Jul 03, 2019
					>A> ODE	Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	001	>A> 8791270	Jan 12, 2026	DP U-1542		
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	002	>A> 8791270	Jan 12, 2026	DP U-1542		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819	001	8663699	Jun 03, 2029	U-124		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288	001	>A> 8784789	Sep 05, 2024	DP		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615	001				PC	Sep 27, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001 >A>	8772338	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277			
	8632760	Jan 15, 2023	U-1487			
	8758733	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001					ODE	Jun 20, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001 >A>	8784888	Jun 09, 2020	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005 >A>	6264980	Dec 18, 2015	DP			
	>A> 6344211	Dec 18, 2015	U-1540			
	>A> RE41408	Sep 29, 2017	U-1540			
	>A> RE41489	Sep 29, 2017	U-1540			
	>A> RE41571	Sep 29, 2017	U-1540			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280			
	8269128	May 26, 2026	DP U-1280			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8703787	Feb 02, 2032	U-1179			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
	8716264	Jan 13, 2024	DP U-257			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001 >A>	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002 >A>	8785632	Mar 01, 2025	DS			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024	U-817			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					>A> ODE	Apr 30, 2020
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					>A> ODE	Apr 30, 2020
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
	7119061	Nov 14, 2023	DP			
	8143212	Nov 14, 2023	U-1517			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	8663685	Jan 18, 2025	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001 >A>	7758890	Jul 01, 2025	DP			
	>A> 8110225	Dec 24, 2022	DP			
	>A> 8604072	Dec 24, 2022	DP			
	>A> 8685460	Feb 15, 2023	U-1546			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001				I-686	Jun 29, 2017
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	001	6664276	Jan 30, 2023	DS DP U-949		
		6664276	Jan 30, 2023	DS DP U-950		
		6664276	Jan 30, 2023	DS DP U-951		
		6664276	Jan 30, 2023	DS DP U-1507		
		6664276*PED	Jul 30, 2023			
		8722084	Oct 15, 2023	DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	002	6664276	Jan 30, 2023	DS DP U-949		
		6664276	Jan 30, 2023	DS DP U-950		
		6664276	Jan 30, 2023	DS DP U-951		
		6664276	Jan 30, 2023	DS DP U-1507		
		6664276*PED	Jul 30, 2023			
		8722084	Oct 15, 2023	DP		
		8722084*PED	Apr 15, 2024			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	001				M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	8648106	Jan 04, 2032	DP	M-61 PED	Jun 17, 2016 Dec 17, 2016
		8648106*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	8648106	Jan 04, 2032	DP	M-61 PED	Jun 17, 2016 Dec 17, 2016
		8648106*PED	Jul 04, 2032			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992	003				PC	May 18, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879	001	RE38115	Jan 26, 2016	DP	Y	
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	001	8679544	Apr 23, 2030	DP		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	002	8679544	Apr 23, 2030	DP		
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234	001	5607690	Apr 13, 2019	DP		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001	6287594	Jan 15, 2019	DP		
		8623920	Feb 24, 2029	U-1482		
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
A 202027	001				>A> PC	Nov 23, 2014
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947	001	8741956	Jul 10, 2029	U-1435		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001	8217078	Jul 10, 2029	U-1477	NP	Jan 16, 2017
		8252838	Apr 21, 2028	DP U-1489		
		8546450	Aug 09, 2030	U-1435		
		8546450	Aug 09, 2030	U-1436		
		8563613	Oct 17, 2027	DP U-1488		
		8618164	Jul 10, 2029	U-1477		
		8741956	Jul 10, 2029	U-1435		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	8759393	Oct 29, 2019	DP		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	8759393	Oct 29, 2019	DP		
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352	001				NC	Jan 17, 2017
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001	8709478	Apr 07, 2024	U-1063		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8716264	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	8716264	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	8716264	Jan 13, 2024	DP U-257			
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP PED	Mar 20, 2017 Sep 20, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5877192	May 27, 2014	U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6978945	Jul 31, 2022	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002 >A>	8722037	Sep 28, 2027	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001 >A>	8778962	Feb 18, 2022	U-1541			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002 >A>	8778962	Feb 18, 2022	U-1541			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003 >A>	8778962	Feb 18, 2022	U-1541			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004 >A>	8778962	Feb 18, 2022	U-1541			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8617598	Sep 27, 2022	DP			
	>A> 8778962	Feb 18, 2022	U-1541			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8617598	Sep 27, 2022	DP			
	>A> 8778962	Feb 18, 2022	U-1541			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8617598	Sep 27, 2022	DP			
	>A> 8778962	Feb 18, 2022	U-1541			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8216180	Jan 12, 2028	DP			
	8439864	Mar 25, 2028	DP			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	8728441	Mar 26, 2019			U-1514	
	8753611	Mar 26, 2019			U-1514	
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	8728441	Mar 26, 2019			U-1514	
	8753611	Mar 26, 2019			U-1514	
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	8728441	Mar 26, 2019			U-1514	
	8753611	Mar 26, 2019			U-1514	
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	8728441	Mar 26, 2019			U-1514	
	8753611	Mar 26, 2019			U-1514	
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	8728441	Mar 26, 2019			U-1514	
	8753611	Mar 26, 2019			U-1514	
	8765100	Mar 26, 2019	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
<u>FLORBETABEN F-18 - NEURACEO</u>						
N 204677 001	7907135	Mar 18, 2029	DS DP	U-1497	NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP	U-336	NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP	U-336		
	8691185	Jan 24, 2023		U-336		
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP	U-336	NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP	U-336		
	8691185	Jan 24, 2023		U-336		
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8746242	Oct 10, 2030	DP		NP	May 10, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	8623922	Jun 22, 2021	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	8686034	Jan 24, 2025		U-1231	ODE	Jun 06, 2019
	8686034	Jan 24, 2025		U-1247		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8686034	Jan 24, 2025		U-1231	ODE	Jun 06, 2019
	8686034	Jan 24, 2025		U-1247		
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	6054430	May 24, 2014	DS		NP	Jan 28, 2017
	6342476	May 24, 2014		U-441		
	6362161	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8232250	Aug 19, 2030		U-441		
	8367605	May 24, 2014	DS			
	8399413	Sep 06, 2030		U-441		
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8642012	Sep 22, 2030		U-1383		
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP	U-1087		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-680	Feb 12, 2017
	8476284	Dec 28, 2026	U-1491		>A> I-689	Jul 28, 2017
	8497277	Dec 28, 2026	U-1456		ODE	Feb 12, 2021
	8497277	Dec 28, 2026	U-1491			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8735452	Sep 30, 2029	U-981			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2015	DS DP U-1187			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NP	Jul 26, 2015
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001					>A> NCE	Jul 23, 2019
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002					>A> NCE	Jul 23, 2019
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8679069	Apr 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	>A> 6071497	May 15, 2015	DP U-1533		>A> NP	Jun 27, 2017
	>A> 6428771	May 15, 2015	DP U-1533			
	>A> 6444226	Jun 29, 2020	DP U-1534			
	>A> 6652885	Jun 29, 2020	U-1535			
	>A> 6663898	Sep 30, 2014	DP			
	>A> 6906030	Sep 30, 2014	DP			
	>A> 7276534	Sep 30, 2014	DP U-1536			
	>A> 7305986	Jan 16, 2023	DP			
	>A> 7464706	Mar 02, 2023	DP			
	>A> 7648960	Jun 29, 2020	U-1535			
	>A> 7943178	Jun 29, 2020	DP U-1535			
	>A> 7943572	Aug 10, 2026	U-1539			
	>A> 8119593	Aug 11, 2029	U-1537			
	>A> 8133514	Sep 30, 2014	DP			
	>A> 8146588	Apr 24, 2023	DP			
	>A> 8156936	Jan 16, 2023	DP			
	>A> 8215300	Nov 24, 2022	DP			
	>A> 8227409	Mar 08, 2031	DP U-1538			
	>A> 8258095	Aug 11, 2029	U-1537			
	>A> 8389470	Jun 29, 2020	DP			
	>A> 8394414	May 15, 2015	DP U-1533			
	>A> 8424518	Oct 17, 2031	DP			
	>A> 8485180	Mar 25, 2030	DP			
	>A> 8499757	Feb 19, 2032	DP			
	>A> 8551528	Jun 11, 2030	DP			
	>A> 8623817	Sep 18, 2029	U-1537			
	>A> 8636001	Jul 12, 2032	DP			
	>A> 8729019	Jun 06, 2028	DP			
	>A> 8734845	Jun 11, 2030	DP			
	>A> 8778403	Jun 11, 2030	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	>A> 6071497	May 15, 2015	DP U-1533		>A> NP	Jun 27, 2017
	>A> 6428771	May 15, 2015	DP U-1533			
	>A> 6444226	Jun 29, 2020	DP U-1534			
	>A> 6652885	Jun 29, 2020	U-1535			
	>A> 6663898	Sep 30, 2014	DP			
	>A> 6906030	Sep 30, 2014	DP			
	>A> 7276534	Sep 30, 2014	DP U-1536			
	>A> 7305986	Jan 16, 2023	DP			
	>A> 7464706	Mar 02, 2023	DP			
	>A> 7648960	Jun 29, 2020	U-1535			
	>A> 7943178	Jun 29, 2020	DP U-1535			
	>A> 8119593	Aug 11, 2029	U-1537			
	>A> 8133514	Sep 30, 2014	DP			
	>A> 8146588	Apr 24, 2023	DP			
	>A> 8156936	Jan 16, 2023	DP			
	>A> 8215300	Nov 24, 2022	DP			
	>A> 8227409	Mar 08, 2031	DP U-1538			
	>A> 8258095	Aug 11, 2029	U-1537			
	>A> 8389470	Jun 29, 2020	DP			
	>A> 8394414	May 15, 2015	DP U-1533			
	>A> 8485180	Mar 25, 2030	DP			
	>A> 8499757	Feb 19, 2032	DP			
	>A> 8551528	Jun 11, 2030	DP			
	>A> 8636001	Jul 12, 2032	DP			
	>A> 8729019	Jun 06, 2028	DP			
	>A> 8734845	Jun 11, 2030	DP			
	>A> 8778403	Jun 11, 2030	DP U-1538			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	>A> 8754224	Dec 28, 2026	DS DP			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	8735393	Dec 04, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027	U-1503			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LOPINA VIR; RITONAVIR - KALETRA</u>						
N 021906 001	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LOPINA VIR; RITONAVIR - KALETRA</u>						
N 021906 002	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8697686	Dec 20, 2025	DS DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8748481	Sep 01, 2025	U-1520			
	>A> 8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	8748481	Sep 01, 2025	U-1519			
	>A> 8779187	Jan 23, 2027	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372	Jul 02, 2018	DS			
	8729085	May 26, 2026	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	5061703	Apr 11, 2015	U-539		>A> M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			>A> PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	5061703	Apr 11, 2015	U-539		>A> M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			>A> PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	5061703	Apr 11, 2015	U-539		>A> M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			>A> PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539		>A> M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			>A> PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663 001					D-139	Feb 19, 2017
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 002 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010 >A>	8664231	Jun 01, 2029	U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001 >A>	8778390	Feb 15, 2031	DP U-1543			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001				NP		Mar 24, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684	001				NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	006	8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	007	8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	008	8722650	Jun 24, 2025	U-1078		
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812	002				NP	Feb 28, 2017
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	RE44872	Dec 18, 2023	U-1527		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	002	RE44872	Dec 18, 2023	U-1527		
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641	001	5889015	Jan 27, 2014	U-645		
		5889015*PED	Jul 27, 2014			
		6057307	Jan 27, 2014	DP U-645		
		6057307*PED	Jul 27, 2014			
		6068832	Aug 27, 2017	DP U-645		
		6365581	Jan 27, 2014	U-645		
		6365581*PED	Jul 27, 2014			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641	002	5889015	Jan 27, 2014	U-645		
		5889015*PED	Jul 27, 2014			
		6057307	Jan 27, 2014	DP U-645		
		6057307*PED	Jul 27, 2014			
		6068832	Aug 27, 2017	DP U-645		
		6365581	Jan 27, 2014	U-645		
		6365581*PED	Jul 27, 2014			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	001	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	002	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	003	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	004	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	005	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	006	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	001	7682633	Jun 19, 2027	U-1510		
		8158156	Jun 19, 2027	U-1510		
		8685443	Jul 03, 2025	U-1508		
		8685444	Jul 03, 2025	DP		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	002	7682633	Jun 19, 2027	U-1510		
		8158156	Jun 19, 2027	U-1510		
		8685443	Jul 03, 2025	U-1508		
		8685444	Jul 03, 2025	DP		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321	003	7682633	Jun 19, 2027	U-1510		
		8158156	Jun 19, 2027	U-1510		
		8685443	Jul 03, 2025	U-1508		
		8685444	Jul 03, 2025	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001 >A>	8778365	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8223610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001 >A>	6277384	Dec 22, 2018	DP			
>A>	6696066	Dec 22, 2018	DP			
>A>	7674799	Mar 30, 2025	DP			
>A>	7674800	Mar 30, 2025	DS			
>A>	7683072	Mar 30, 2025	DS			
>A>	8673355	Dec 22, 2018	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002 >A>	6277384	Dec 22, 2018	DP			
>A>	6696066	Dec 22, 2018	DP			
>A>	7674799	Mar 30, 2025	DP			
>A>	7674800	Mar 30, 2025	DS			
>A>	7683072	Mar 30, 2025	DS			
>A>	8673355	Dec 22, 2018	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003 >A>	6277384	Dec 22, 2018	DP			
>A>	6696066	Dec 22, 2018	DP			
>A>	7674799	Mar 30, 2025	DP			
>A>	7674800	Mar 30, 2025	DS			
>A>	7683072	Mar 30, 2025	DS			
>A>	8673355	Dec 22, 2018	DP			
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8663680	Feb 13, 2020	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002					M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	5840757	Nov 24, 2015	DP		NP	Oct 03, 2016
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001					>A> NCE	Jul 31, 2019
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
	>A> 8772353	Feb 13, 2024	U-1369			
	>A> 8772353	Feb 13, 2024	U-1370			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001 >A>	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002 >A>	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003 >A>	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004 >A>	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005 >A>	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006 >A>	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			
	8685441	Jan 13, 2019			U-665	
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	8734833	May 26, 2020	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
	8735428	May 15, 2023			U-1360	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
	8735428	May 15, 2023			U-1360	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
	8735428	May 15, 2023			U-1360	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
	8735428	May 15, 2023			U-1360	
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001 >A>	8791127	Mar 23, 2027	DP			
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-257		
	7754731	Mar 11, 2029	DS DP	U-257		
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001					I-685	May 29, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002					I-685	May 29, 2017
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	8680124	Jul 20, 2028		U-1506		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Feb 27, 2026		DP		
	8741904	Feb 27, 2026	DS	U-1526		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029		U-1481		
	8741904	Feb 27, 2026	DS	U-1526		
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8691878	Aug 25, 2024		U-688		
	8691878*PED	Feb 25, 2025				
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8722693	Jun 12, 2028	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156			
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8618141	Feb 11, 2023	U-1480			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	8241243	Aug 10, 2023	DP			
	8491524	Nov 21, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8741620	Feb 24, 2024	DS DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
	>A> 8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	>A> 7582621	May 26, 2027	U-718		>A> NCE	Jul 07, 2019
	>A> 7767657	May 22, 2027	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					I-687	Jun 13, 2017
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	>A> 5861379	May 26, 2020	DS DP U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	>A> 8784878	Jul 13, 2023	DP U-1545			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	>A> 8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	>A> 8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026	U-1500			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	8626531	Oct 23, 2020	U-1465			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 16, 2018	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8722735	Oct 10, 2029	DP		NP	May 15, 2017
	8754123	May 19, 2029	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Oct 08, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8735380	Feb 20, 2029	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
>A>	8746242	Oct 11, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8201556	Feb 05, 2029	DP		NP	Dec 18, 2016
>A>	8746242	Oct 11, 2030	DP			
RE44874		Mar 23, 2023	DS DP	U-1476		
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					PC	Jan 03, 2015
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP	U-1512		
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Nov 11, 2030	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIC</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>